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Summary 
 
Telomeres are repetitive nucleotide sequences of TTAGGG that cap the ends of linear 
eukaryotic chromosomes.  Short dysfunctional telomeres have previously been identified 
as a driving force in cancer, resulting in chromosomal fusion and rearrangement that 
acts to facilitate progression of the malignancy.  As it has recently been demonstrated 
that telomere length is an accurate predictor of clinical outcome in patients with chronic 
lymphocytic leukaemia (CLL), we aimed to determine whether a similar relationship 
existed in multiple myeloma (MM).  Having used single telomere length analysis (STELA) 
to measure the mean XpYp telomere length of whole bone marrow aspirates from 141 
MM patients, a telomere length threshold of 3.92kb was identified which could be used 
to stratify patients as either low- or high-risk.  Incorporation of this threshold into the 
international staging system (ISS) for MM increased its prognostic resolution, allowing 
each prognostic subset to be further risk-stratified.   
 
Having demonstrated that a shorter mean XpYp telomere length (<3.92kb) was 
associated with inferior patient outcome in MM, we next sought to identify a potential 
cause for this observation.  Using clonal populations of the JJN-3 cell line, each 
expressing DN-hTERT, we observed that telomeric shortening resulted in a greater 
frequency of fusion and the initiation of a telomere-driven crisis.  Cells were eventually 
able to escape crisis, driven by the spontaneous reactivation of telomerase which led to 
increasing telomere length and decreasing fusion frequency.  Finally, we sought use the 
PARP inhibitors Rucaparib and Olaparib to prevent the escape of these clonal JJN-3 
populations from a telomere-driven crisis.  It was thought that PARP inhibition would 
interfere with the DNA repair pathways that are known to be responsible for processing 
telomere-deficient chromosomes.  It was established that treating JJN-3 cells with either 
7.50μM Rucaparib or 3.75μM Olaparib prevented their escape from a telomere-driven 
crisis.  
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Introduction 
 
1.1 Telomere Structure and Function 
The telomere was first described by Hermann Muller in 1938.  Using Drosophila 
melanogaster, it was demonstrated that a structure existed at the chromosomal ends 
which offered protection from genetic alteration.  Unlike the rest of the genome, 
chromosomal ends did not undergo translocations or inversions when exposed to 
ionising radiation (Muller, 1938).  Soon after this, Barbara McClintock utilised Zea mays 
as a model to identify the telomere as a protective cap which was necessary for 
preventing the fusion of chromosomal ends (McClintock 1941).  Since then, it has been 
established that the telomere is a repetitive double-stranded nucleotide sequence which 
terminates in a short single-stranded overhang.  This sequence recruits a protein 
complex to the telomere, initiating the formation of a looped structure.  It is in this way 
that the telomere prevents a DNA damage response from being triggered, inhibiting the 
erroneous repair of chromosomal ends which would otherwise result in genetic 
rearrangement and instability. 
 
1.1.1 The Telomeric Sequence 
In humans, the repetitive nucleotide sequence that makes up the telomere is primarily 
composed of the hexameric sequence TTAGGG and tandemly repeated into arrays 
extending for up to 25kb depending on the tissue analysed (Capper et al. 2007; Griffith 
et al. 1999).  However, telomeres vary in both sequence and length depending on the 
organism being examined.  For example, most plants share the telomeric sequence 
TTTAGGG which can range from 2-4kb (Adams et al. 2001; Bundock, van Attikum, and 
Hooykaas 2002).  Meanwhile, the budding yeast telomeric sequence is an irregular 
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structure of T(G1-3) repeats which stretches for ~350bp (McEachern and Blackburn 1994; 
Kupiec 2014). 
 
In humans, telomeres are found at both the short p-arm and long q-arm of the 
chromosome (see figure 1.1).  The telomeric sequence of TTAGGG is well conserved 
throughout vertebrates, although this is not the only nucleotide sequence that can be 
found within a telomere.  Telomeric variant repeats (TVRs) exist which are primarily 
localised to the most centromeric 2kb region of the telomere.  Examples of nucleotide 
sequences that make up the human TVR include TGAGGG, TTGGGG and TCAGGG 
(Coleman, Baird, and Royle 1999; Baird et al. 2000).  These TVR sequences are not 
thought to provide the same telomeric function as TTAGGG, with studies showing that 
telomeres lose their protective capacity once a telomere has shortened to within the TVR 
region (Capper et al. 2007).  The presence of certain TVR sequences, most notably 
CTAGGG, has also been associated with telomeric instability (Mendez-Bermudez et al. 
2009).  However, the telomere is not simply defined by its nucleotide sequence.  Various 
proteins are bound to the telomere, most notably those comprising the shelterin complex, 
which are crucial for shaping its structure and maintaining its protective function.   
 
1.1.2 The Shelterin Complex 
The human shelterin complex is a collection of six telomere-associated proteins; TRF1, 
TRF2, TIN2, RAP1, TPP1 and POT1.  Together, these proteins induce the formation of 
the t-loop structure (see figure 1.1) which ensures that chromosomal ends are not 
mistakenly recognised as double-strand DNA breaks (Liu et al. 2004).  
 
1.1.2.1 Telomeric Repeat-binding Factor 1 (TRF1) 
TRF1 exists as a homodimer and localises to double-stranded telomeric sequences.  Its 
main function is to regulate telomere length by blocking the binding of telomerase, a 
ribonucleoprotein which is responsible for the synthesis of telomeric repeats at the 3′ end 
  Chapter 1 - Introduction 
3 
 
  Chapter 1 - Introduction 
4 
 
of a telomere (Ancelin et al. 2002).  This is likely achieved via the recruitment of POT1 
to the telomere which is known to inhibit telomerase activity (Xin et al. 2007).  Artificially 
reducing the expression of TRF1 has been shown to cause telomere lengthening, while 
TRF1 overexpression results in telomere shortening (van Steensel and de Lange 1997).  
The binding of TRF1 at the telomere is thought to be regulated by PARP5a and PARP5b, 
also known as tankyrase-1 (TNK1) and tankyrase-2 (TNK2) respectively.  These proteins 
act to positively regulate telomere length by modifying TRF1, preventing its binding to 
the telomere and instead allowing telomere synthesis by telomerase (Smith and de 
Lange 2000).  It is this way that telomere length is maintained, with a homeostasis 
existing between TRF1 binding and TRF1 dissociation at the telomere.   
 
1.1.2.2 Telomeric Repeat-binding Factor 2 (TRF2) 
Like TRF1, TRF2 also exists as a homodimer and localises to double-stranded telomeric 
sequences.  However, TRF2 is responsible for stabilising the t-loop structure which 
sequesters the single-stranded telomeric end and prevents it from being mistakenly 
identified as double-strand DNA breaks (Doksani et al. 2013).  It is in this way that TRF2 
also acts as a negative regulator of telomere length, shielding the telomere from 
elongation by telomerase (Smogorzewska et al. 2000).  TRF2 works to inhibit signalling 
by the ATM-mediated DNA damage response pathway which would otherwise trigger 
non-homologous end joining (NHEJ) at the chromosomal ends (Herbig et al. 2004).  
Deletion of TRF2 results in the formation of chromosomal fusion events, effectively 
eliminating the end-capping function of the telomere (van Steensel, Smogorzewska, and 
de Lange 1998).  These fusion events are not dependent on telomere length, with even 
long telomeres generating a ATM-mediated DNA damage response if TRF2 is not 
present (Celli and de Lange 2005).    
 
1.1.2.3 TRF1-interacting Nuclear Factor 2 (TIN2) 
TIN2 does not directly bind DNA, but instead acts as a bridge between the TRF1 and 
TRF2 subunits.  It also binds to the TPP1 subunit, which is itself bound to POT1 (Kim et 
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al. 2004).  Overexpression of TIN2 results in telomere shortening, while TIN2 
suppression causes telomere elongation (Kim, Kaminker, and Campisi 1999; Ye and de 
Lange 2004).  This may be explained by the ability of TIN2 to prevent the modification of 
TRF1 by tankyrase proteins, thus prohibiting TRF1 dissociation from the telomere and 
inhibiting the binding of telomerase (Ye and de Lange 2004).  
 
1.1.2.4 Repressor Activator Protein 1 (RAP1) 
RAP1 binds to the TRF2 protein, although its purpose within the shelterin complex is 
disputed.  Deletion of the gene encoding RAP1 failed to induce genomic abnormalities 
or generate significant telomere dysfunction in human cell lines.  Data also exists which 
appears to suggest that RAP1 does not play a role in telomere length regulation (Kabir, 
Hockemeyer, and de Lange 2014).  However, contradictory reports demonstrate that 
overexpressing RAP1 results in telomere elongation (Li, Oestreich, and de Lange 2000). 
RAP1 is also thought to play a role in preventing NHEJ in telomere-deficient senescent 
cells (Benarroch-Popivker et al. 2016).  Furthermore, it has been suggested that RAP1 
reduces the binding affinity of TRF2 for DNA, acting to regulate the selectivity of TRF2 
to specific areas within the telomere (Janouskova et al. 2015).   
 
1.1.2.5 TIN2/PTOP/PIP1 (TPP1) 
TPP1 is necessary for linking together POT1 and TIN2, as well as localising POT1 to the 
telomere.  Knockout studies identify TPP1 as a negative regulator of telomere length, 
likely due to the ability of TPP1-bound POT1 to inhibit telomerase activity (Ye et al. 2004).  
However, phosphorylation of TPP1 was shown to be responsible for the direct 
recruitment of telomerase to telomeres.  It is thought that this mechanism of TPP1-
modification acts to regulate telomere length by recruiting either POT1 or telomerase 
when necessary (Zhang et al. 2013; Zhong et al. 2012).  
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1.1.2.6 Protection of Telomeres 1 (POT1) 
POT1 rarely binds to the double-stranded telomeric sequence, instead binding almost 
exclusively to the single-stranded 3′-overhang of TTAGGG repeats at the end of a 
telomere (Takai et al. 2010).  While it is recruited to the shelterin complex by TPP1, this 
association is not strictly necessary for POT1 binding to the telomere.  However, TPP1 
is known to significantly increase the affinity of POT1 for telomeric DNA (Colgin et al. 
2003; Xin et al. 2007).  Around 50-100 copies of POT1 are thought to be present at each 
telomere, with this shelterin subunit being responsible for stabilising the t-loop structure 
that protects the telomeric ends from being recognised as double-strand DNA breaks 
(Takai et al. 2010).  It has been demonstrated in knockdown studies that loss of POT1 
results in telomere elongation and chromosomal fusion (Kelleher, Kurth, and Lingner 
2005; Veldman, Etheridge, and Counter 2004).  As a negative regulator of telomere 
length, POT1 preferentially binds to the telomeric sequence 5′-TTAGGGTTAG-3′ at the 
3′-overhang.  This limits the access of telomerase to the terminal G residue of a telomere 
and inhibits elongation (Lei, Podell, and Cech 2004).  POT1 also plays a role in 
preventing an ATR-mediated DNA damage response which would otherwise trigger 
aberrant homologous recombination at the telomere end (Thanasoula et al. 2012).   
 
1.1.2.7 Mutations in Shelterin Components 
Germline and somatic mutations involving shelterin proteins have been associated with 
predisposition to various cancers and diseases.  For example, a single amino acid 
deletion in the TPP1 protein has been associated with compromised telomerase 
recruitment and the development of Hoyeraal-Hreidarsson syndrome (Kocak et al. 
2014), a severe form of dyskeratosis congenita (see section 1.4.2 – Critically 
Shortened Telomeres).  A R282H mutation in TIN2 has also been associated with 
dyskeratosis congenita and Revesz syndrome (Savage et al. 2008).   
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Meanwhile, POT1 germline mutations have mostly been associated with the increased 
incidence of cancer.  Familial glioma has been associated with a D617E mutation in 
POT1 which disrupts the binding of TPP1, as have G95C and E450X mutations 
(Bainbridge et al. 2015).  A rare S270N mutation in POT1 has also been observed in a 
small number of familial cutaneous malignant melanoma cases, resulting in carriers 
having an increased telomere length and more fragile telomeres (Shi et al. 2014).  
Familial chronic lymphocytic leukaemia (CLL) is associated with loss-of-function 
mutations in POT1, with a Y36C mutation disrupting the interaction between POT1 and 
the telomeric overhang (Speedy et al. 2016).    
 
1.1.3 The T-Loop Structure 
Although much of the telomere is comprised of double-stranded DNA, the most distal 50-
200bp are single-stranded (Wright et al. 1997; Makarov, Hirose, and Langmore 1997).  
These TTAGGG repeats make up the G-rich 3′-overhang (otherwise known as the G-
tail) which is able to fold back and insert itself, utilising a TRF2-dependent mechanism, 
within the upstream double-stranded section of the telomere.  This sequesters the G-tail 
away from cellular repair pathways that would otherwise seek to trigger a DNA damage 
response after detecting an unprotected chromosomal end (Griffith et al. 1999; Doksani 
et al. 2013).  The displaced strand of the previously-double-stranded telomere is known 
as the D-loop and is stabilised by the binding of POT1 (Lei, Podell, and Cech 2004; 
Loayza et al. 2004).  Unwinding of the t-loop in preparation of DNA replication is 
performed by RTEL1, a helicase which is recruited to the telomere during S-phase by 
TRF2 (Sarek et al. 2015).    
 
1.1.4 The Subtelomeric Region  
A subtelomeric region exists between each telomere and the chromosome-specific 
sequence, ranging from 10-300kb in humans (see figure 1.2).  These regions are 
comprised of diverse ‘blocks’ of nucleotide sequences whose order varies between the 
  Chapter 1 - Introduction 
8 
 
  Chapter 1 - Introduction 
9 
 
subtelomeric regions of each chromosome (Mefford and Trask 2002).  Certain 
sequences may even be unique to a specific subtelomeric region, a feature which has 
been exploited to allow the development of a novel PCR-based technique for measuring 
telomere length (see section 1.3.5 - Single Telomere Length Analysis).  Mapping data 
for the subtelomeric regions of each chromosome has also identified several 
(TTAGGG)n-like sequences which range in size from 24 to 823bp (Riethman et al. 2004).   
 
1.1.5 Telomere Function 
The telomeres cap the ends of linear chromosomes and act to protect genomic DNA 
from erroneous DNA repair, rearrangement and erosion.  They also function as a 
biological clock, triggering senescence after a set number of cell divisions.  It is in this 
way that the telomeres are thought of as a tumour suppressive mechanism.   
 
1.1.5.1 Protection from DNA Repair Pathways 
The sources of DNA damage are multiple, but their effects are almost universally 
identical.  From ionising radiation to chemical carcinogens, each causes the bonds 
between nucleotides in double-stranded DNA to break.  Without a targeted repair 
mechanism, these DNA ends are at risk of undergoing fusion with other damaged 
sections of the genome.  This can then result in genomic rearrangement and 
chromosomal instability (Helleday, Eshtad, and Nik-Zainal 2014).  In humans, the 
homologous recombination and non-homologous end joining pathways (see section 
1.6.2 – Double-strand DNA breaks) are responsible for the recognition and repair of 
double-strand DNA breaks (Chapman, Taylor, and Boulton 2012).  However, these 
pathways are unable to distinguish between a legitimate double-strand DNA break and 
the unprotected ends of linear chromosomes.  To avoid the erroneous repair of each 
chromosomal ends, each is capped with a repeating TTAGGG nucleotide sequence 
called the telomere.  Along with the shelterin complex, the telomere works to sequester 
the G-tail of chromosomal ends within the upstream double-stranded DNA.  This 
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prevents the activation of an ATM- or ATR-mediated DNA damage response (see 
section 1.6 – DNA Repair and PARP Inhibition).  In cases where either the telomere 
or subunits of the shelterin complex are removed, significant chromosomal end-end 
fusion is observed (Diotti and Loayza 2011; van Steensel, Smogorzewska, and de Lange 
1998; Capper et al. 2007; Veldman, Etheridge, and Counter 2004).   
 
Inhibition of a DNA damage response at chromosomal ends is not thought to be solely 
due to binding of the G-tail within the double-stranded section of the telomere.  Subunits 
of the shelterin complex have also been observed interacting with members of the ATM- 
and ATR-mediated signalling pathways which trigger DNA damage repair.  TRF2 can 
directly bind the ATM-kinase and prevent its phosphorylation, thus inhibiting the 
dissociation of inactive ATM dimers into active monomers (Karlseder et al. 2004).  This 
process blocks the phosphorylation of proteins by ATM-kinase, an action which is 
necessary for initiating the non-homologous end joining pathway (Okamoto et al. 2013).  
Meanwhile, POT1 prevents the activation of an ATR-mediated DNA damage response 
by coating the single-stranded DNA within the telomere.  This prevents the binding of 
replication protein A (RPA) which would otherwise activate the homologous 
recombination pathway (Denchi and de Lange 2007; Guo et al. 2007).   
 
1.1.5.2 The End-Replication Problem 
The end-replication problem occurs during the semi-conservative replication of DNA in 
preparation of cell division (see figure 1.3).  It exists due to the inability of cells to 
completely replicate all the DNA in a chromosome, with a small number of nucleotides 
lost from each chromosomal end after every cell division.  The reason for this lies 
primarily in the method used to replicate the lagging strand, whereby DNA cannot be 
copied in a 3′ to 5′ direction due to the nature of DNA polymerase.  While the leading 
strand is synthesised continuously in the 5′ to 3′ direction, RNA primers are necessary 
for the discontinuous synthesis of the lagging strand in the 5′ to 3′ direction.  These are 
added to the lagging strand and allow short sequences of complementary DNA, called 
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Okazaki fragments, to be synthesised.  The RNA primers are then degraded, the 
resulting gaps are filled, and the Okazaki fragments are ligated (Gilson and Geli 2007; 
O'Sullivan and Karlseder 2010; Burgers 2009). 
 
However, the terminal primer is added 70-100 nucleotides from the end of the 
chromosome.  This results in a section of the lagging strand not being synthesised, 
producing a single-stranded DNA overhang that will eventually become the G-tail (Chow 
et al. 2012; Lundblad 2012).  On the blunt-ended leading strand, resectioning of the 
chromosomal end produces the corresponding G-tail.    This is initiated by TRF2 which 
recruits the exonuclease Apollo, resulting in 5’ cleavage that is eventually blocked by 
POT1 binding (Wright et al. 1997; Arnoult and Karlseder 2015).  Chromosomal 
shortening occurs during each cell division, with telomeres acting to absorb the loss of 
nucleotides.  Without the telomere acting as a buffer, genomic DNA would instead be 
eroded which would result in the gradual loss of the most distal genes.  This periodic 
shortening of the telomere also contributes to the Hayflick limit and the eventual 
triggering of senescence (see section 1.1.5.4 - Senescence).  The rate of telomeric 
erosion varies depending on the cell type under examination and whether the cell is 
healthy or diseased, but is thought to be ~99bp/PD in healthy human fibroblasts.  In 
comparison, the rate of telomeric erosion in the fibroblasts of patients with Werner 
syndrome can be up to 355bp/PD (Baird et al. 2004).   
 
1.1.5.3 Telomeric Position Effect  
The telomeric position effect (TPE) is described as the epigenetic silencing of telomere-
proximal genes in relation to telomere length.  This mechanism is thought to involve the 
spread of telomeric heterochromatin towards the subtelomeric DNA, as telomere length 
increases. The result is a silencing of the telomere-proximal genes via the modification 
of chromatin structure.  Conversely, shorter telomeres lead to a more ‘open’ chromatin 
structure and the expression of these telomere-proximal genes (Doheny, Mottus, and 
Grigliatti 2008).   
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Little is known about this mechanism in humans, with most research being conducted in 
yeast cells, Saccharomyces cerevisiae.  Here, the mechanism involves the recruitment 
of silent information regulator (Sir) proteins to the telomere by Rap1 and Ku70/80.  A 
Sir2/Sir3/Sir4 complex is then responsible for initiating the formation of heterochromatin.  
The spread of this heterochromatin, towards the subtelomeric region, is catalysed by the 
histone deacetylase activity of Sir2 (Ottaviani, Gilson, and Magdinier 2008; Boulton and 
Jackson 1998).  It is thought that this mechanism can be regulated by the expression of 
Rif1 and Rif2, proteins which compete with the Sir proteins for binding at the telomere.  
This was demonstrated experimentally by the inactivation of the Rif proteins in 
Saccharomyces cerevisiae which increased the efficiency of TPE (Mishra and Shore 
1999).   
 
Although it has been demonstrated that TPE can occur in human cells in vitro, the extent 
to which TPE influences human gene expression is not known (Robin et al. 2014).  It has 
even been suggested that TPE does not occur in human cells, with experiments involving 
human fibroblasts failing to show a change in the expression of a reporter gene when 
telomere length was reduced from 25kb to 0.5kb (Sprung, Sabatier, and Murnane 1996).  
However, this has not stopped TPE from being suggested as the mechanism underlying 
various observations in several rare disease types (van Karnebeek et al. 2002; Inoue et 
al. 2002).   
 
New research has even been presented that suggests TPE is responsible for the 
increased transcription of hTERT when telomere length decreases significantly.   This 
involves the telomeric position effect over long distances (TPE-OLD), a process by which 
telomere length can change the expression of genes which are up to 10Mb away due to 
telomere looping (Robin et al. 2014).  It has been observed that longer telomeres result 
in the 5p sub-telomeric region co-localising with the hTERT locus, repressing its 
expression.  Contrary to this, telomeric shortening causes the hTERT locus to dissociate 
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from the subtelomeric region, triggering a change in chromatin structure which leads to 
increased hTERT expression and telomere lengthening (Kim et al. 2016).   
 
1.1.5.4 Senescence 
Cellular senescence is the process by which a normal cell ceases to divide, despite 
remaining metabolically active.  The Hayflick limit, described by Leonard Hayflick, 
defines the number of times a normal telomerase-deficient somatic cell can undergo 
division before becoming senescent.  This was identified as being 50±10 cell divisions 
by Hayflick (1965), but is thought to vary between 20-90 cell divisions depending on the 
age of the individual and the disease state of the cell (Rubin 2002).  The cause of this 
replicative limit is the telomere, whereby successive rounds of genomic erosion after cell 
division result in telomeric shortening.  When a telomere becomes critically shortened, 
the protective functions of the shelterin complex are lost and a DNA damage response 
is triggered.  This commonly occurs through the ATM- and ATR-mediated signalling 
pathways (see section 1.6 – DNA Repair and PARP Inhibition), both of which 
culminate in the activation of a p53-driven irreversible cell cycle arrest in G1 phase 
(Herbig et al. 2004).  It has been demonstrated that the loss of p53, p21 or Rb (but not 
p16) can allow fibroblasts to bypass the cell cycle arrest that would normally be triggered 
by the loss of a telomere (Wei et al. 2003).   
 
It is in this way that telomeres act as a ‘biological clock’ and confer a tumour suppressive 
mechanism.  Cells acquire genetic damage over time, with senescence triggered by 
telomeric shortening preventing abnormal cells from growing indefinitely (Shay and 
Wright 2000).  It is known that replicative senescence is triggered by the shortest 
telomere, not the average telomere length (Hemann et al. 2001).  Most cancers are able 
overcome this process (see section 1.4.1 – Abnormal Senescent-Signalling 
Pathways), dividing beyond the Hayflick limit by elongating telomeres and avoiding cell 
cycle arrest (Shay and Wright 2005).  However, it is not just cancerous cells that are able 
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to lengthen telomeres.  Most stem and germline cells contain telomerase, a 
ribonucleoprotein which elongates telomeres and allows cell division beyond the Hayflick 
limit without the accompanying genomic erosion. 
 
1.1.5.5 TERRA 
Although it was originally thought that telomeres were transcriptionally inactive, it is now 
known that they produce a long non-coding RNA.  Referred to as telomeric repeat-
containing RNA (TERRA), it is made up of varying stretches of 5′-UUAGGG-3′ repeats 
which are transcribed from the C-rich strand of the telomere (Xu et al. 2010).  The 
transcription of TERRA is performed by DNA-dependent RNA polymerase II and 
facilitated by TRF1 (Schoeftner and Blasco 2008).  It is thought that the primary function 
of TERRA is to act as a regulator of telomerase activity, blocking the enzyme’s active 
site by base pairing with the RNA template sequence within the TERC subunit (see 
section 1.2.1 – Telomerase Structure).  In this way, TERRA acts as a competitive 
inhibitor of telomerase and prevents the elongation of telomeres (Redon, Reichenbach, 
and Lingner 2010).   
 
However, this is not the only function of TERRA.  It can also alter the expression of genes 
involved with the innate immune system, including STAT1 and ISG15 (Hirashima and 
Seimiya 2015).  TERRA also directly interacts with the TRF2 Shelterin component, 
triggering the recruitment of the origin recognition complex (ORC1) which is responsible 
for the formation of heterochromatin at the telomeres (Deng et al. 2009).  It also recruits 
LSD1 to uncapped chromosomal ends, which in turn recruits MRE11 and triggers their 
erroneous repair by the NHEJ pathway (Porro, Feuerhahn, and Lingner 2014).  The 
depletion of TERRA is known to result in telomere dysfunction, aberrations in metaphase 
telomeres, and the loss of histone H3 K9me3 at the telomere (Deng et al. 2009).   
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1.2 Telomerase and Telomere Elongation 
The telomerase enzyme is responsible for adding GTTAGG repeats to the 3′ end of the 
telomere, thereby increasing the capacity of a cell to divide without triggering 
senescence.  Telomerase is not normally found in somatic cells, with its expression 
localised to stem and germline cells.  However, its routine expression in cancer has made 
it a novel therapeutic target.   
 
1.2.1 Telomerase Structure 
Telomerase is a reverse transcriptase which uses an internal RNA template to generate 
GTTAGG repeats at the telomeric ends.  It is mainly comprised of a telomerase reverse 
transcriptase (TERT) subunit and a telomerase RNA component (TERC) subunit (Wenz 
et al. 2001).  TERT forms the catalytic domain of telomerase and includes four conserved 
structural domains; the telomerase essential N-terminal (TEN), telomerase RNA binding 
(TRBD), reverse transcriptase (RT) and C-terminal extension (CTE) domains.  The TEN 
domain binds to the single-stranded DNA that makes up the telomeric G-tail, while the 
TRBD has been implicated in telomerase assembly and GTTAGG repeat processing 
(Sealey et al. 2010; Moriarty, Marie-Egyptienne, and Autexier 2004). 
 
Partially embedded within the TERT subunit is the non-coding RNA that makes up the 
TERC subunit.  It includes three extremely well-conserved domains; the template 
domain, the CR4/5 domain and the H/ACA domain.  The template and CR4/5 domains 
bind to the TERT subunit and are sufficient for the enzymatic activity of telomerase 
(Tesmer et al. 1999; Mitchell and Collins 2000).  While the H/ACA domain is not strictly 
necessary for telomerase activity in vitro, it binds to several telomerase-associated 
proteins; dyskerin, NOP10, NHP2 and GAR1 (Egan and Collins 2010).  These proteins 
form a complex which are responsible for the stability and accumulation of the TERC 
subunit in adult stem cells (Schmidt and Cech 2015).  The loss of functional dyskerin, 
NOP10 or NHP2 is known to cause dyskeratosis congenita, a rare disorder which is 
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characterised by a reduction in telomerase activity and significantly reduced telomere 
length (Mitchell, Wood, and Collins 1999; Walne et al. 2007; Vulliamy et al. 2008).   
 
1.2.2 Telomerase Mechanism of Action 
The telomerase TERC subunit contains a small RNA template sequence of 3′-AAUCCC-
5′ repeats which can be divided into an ‘alignment’ and ‘sequencing’ section (see figure 
1.4).  The alignment section binds to the 5′-TTAGGG-3′ repeats at the most distal end of 
the telomere, the single-stranded G-tail, to form a DNA/RNA hybrid.  The sequencing 
section is then used as a template with which to reverse transcribe 5′-GGTTAG-3′ onto 
the 3′-end of the telomere.  The RT domain of the TERT subunit is responsible for 
catalysing this reaction.  After the addition of these six nucleotides, the RNA template 
will dissociate from the telomere and reposition itself so that another round of telomeric 
synthesis can begin (Podlevsky and Chen 2012; Blackburn and Collins 2011).  This 
template-translocation step is thought to take place outside of the telomerase active site 
(Qi et al. 2012).  It has been demonstrated that each episode of elongation results in the 
addition of ~60 nucleotides or ~10 telomeric repeats (Zhao et al. 2011).   
 
1.2.3 Regulation of Telomerase Activity 
Specificity protein 1 (SP1) is a zinc finger transcription factor that upregulates the 
expression of the TERT gene.  It binds to one of the five CG-boxes that exist within the 
TERT promotor, with mutations in these CG-boxes significantly inhibiting promotor 
activity (Kyo et al. 2000).  c-MYC is also known to upregulate TERT expression by 
binding to the E-boxes that are present within the TERT promotor (Kyo et al. 2008).  
Many cancers that overexpress c-MYC are also known to have an increased TERT 
expression (Sagawa et al. 2001).  It is therefore unsurprising that c-MYC inhibition has 
been explored as a potential mechanism by which to target cancer cell immortality 
(Kretzner et al. 2011; Xu, Popov, et al. 2001).   
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Wilm’s tumour suppressor (WT1) can act as a negative regulator of TERT expression by 
binding to its promotor and inhibiting transcription (Oh et al. 1999).  Mad1 has also been 
identified as a repressor of TERT, binding to the E-boxes and preventing the association 
of c-MYC (Oh et al. 2000).  However, not all telomerase regulation takes place at the 
genetic level.  Telomeres produce a non-coding RNA called TERRA that is made up of 
5′-UUAGGG-3′ repeats (Azzalin and Lingner 2015).  They are transcribed from the C-
rich strand and have been shown in vitro to block the activity of telomerase by base-
pairing with the RNA template sequence within the TERC subunit.  As would be 
expected, cells with longer telomeres produce a greater number of transcripts 
(Schoeftner and Blasco 2008).  It has also been demonstrated that TERRA levels 
significantly decrease in S-phase, when telomerase is most active (Porro et al. 2010).  
The activity of telomerase outside of the S-phase is also thought to be negatively 
regulated by the C-terminus of Hsc70-interacting protein (CHIP).  This prevents nuclear 
translocation of TERT by dissociating the p21 chaperone, resulting in the degradation of 
TERT in the cytoplasm before it can reach the telomere (Lee et al. 2010).   
 
It has been demonstrated that the TERT subunit can directly bind to an 
oligonucleotide/oligosaccharide-binding (OB)-fold of the TPP1 shelterin subunit, 
delaying the release of telomerase from the telomere.  It is in this way that TPP1 can 
positively regulate telomere length, by increasing the number of telomeric repeats 
synthesised by telomerase before its dissociation (Zhong et al. 2012).  Other shelterin 
subunits, such as TRF1 and POT1, inhibit the binding of telomerase by competitively 
binding at the telomere (Smith and de Lange 2000; Lei, Podell, and Cech 2004).  
 
1.2.4 Alternative Lengthening of Telomeres 
Alternative lengthening of telomeres (ALT) is a process by which a cell can elongate its 
telomeres without the need for telomerase.  It is almost exclusive to abnormal cells, with 
around 10% of cancers thought to avoid senescence in this way (Henson et al. 2009).  
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So far, two potential mechanisms have been described by which ALT may occur.  The 
first involves the presence of telomeric DNA which exists separately from the 
chromosome.  This extrachromosomal telomere can be double-stranded and circular (t-
circles), partially single-stranded and circular (C-circles), or double-stranded and linear 
(Cesare and Griffith 2004; Nabetani and Ishikawa 2009).   
 
While t-circles have also been identified in ALT-negative cells, C-circles are thought to 
be localised almost exclusively to ALT-positive cells (Wang, Smogorzewska, and de 
Lange 2004; Henson et al. 2009).  It is thought that t-circles are produced by the telomeric 
trimming that occurs during 3′-overhang formation, a process which is known to rely on 
the HR proteins XRCC3 and NBS1 (Wang, Smogorzewska, and de Lange 2004).  How 
C-circles are generated is not known, but it has been proposed that they are simply 
formed by the nucleolytic degradation of t-circles (Cesare and Reddel 2010).   
 
Telomeric recombinational events act to join this extrachromosomal DNA to the 
telomere, allowing it to be used as a template for telomeric repeat synthesis (Dunham et 
al. 2000; Henson et al. 2002).  It has also been suggested that this mechanism can occur 
without the need for extrachromosomal DNA, with a chromosome utilising either its own 
telomere or the telomere of a second chromosome as a template (Muntoni et al. 2009).  
It was expected that this mechanism would be suppressed in normal cells by the action 
of TRF2 and POT1, subunits of the shelterin complex which are responsible for the 
formation of the telomeric t-loop structure that would insulate the chromosomal ends 
from this recombination-mediated synthesis.  However, experiments have demonstrated 
that preventing TRF2 expression triggers telomeric erosion and senescence in ALT-
positive cell lines (Stagno D'Alcontres et al. 2007).  This begs the question of whether 
subunits of the shelterin complex are either directly or indirectly involved in maintaining 
the ALT pathway? 
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The second ALT mechanism is considered to utilise unequal telomere sister chromatid 
exchange (T-SCE) and occurs during cell division.  Abnormal regions of unrepaired 
single-stranded DNA have been commonly observed within the telomeres of ALT-
positive cells (Nabetani and Ishikawa 2009).  These structural faults are unstable and 
result in the uneven separation of sister chromatids during anaphase.  As a 
consequence, one daughter cell will have a longer telomere length and increased 
replicative capacity when compared to the other daughter cell (Bailey, Brenneman, and 
Goodwin 2004).  However, this mechanism is thought to occur less frequently.  Not only 
is it known that the amplification of telomeric DNA occurs during ALT, but a population 
of cells that predominantly utilised the T-SCE mechanism would still eventually succumb 
to cellular senescence as no new telomere was being generated (Muntoni et al. 2009; 
Henson and Reddel 2010).  
 
Inactivating mutations in the alpha thalassemia/mental retardation syndrome X-linked 
(ATRX) and death-domain associated (DAXX) proteins have commonly been observed 
in ALT-positive cells (Bower et al. 2012).  ATRX is a chromatin-remodelling protein which 
contains both a zinc finger domain and an ATPase/helicase domain (Xue et al. 2003).  It 
colocalises with DAXX, a histone H3.3 chaperone, acting to incorporate this histone 
variant into telomeric chromatin (Goldberg et al. 2010).  It is in this way that ATRX is 
thought to supress ALT, condensing chromatin and inhibiting the formation of telomeric 
G-quadruplex structures which allow adjacent telomeres to be used as templates for 
telomere synthesis (Napier et al. 2015).  It is also thought that ATRX might facilitate the 
replication and resolution of G-quadruplex structures, preventing the HR-mediated repair 
of double-strand DNA breaks which can result in extrachromosomal DNA being ligated 
to the telomere (Amorim et al. 2016).  In this way, ATRX expression acts as a suppressor 
of ALT.  ATRX mutations have been identified 11% of high-risk neuroblastoma cases, 
resulting in telomere elongation via ALT (Valentijn et al. 2015).   
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1.3 Measuring Telomere Length 
Due to the repetitive sequences that make up the telomere, attempting to measure 
telomere length using a PCR-based technique had always proved to be difficult.  Of the 
techniques that have been developed, each varies in both accuracy and ability to 
recognise the telomere lengths of specific chromosomal ends.  
 
1.3.1 Terminal Restriction Fragment (TRF) Analysis 
TRF employs several restriction enzymes to digest non-telomeric DNA, whilst leaving 
the telomeres intact.  The resulting genomic fragments and telomeric DNA are resolved 
by agarose gel electrophoresis.  After southern blotting, a telomere-repeat containing 
labelled probe is used to hybridise to the telomeric repeats.  Due to the heterogeneous 
nature of telomere lengths between different chromosomes and cells, the labelled 
telomeric DNA produces a smear which can then be used to estimate average telomere 
length.  This estimation is based on comparisons to a ladder of standardised DNA sizes, 
as well as normalisation to a reference sample (Baird et al. 2003).   
 
The disadvantages of using this technique are numerous, with the most obvious being 
that the estimated average length generated is too inaccurate for subtle changes in 
telomere length to be observed.  Even if the accuracy of the estimation was improved, 
TRF analysis fails to distinguish between the different telomeric lengths of each 
chromosomal end.  Substantial quantities of DNA are also required for this technique, 
with the need for a minimum of 106 cells restricting its ability to be used when the genetic 
material being analysed is scarce.  Also, the quantity of probe that binds to a telomere is 
proportional to the length of that telomere.  This makes shorter telomeres difficult to 
detect and places a lower limit on the telomeric lengths that can be measured (Aubert, 
Hills, and Lansdorp 2012).   
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1.3.2 Quantitative Polymerase Chain Reaction (Q-PCR)  
A standard Q-PCR uses a machine which can perform PCR, but that also has the ability 
to detect fluorescence emitted by an excited fluorophore.  Fluorescent probes are added 
to the PCR mixture which fluoresce only when bound to a target DNA sequence.  As the 
PCR amplifies the target DNA sequence, greater quantities of probe can bind.  This 
produces a fluorescent signal that is in proportion to the quantity of target DNA present.  
The signal emitted is recorded after each round of PCR.  The quantity of template present 
at the start of the reaction can then be calculated, based on the intensity of the 
fluorescent signal throughout the reaction.   
 
For use in telomere length measurements, primers are designed to both the G-rich and 
C-rich strands of the telomere.  These primers have mismatches across their length 
which prevents primer dimerization.  For the first two rounds of PCR, a low annealing 
temperature is used to allow mismatched-primer binding to the telomere.  After this, a 
higher annealing temperature is used which ensures that the primers only bind to the 
amplified telomeric sequence (which contains the mismatched sequence) and not to the 
template telomeric sequence.  Telomere-specific fluorescent probes then bind to the 
amplified telomeric-sequence, allowing a signal to be recorded.  The longer the telomere, 
the greater the quantity of probe that binds and so the greater the fluorescent signal.  
Signal intensity is then compared to that of a standard gene, allowing the ratio of telomere 
signal vs standard gene signal intensity to be calculated.  This yields a value which 
correlates with that of a known average telomere length (Cawthon 2002).   
 
Although this technique requires less DNA to perform than TRF analysis, Q-PCR is not 
flawless and is also less accurate than TRF analysis (Aviv et al. 2011).  Small pipetting 
volume discrepancies between the wells containing the telomeric template and standard 
gene template samples are known to lead to significant errors.  For this reason, a revised 
technique called monochrome multiplex quantitative PCR (MMQ-PCR) was developed.   
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Table 1.1 – Table detailing the advantages and disadvantages of each telomere-
measurement technique (Nussey et al. 2014; Vera and Blasco, 2012) 
 
 
 Advantages Disadvantages 
 
 
 
 
 
TRF 
Analysis 
 
• Widely used 
• No special requirements 
 
• Estimated average telomere 
length is inaccurate.  Does not 
allow subtle changes in telomere 
length to be observed 
• Cannot distinguish between 
different telomeric ends 
• Substantial quantities of DNA 
required (106 cells) 
• Shorter telomeres are difficult to 
detect, relative to longer 
telomeres   
 
 
 
 
Q-PCR 
 
• High throughput  
• Little DNA required (50ng) 
 
 
• Small pipetting volume 
discrepancies can lead to 
significant errors 
• Cannot quantify individual length 
of individual telomeres 
 
 
 
 
 
 
Q-FISH 
 
• Allows telomere length of 
specific chromosomal ends 
in individual cells to be 
observed 
• Small number of cells 
required 
• Can be used to measure 
critically shortened 
telomeres 
 
 
• Low throughput/time consuming 
• Labour intensive 
• Cannot be used to observe non-
dividing cells (e.g. senescent)  
 
Dot Blot 
 
• Little DNA required (20ng) 
• Inexpensive 
 
 
 
• Requires a unique dye (SYBR 
Dx) which is costly 
 
 
 
STELA 
 
• Most accurate technique 
• Can be used to measure 
length of individual 
telomeres 
• Can be used to measure 
specific telomere ends 
• Requires little DNA (<2ng) 
  
 
• Use is restricted to several 
chromosomal ends: XpYp, 17p, 
2p, 11q and 12q 
• Labour Intensive 
• Low throughput 
• Bias towards shorter telomeres 
• Cannot detect telomeres >25kb 
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This measures the signal intensity of the telomeric template and standard gene template 
from a single PCR well.  Differences between the concentration of DNA in the telomeric 
template and standard gene template wells can then be avoided (Cawthon 2009).   
 
1.3.3 Fluorescence in Situ Hybridisation 
Quantitative fluorescence in situ hybridisation (Q-FISH) utilises fluorescently-labelled 
nucleic acid probes to visualise the individual telomeres of metaphase chromosomes.  
These probes carry a (CCCTAA)3 sequence that can hybridise to the telomeric regions 
of single-stranded denatured DNA.  A fluorescence microscope is then used to visualise 
the chromosomes, allowing the average telomere length to be estimated by comparing 
the intensity of the telomeric fluorescent signal to that of known standards (Lansdorp et 
al. 1996).  This technique carries a number advantages over both TRF and Q-PCR 
methods, such as the small number of cells required for analysis.  It also allows the 
telomere length of specific chromosomal ends to be observed, as well as providing a 
method of measuring the length of telomeres which are critically shortened (up to 0.2kb).  
However, the need for metaphase cells means that this technique cannot be employed 
for those populations which are senescent or otherwise unable to divide.  As well as this, 
Q-FISH is both labour and time intensive which allows only a small number of metaphase 
cells to be analysed (Aubert, Hills, and Lansdorp 2012; Montpetit et al. 2014).   
 
Several variations of this technique exist, the first of which is called high throughput 
quantitative fluorescent in situ hybridisation (HT Q-FISH).  Here, the fluorescent signal 
emitted by the telomeric probe is normalised to that of a second probe at the centromere.  
This automated process allows interphase cells to be analysed, as well as increasing the 
number of cells being examined and so improving the accuracy of the technique.  
However, neither specific telomeric ends or telomere-deficient chromosomes can be 
recognised using this method (Canela et al. 2007).   
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The second variation is called flow-FISH and requires that the cells being examined are 
in suspension.  This is in comparison to Q-FISH and HT Q-FISH, whereby the cells are 
fixed in place before the probe is added.  The cells are then treated with a fluorescently 
labelled (CCCTAA)3 probe, before being analysed using flow cytometry.  Although flow-
FISH is both fast and accurate, the need for a cell suspension limits its use to fresh blood 
samples.  Also, this technique cannot be used to analyse the telomere length of individual 
chromosomes.  As with all variations of FISH, the (CCCTAA)3 probe cannot bind to the 
telomeric variant repeats that exist within the most proximal end of the telomere.  This 
reduces the accuracy of the technique (Hultdin et al. 1998; Rufer et al. 1998; Aubert, 
Hills, and Lansdorp 2012).  
 
1.3.4 Dot Blot Analysis 
Dot blot analysis uses the intensity of a luminescent probe to calculate the average 
telomere length of a sample, based on the luminescent intensity of known standards.  
First, DNA from each sample is loaded onto a nylon membrane.  A dye called SYBR Dx 
is then added which fluoresces when bound to double-stranded DNA.  Fluorescent 
intensity is measured to identify the concentration of DNA bound to each part of the 
membrane.  After washing, a digoxigenin-labelled telomeric probe is added to the 
samples which then undergo a luminescent detection procedure.  An image is produced 
by exposing the samples to X-ray film.  Average telomere length is then calculated from 
the ratio of DNA concentration vs luminescent intensity (Kimura and Aviv 2011).   
 
1.3.5 Single Telomere Length Analysis  
Single telomere length analysis (STELA) is a single-molecule PCR-based technique 
which allows individual telomeres from specific chromosomal ends to be measured (see 
figure 1.5).  It uses a primer which contains a TTAGGG-binding sequence, as well as a 
unique nucleotide sequence.  By exploiting the fact that the G-rich strand of a telomere 
ends with a 3′ single-stranded overhang, this primer is able to anneal via complementary 
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base pairing before the chromosome has undergone the dissociation stage of PCR.  
Ligation of the primer to the C-rich telomeric end then endows the telomere with a unique 
sequence at its most distal point.  Combined with a unique sequence within the 
subtelomeric region, this provides two primer-binding sites which flank the telomere and 
generate a targeted PCR.  The sequence of the subtelomeric primer can also be 
changed, allowing STELA to be performed at specific telomeric ends.  After this PCR 
step, the products are resolved using agarose gel electrophoresis and imaged by a 
southern blot procedure which utilises a telomere-specific radiolabelled probe (Baird et 
al. 2003).   
 
STELA has the advantage of being one of the most accurate techniques for measuring 
telomere length, as well as being able to analyse individual chromosomal ends and 
critically shortened telomeres.  STELA can also be carried out when starting material is 
scarce, with less than 105 cells necessary to generate a mean telomere length 
measurement.  However, it is limited only to those chromosomal ends for which a specific 
sub-telomeric primer can be designed.  The sub-telomeric regions of many 
chromosomes do not contain a unique binding site and so STELA is currently limited to 
the XpYp, 17p, 2p, 11q and 12q chromosomal ends (Britt-Compton et al. 2006).   
 
There is also the issue that the analysis of a single chromosomal end may not be 
representative of all the telomeres within a cell.  While this could be mitigated by 
measuring the telomere length at multiple chromosomal ends, STELA is a very labour-
intensive process and this option would not be realistic for a large number of samples.  
A further limitation is that telomeres larger than 25kb cannot be detected using STELA, 
creating a bias towards the measurement of shorter telomeres (Aubert, Hills, and 
Lansdorp 2012; Montpetit et al. 2014; Nussey et al. 2014; Martin-Ruiz et al. 2015). 
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1.4 Telomeres and Disease  
As with any tumour suppressive mechanism, the absence of a functional telomere-driven 
senescent pathway has been implicated in cancer.  Critically shortened telomeres are 
thought to play a role in chromosomal fusion and rearrangement, driving progression of 
the disease.  Meanwhile, unregulated lengthening by telomerase is known to be partially 
responsible for the immortality of cancer cells.   
 
1.4.1 Abnormal Senescent-Signalling Pathways 
Telomeric shortening acts to limit the replicative capacity of a cell, activating the ATR 
and ATM signalling pathways once a critical length is reached.  This triggers cellular 
senescence, a process which exists to prevent the unrestrained growth of abnormal 
cells.  Defects in these pathways diminish the effectiveness of the cell cycle checkpoints, 
as well as contributing to the continued division of a cell beyond the Hayflick limit (Chin 
et al. 1999).  Due to the complexity of these pathways, inactivation can occur via several 
mechanisms.  The loss of a functional p53 protein is possibly the most well characterised 
of these, with mutations in the TP53 gene thought to be present in around 50% of all 
cancers (Merkel et al., 2017).   
 
Disruption of the ATR signalling pathway alone may also be enough to lead to the 
formation of cancer, with ATR+/- mice displaying a slight increase in tumour incidence 
(Brown and Baltimore 2000).  The complete loss of ATR in adult mice also results in 
stem cell depletion, limited capacity for tissue renewal, and an ageing phenotype 
(Ruzankina et al. 2007).  In humans, disruption of this signalling pathway is known to 
cause Seckel syndrome, a disease characterised by dwarfism and intellectual disability 
(Alderton et al. 2004).  A limited number of cases have also presented with leukaemia or 
lymphoma, leading to the suggestion that this syndrome may be associated with a 
slightly increased risk of developing cancer (Hayani et al. 1994; Chanan-Khan et al. 
2003).  
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The importance of ATM signalling in response to critically shortened telomeres is 
highlighted by the disease ataxia-telangiectasia.  This is caused by a failure to produce 
a functioning ATM protein, resulting in cells being unable to efficiently respond to DNA 
damage.  As well as being characterised by neurodegeneration and a weakened immune 
system, the disease is also known to confer a sensitivity to ionising radiation and a 
significantly increased risk of developing cancer (Chun and Gatti 2004). 
 
1.4.2 Critically Shortened Telomeres 
In the absence of a functioning senescent pathway, the telomeric erosion that occurs 
during cell division can result in the loss of the telomere and the protection that it confers.  
This often proves disastrous for genomic stability, with the ends of chromosomes now 
being recognised as double-strand DNA breaks (Murnane 2006).  Erroneous repair can 
occur via the non-homologous end joining pathways (see section 1.6.2.2 – Non-
Homologous End Joining), causing two ends to be fused together and creating a 
dicentric chromosome (Capper et al. 2007).  This structure is inherently unstable, 
eventually breaking apart in an unequal manner.  As the new chromosomal ends 
produced by this break are also unprotected, the response by the various DNA repair 
mechanisms is a further attempt at fusion.  These cycles of breakage-fusion-bridge are 
known to cause genomic rearrangements that help to drive cancer progression 
(Maciejowski and de Lange 2017).   
 
Dicentric chromosomes, generated during a telomere driven crisis, have also been 
implicated in chromothripsis.  This is a process by which localised areas within a 
chromosome shatter, with the associated repair of these regions resulting in the 
significant rearrangement and deletion of genetic material (Ernst et al. 2016).  The 
process by which this occurs begins with the joining together of two telomere-deficient 
chromosomal ends.  During anaphase, the resulting dicentric chromosome is pulled to 
opposite ends of the cell, spanning the gap between the two daughter nuclei.  To resolve 
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this, the exonuclease TREX1 generates single-stranded DNA within the chromatin 
bridge which eventually causes it to break. Each half of the dicentric chromosome then 
retreats to a corresponding daughter nuclei, where an attempt is made to repair the 
shattered ends by ligating random DNA segments (Maciejowski et al. 2015). 
 
Dyskeratosis congenita (DKC) is an example of a condition which is characterised by 
critically shortened telomeres and genetic instability.  Its symptoms may include a 
progressive bone marrow failure, lacey reticular pigmentation, aplastic anaemia, 
dystrophy of the nails and oral leukoplakia (Alter et al. 2007).  It is the result of several 
possible defects in telomere maintenance biology, with the specific cause of DKC 
partially dependent on the mode of inheritance.  For example, X-linked DKC is due to 
mutations in the DKC1 gene which encodes dyskerin, a telomerase-associated protein 
which works as part of a protein complex to stabilise TERC.  Autosomal dominant DKC 
is caused by mutations in either the TERT or TERC subunits of telomerase, or the TIN2 
subunit of the shelterin complex (Savage et al. 2008).  While autosomal recessive DKC 
is due to mutations in TCAB1, a protein which is responsible for localising telomerase to 
Cajal bodies (Batista et al. 2011).  In any case, the result is an inability of stem cells to 
elongate telomeres, leading to critically shortened telomeres and chromosomal 
instability.  DKC is also associated with an increased risk of developing cancer, most 
frequently acute myeloid leukaemia and squamous cell carcinomas (Alter et al. 2009). 
 
Critically shortened telomeres have been observed in a significant number of cancers.  
Colorectal, prostate, renal and bladder cancers have all been shown to express a mean 
telomere length that was significantly shorter than healthy cellular controls (Roger et al. 
2013; Sommerfeld et al. 1996; Mehle, Ljungberg, and Roos 1994; Broberg et al. 2005).  
Studies into the dynamics of telomere length in breast cancer and chronic lymphocytic 
leukaemia (CLL) have not only demonstrated that mean telomere length is reduced in 
the diseased cells, but that the extent of telomeric shortening can be used as a prognostic 
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indicator.  In both breast cancer and CLL, a shorter mean telomere length correlates with 
a reduced median overall survival (Simpson et al. 2015; Strefford et al. 2015).   
 
This is unsurprising, as telomeric shortening has also been observed to correlate with an 
increased frequency of chromosomal end-end fusion in CLL.  Fusion events were only 
observed in those patients whose mean telomere length fell below a 3.81kb threshold, 
with cells below this threshold being at a significantly increased risk of undergoing a 
telomere-driven crisis (Lin et al. 2014).  For most cancerous cells, the chromosomal 
rearrangements that underpin crisis will be catastrophic.  However, the potential exists 
for a small number of cells to survive this process and escape from crisis with a survival 
advantage (Jones et al. 2014).  Although this can include the further disruption of 
apoptotic mechanisms, one of the most important and pervasive stages of cancer 
development is the reactivation of telomerase. 
 
1.4.3 Unregulated Telomeric Lengthening 
Lung cancer, breast cancer and multiple myeloma are just a small number of 
malignancies where telomerase is known to be reactivated (Albanell et al. 1997; Hayani 
et al. 1994; Wu et al. 2003).  In total, telomerase is thought to be expressed in around 
85% of all cancers (Buseman, Wright, and Shay 2012).  This is unsurprising given that 
gain of the 5p chromosomal arm is one of the most common genetic events that occurs 
in the early stages of solid tumour development, with the 5p arm being host to the gene 
encoding the TERT subunit of telomerase (Rooney et al. 1999; Cao, Bryan, and Reddel 
2008; Kang et al. 2008).  Translocations that place enhancer elements close to the TERT 
locus have also been identified, with 21% of all high-risk neuroblastoma cases thought 
to involve 5p15.33 rearrangements (Peifer et al. 2015).  Telomerase reactivation is also 
frequently accompanied by mutations in the TERT promoter, leading to its upregulation 
(Vinagre et al., 2013).  Telomeres in the remaining 15% of cancers are elongated using 
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ALT.  Regardless of which mechanism is utilised, the result is the immortalisation and 
limitless replicative capacity of cancer cells (Mocellin, Pooley, and Nitti 2013).   
 
Due to the prevalence of telomerase reactivation in cancer, as well as the fact that 
telomerase is not normally expressed in healthy somatic cells, telomerase inhibition as 
a selective cancer treatment has become a significant area of research.  Imetelstat is a 
promising example of an inhibitor which binds to the TERC subunit and supresses the 
reverse transcriptase activity of telomerase.  Phase III clinical trials in pancreatic cancer, 
as well as phase II clinical trials in multiple myeloma, leukaemia, melanoma, breast 
cancer and lung cancer have recently been completed (Buseman, Wright, and Shay 
2012; Barata, Sood, and Hong 2016; Arndt and MacKenzie 2016).  However, a failure to 
improve progression free survival in several of these trials suggests that telomerase 
inhibition may not always be the most effective approach (Chiappori et al. 2015; Tefferi 
et al. 2015).   
 
Telomerase-targeted immunotherapy has also been explored as a method of preventing 
telomere elongation in cancer.  This process involves sensitising the patient’s own 
immune system against cells which express TERT peptides as a surface antigen.  The 
result should be an expansion of cytotoxic T lymphocytes which selectively target the 
telomerase-producing cancerous cells (Khalil et al. 2016).  Promising phase II clinical 
trials have been described, with each targeting a number of solid tumours (Kotsakis et 
al. 2012; Ellebaek et al. 2012; Fenoglio et al. 2013).  Unfortunately, disappointing phase 
III clinical trials in pancreatic cancer and phase II clinical trials in hepatocellular 
carcinoma have also been described, suggesting that telomerase inhibition may not be 
the universal cure that was hoped for (Middleton et al. 2014; Greten et al. 2010).   
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1.5 Multiple Myeloma 
Multiple myeloma (MM) is a disease characterised by the accumulation of abnormal 
plasma cells within the bone marrow.  It is commonly preceded by a related disorder 
which is known as monoclonal gammopathy of undetermined significance (MGUS).  The 
first stages of MM are asymptomatic, eventually becoming symptomatic as the disease 
progresses.  In more aggressive cases, MM may evolve into plasma cell leukaemia 
(PCL).   
 
1.5.1 Plasma Cell Development  
The plasma cell is the antibody-producing, terminally differentiated form of the B-
lymphocyte.  Maturation begins with the development of an immature B cell from the 
hematopoietic stem cells that reside within the bone marrow.  Here, B cells undergo 
V(D)J recombination to produce the immunoglobulin heavy (Variable-Diversity-Joining) 
and light (Variable-Joining) chains.  Selection occurs between 44 variable, 27 diversity, 
and 6 joining gene segments, resulting in roughly 3x1011 possible antibody combinations.  
This process, along with somatic hypermutation which drives a controlled process of 
mutation within the variable-region genes, acts to generate a high-affinity 
immunoglobulin binding site.  B cells are tested for autoreactivity against the host, with 
those cells that elicit a response being subject to apoptosis.  Meanwhile, unresponsive 
cells migrate from the bone marrow to the spleen and lymph nodes.  In rare cases, 
autoreactive or low-affinity B cells may escape the bone marrow, but are unable to 
mature further and are eventually destroyed (Shapiro-Shelef and Calame 2005; 
Halverson, Torres, and Pelanda 2004).   
 
Immature B cells are activated in either a T cell-independent or T cell-dependent manner.  
The independent route involves a subset of B cells called marginal zone (MZ) B cells, 
which are activated after coming into direct contact with a specific antigen.  This causes 
the MZ B cells to undergo class switching, a process by which the constant regions of 
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the immunoglobulins produced by the B cells switch from IgM and IgD to either IgA, IgG 
or IgE (Stavnezer, Guikema and Schrader, 2009).  The B cells also undergo rapid 
proliferation and antibody secretion, forming a primary response which lasts for around 
14 days (Lopes-Carvalho and Kearney 2004; Smith et al. 1996).  Meanwhile, T cell-
dependent activation is a slower process that produces a more targeted and long-term 
response.  After encountering an antigen, the B cell internalises and degrades it.  Antigen 
peptides are then displayed on the surface of the B cell, awaiting recognition by T helper 
(TH) cells.  Upon sensing the MHCII-bound peptide, the TH cell releases the interleukins 
IL-2, IL-4, IL-10 and IL-21.  This, along with contact between the CD40 protein on the B 
cell and CD40 ligand on the T cell, causes the B cell to become activated (Oracki et al. 
2010; Kuchen et al. 2007).   
 
The activated B cells proliferate, with a small number forming germinal centres within the 
spleen and lymph nodes.  The remaining B cells terminally differentiate to form short-
lived, antibody-secreting plasma cells (Allen, Okada, and Cyster 2007).  In the germinal 
centres, activated B cells undergo further rounds of proliferation, as well as affinity 
maturation.  This process involves somatic hypermutation of the immunoglobulin variable 
region and clonal selection, resulting in the formation of plasma cells which secrete a 
high-affinity antibody against the antigen (Jacob et al. 1991).  This process also produces 
memory B cells which remain dormant until being activated by the original antigen, 
facilitating the rapid production of high-affinity antibody-producing plasma cells 
(Shlomchik and Weisel 2012).   
 
1.5.2 Monoclonal Gammopathy of Undetermined Significance  
MGUS is an asymptomatic disorder, characterised by the presence of abnormal plasma 
cells within the bone marrow.  Non-functioning antibodies can also be detected within 
the blood serum, a product of the clonal populations of these abnormal cells.  Known as 
paraproteins or M proteins, these antibodies can either be IgA, IgD, IgE, IgG, IgM or free 
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light chains (Dispenzieri et al. 2009).  Diagnostic criteria for MGUS includes the presence 
of less than 10% clonal plasma cells within the bone marrow; a paraprotein concentration 
of less than 30g/L in the blood serum; and an absence of hypercalcaemia, renal 
insufficiency, anaemia, bone lesions and amyloidosis that can be attributed to the 
abnormal plasma cells (Rajkumar et al. 2014).   
 
As MGUS is asymptomatic, treatment is not usually advised.  However, it is necessary 
to continually monitor the disease for the remaining life of the patient.  This requires a 
measurement of the serum paraprotein concentration every 2-3 years for low-risk MGUS 
(defined as having a serum paraprotein concentration <15g/L), or every 6 months for 
intermediate- and high-risk MGUS (defined as either an IgA- or IgM-producing subtype, 
or having a serum paraprotein concentration >15g/L) (Kyle et al. 2010).  Monitoring is 
necessary due to the possibility of progression to either MM or Waldenstrom’s 
macroglobulinemia (WM).  The risk to a patient that their MGUS will develop into MM is 
around 1% per year for that individual.  This raises to 1.5% per year for those individuals 
harbouring the IgM subtype.  Meanwhile, approximately 1.5% of MGUS patients 
harbouring the IgM-subtype will develop WM, a lymphoproliferative disorder which is 
characterised by lymphadenopathy and elevated serum globulin levels (International 
Myeloma Working 2003; Ghobrial, Gertz, and Fonseca 2003).   
 
It is estimated that around 3.2% of people over the age of 50 have MGUS (Wadhera and 
Rajkumar 2010).  In fact, one of the greatest risk factors for developing MGUS is aging. 
The average age at diagnosis is 70, with less than 2% of all cases being linked to people 
younger than 40 (Therneau et al. 2012; Cheema et al. 2009).  Gender also plays a role, 
with men being slightly more likely than women to develop MGUS.  Other risk factors 
include race, family history and environmental factors such as radiation and pesticide 
exposure (Landgren et al. 2006; Vachon et al. 2009; Iwanaga et al. 2009; Landgren et 
al. 2009).   
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1.5.3 Smouldering Multiple Myeloma 
Although MGUS does not always develop into MM, it is thought that MM almost always 
develops from cases of MGUS (Landgren et al. 2009).  MM can be categorised as either 
smouldering (asymptomatic) or symptomatic.  Smouldering MM shares a significant 
number of its characteristics with MGUS, but is identified as having a greater plasma cell 
presence within the bone marrow and larger quantities of paraprotein within the blood 
serum.  Officially, the diagnostic criteria for smouldering MM includes the presence of 
between 10-60% plasma cells within the bone marrow; and/or a paraprotein 
concentration >30g/L in the blood serum; and an absence of hypercalcaemia, renal 
insufficiency, anaemia, bone lesions and amyloidosis that can be attributed to the 
abnormal plasma cells (Rajkumar et al. 2014).  The risk of progression to malignancy is 
also greater than MGUS, with each smouldering MM patient having around a 10% 
chance of developing symptomatic MM per year in the first five years following diagnosis.  
After this, the risk of progression diminishes to 3% per year for the next five years, 
followed by 1% per year thereafter (Kyle, Remstein, et al. 2007).   
 
The risk of smouldering MM progression can be subcategorised as either low, 
intermediate, or high.  This is based on three factors; plasma cell bone marrow infiltration 
>10%, paraprotein concentration >30g/L, and a serum free light chain ratio <0.125 or >8.  
Low risk patients display one of these factors, intermediate risk patients display any two 
of these factors, while high risk patients display all three factors (Dispenzieri et al. 2008).  
However, an ultra-high risk group of smouldering MM patients have also been identified 
which demonstrate a plasma cell bone marrow infiltration >60%.  In these cases, it is 
recommended that patients begin treatment immediately, regardless of whether 
symptoms are present (Rajkumar, Larson, and Kyle 2011).   
 
Other than this, treatment for smouldering MM is not normally recommended.  The 
standard procedure is to continue monitoring plasma cell and paraprotein levels, as well 
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as blood calcium and creatinine values which measure bone loss and renal function 
respectively.  X-rays are also performed to determine whether bone lesions are present.   
Measurements should continue for 2-3 months to determine baseline values.  If stable, 
monitoring can be repeated every 3 months thereafter (Kyle et al. 2010).  However, 
recent phase III clinical trials have suggested that earlier treatment of high risk 
smouldering MM with lenalidomide and dexamethasone has a positive impact on overall 
patient survival when compared to observation alone (Mateos et al. 2016).   
 
 
1.5.4 Symptomatic Multiple Myeloma 
Symptomatic MM is primary differentiated from smouldering MM by the presence of 
organ damage, clonal bone marrow plasma cell infiltration ≥60%, serum free light chain 
(SFLC) ≥100mg/L, or more than one focal lesion ≥5mm in size on a magnetic resonance 
imaging (MRI) scan.  As MM is incurable, the onset of symptoms usually confers a 
heterogeneous but poor prognosis, with 25% of individuals living less than 3 years 
(Rajkumar et al. 2010).  Even with treatment, the 5-year overall survival rate was shown 
to be 82% for low risk MM and 40% for high risk MM (Palumbo et al. 2015).   
 
1.5.4.1 Bone Pain and Lesions 
Symptoms usually begin with lower back pain, one of the most common symptoms which 
is a result of the loss of bone density in the spine and ribs.  Bone reabsorption is 
facilitated by osteoclasts whose activity is stimulated by the presence of MM cells in the 
bone marrow (Roodman 2004).  These abnormal plasma cells produce macrophage 
inflammatory protein-1α (MIP-1α), a chemokine which has been shown to promote 
osteoclastogenesis (Choi et al. 2000).  MM cells also interact with bone marrow stromal 
cells via the integrin VLA-4, resulting in the release of receptor activator of NF-κB ligand 
(RANKL) from these stromal cells (Giuliani et al. 2001).  RANKL directly promotes 
osteoclastogenesis while simultaneously inhibiting osteoclast apoptosis.  MM cells also 
inhibit the production of a decoy receptor for RANKL called osteoprotegerin (OPG) by 
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osteoblastic cells, further increasing the activation of osteoclasts and the shift from bone 
formation to bone reabsorption (Giuliani, Colla, and Rizzoli 2004; Qiang et al. 2008). 
 
For this reason, serum calcium levels are an important indicator of MM progression.  
Hypercalcaemia (>2.75mmol/L serum calcium) is primarily treated by administering 
bisphosphonates which encourage osteoclast apoptosis (Kyle, Yee, et al. 2007).  MRI 
scans are also commonly performed to observe the presence and severity of bone 
lesions that result from the breakdown of bone by osteoclasts (Rajkumar et al. 2014).  In 
severe cases, compression fractures can cause chronic pain, deformity or poor mobility, 
and may necessitate repair using a technique known as kyphoplasty.  This fills the 
fracture with a viscous polymethylmethacrylate cement which has been shown to reduce 
the pain associated with vertebral compression fractures.  However, there is a risk of the 
procedure causing nerve injury, spinal cord compression or paralysis (Berenson et al. 
2011).  
 
1.5.4.2 Renal Failure  
Renal impairment is thought to affect around 50% of MM patients during the course of 
their disease (Dimopoulos et al. 2010).  It is measured using serum creatinine levels and 
defined as having a creatinine concentration greater than 2mg/dL (Dimopoulos et al. 
2008).  Renal impairment is caused by the excess free light chains that are produced by 
abnormal plasma cells, overwhelming the ability of the kidneys to filter out this protein 
from the blood (Mead et al. 2004).  The free light chains bind to Tamm-Horsfall 
glycoproteins in the loop of Henley, forming aggregates that obstruct distal parts of the 
nephron (Ying and Sanders 2001).  In a small number of patients, increased 
concentrations of free light chains in the serum can lead to light-chain amyloidosis.  This 
is characterised by the deposition of monoclonal light chain fibres within various tissues 
throughout the body.  Deposits of these fibres in the kidneys can contribute to renal 
failure (Dimopoulos et al. 2010).  Around 10% of MM patients require long-term dialysis 
(Yadav et al. 2015). 
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Dialysis is commonly used to treat renal impairment, acting to remove excess free light 
chains as well as replacing kidney function after failure (Hutchison et al. 2007).  As 
hypercalcaemia is also known to negatively impact renal function, reducing calcium 
concentrations in the blood though hydration and bisphosphonate administration is also 
recommended (Dimopoulos et al. 2008).  However, bisphosphonates themselves may 
cause further renal impairment and so an assessment of the risk to the patient must first 
be made (Faiman et al. 2011).  The effective management of renal impairment 
significantly improves the overall survival of patients with MM.  Unfortunately, patients 
who present with renal impairment at diagnosis are known to have an inferior survival 
when compared to those who do not (Gonsalves et al. 2015).   
 
1.5.4.3 Anaemia and Infection 
The growth of abnormal plasma cells throughout the bone marrow reduces the quantity 
of healthy stromal cells.  This leads to a decrease in the production of red blood cells, 
resulting in anaemia (Mittelman 2003).  However, it has also been observed that hepcidin 
is upregulated in cases of MM.  This protein inhibits ferroportin, an iron export channel 
which is responsible allowing iron to pass into the bloodstream from the interior of a cell.  
While the cause for this increase in hepcidin has yet to be fully elucidated, it is 
nevertheless thought to play a role in the cellular retention of iron and the development 
of anaemia during MM (Sharma et al. 2008; Maes et al. 2010).  The definition of anaemia 
in the case of MM is either a haemoglobin value >20g/L below the lower limit of normal, 
or simply <100g/L (Rajkumar et al. 2014).    It is thought that anaemia presents in around 
73% of all MM cases, resulting in the characteristic tiredness and weakness of the 
disease (Kyle et al. 2003).   
 
As well as disrupting red blood cell production, immunodeficiency is also a common 
feature of MM.  The immunodeficiency in MM is not due to a lack of neutrophils but is 
due to a more global effect on function of B and T cells, normal antibody production, 
dendritic cells, antigen presentation and function of innate immune cells. There are 
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increases in a range of immunosuppressive cytokines, inhibitory signalling pathways and 
an increase in immunosuppressive cells.  This increases the risk of developing infections, 
with one UK study suggesting that bacterial infection directly causes 45% of all MM 
deaths observed within 6 months of diagnosis (Augustson et al. 2005).  Further studies 
have observed that the risk of infection in MM patients, particularly from pneumonia and 
septicaemia, is seven times higher than in matched controls (Blimark et al. 2015).  It has 
been suggested that recurrent infections may play a role in promoting the proliferation 
and survival of abnormal plasma cell populations.  This is due to the presence of toll-like 
receptors on the surface of B cells, membrane-spanning proteins which act as sensors 
for the innate immune system and initiators of the adaptive immune system.  The 
expression of these receptors, particularly that of toll-like receptors 4 and 9, is known to 
be upregulated in MM when compared to the plasma cells of healthy donors (Bohnhorst 
et al. 2006).  Activation of these toll-like receptors during infection is thought to promote 
abnormal plasma cell proliferation and the avoidance of serum-deprivation induced 
apoptosis (Xu et al. 2010).  
 
1.5.5 Plasma Cell Leukaemia  
Plasma cell leukaemia (PCL) is a lymphoproliferative disorder which can either occur de 
novo, or evolve from an existing case of MM.  It is characterised by the significant 
presence of abnormal plasma cells within the circulating blood, and officially defined as 
having >2x109 plasma cells/litre of blood or >20% plasma cells in the peripheral blood 
differential white cell count (Kyle et al. 2003).   Although it is estimated that up to 4% of 
MM patients will eventually develop PCL, it is highly aggressive and confers an overall 
median survival of 2-15 months depending on the chemotherapeutic regimens used 
during treatment (Jimenez-Zepeda and Dominguez-Martinez 2009).  Many of the 
symptoms displayed are identical to that of MM; bone lesions, hypercalcaemia, renal 
impairment and anaemia.  However, around 11% of PCL cases that develop from MM 
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will present with hepatomegaly (enlargement of the liver), while 8% of cases will present 
with splenomegaly (enlargement of the spleen) (Tiedemann et al. 2008).   
 
1.5.6 MM Staging Systems 
Two different staging systems exist which are used to measure the extent of MM 
progression.  The oldest of these was developed in 1975 by Brian Durie and Sydney 
Salmon and is known as the Durie-Salmon staging system.  This categorises patients by 
analysing the concentrations of serum calcium, haemoglobin, paraprotein and urinary 
light chains (Durie and Salmon 1975).  A competing model was developed in 2005 which 
is known as the international staging system (ISS) for MM.  This simply measures 
serum β2 microglobulin and albumin levels (Greipp et al. 2005).  An updated version of 
the ISS was released in 2015 which sought to improve prognostic resolution by 
combining these measurements with the presence or absence of high-risk chromosomal 
abnormalities, as well as measurements of serum lactate dehydrogenase concentration 
(Palumbo et al. 2015).   
 
1.5.6.1 The Durie-Salmon Staging System  
Although the Durie-Salmon staging system is still employed as a method of predicting 
an individual’s prognosis, its use has become limited since the development of the ISS 
for MM.  Patients are categorised as either stage I, II, or III (see Table 1.2).  The main 
drawback of the Durie-Salmon staging system is the requirement to locate and identify 
lytic bone lesions from X-rays, a process which can be subjective and lacks sensitivity.  
To combat this, an updated system was published in 2003 (Durie-Salmon PLUS) which 
utilises magnetic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose positron 
emission tomography (FDG-PET) to more accurately quantify the number of bone 
lesions present (Durie et al. 2003).  Measurements of haemoglobin, serum calcium and 
paraprotein concentrations are also substituted for creatinine levels, allowing each stage 
to be further subdivided into either A or B (see Table 1.3).   
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Table 1.2 – Staging Criteria for the Durie-Salmon staging system 
 
 
Table 1.3 – Staging Criteria for the Durie-Salmon PLUS staging system 
 
 
 
 
 
Stage I 
 
All of the following must be present: 
• Haemoglobin >10g/dL 
• Serum calcium <12mg/dL 
• No evidence of bone lesions 
• IgG paraprotein <5g/dL or IgA paraprotein <3g/dL or urine light 
chain M-component on electrophoresis <4g/24 hours 
 
 
Stage II 
 
Neither stage I or III 
 
 
 
 
Stage III 
 
One or more of the following must be present:  
• Haemoglobin <8.5g/dL 
• Serum calcium >12mg/dL 
• Three or more bone lesions 
• IgA paraprotein >5g/dL or IgG paraprotein >7g/dL or urine light 
chain M-component on electrophoresis >12g/24 hours 
 
Stage I A 0 – 4 bone lesions; <2mg/dL serum creatinine 
B 0 – 4 bone lesions; >2mg/dL serum creatinine 
Stage II A 5 - 10 bone lesions; <2mg/dL serum creatinine 
B 5 - 10 bone lesions; >2mg/dL serum creatinine 
Stage III A >20 bone lesions; <2mg/dL serum creatinine 
B >20 bone lesions; >2mg/dL serum creatinine 
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Table 1.4 – Staging Criteria for the MM ISS 
 
Table 1.5 – Staging Criteria for the Revised ISS 
 
 
 
Stage I 
 
β2 microglobulin < 3.5mg/dL and albumin >3.5g/dL 
 
 
 
Stage II 
 
Either: 
• β2 microglobulin < 3.5mg/dL and albumin < 3.5g/dL 
• β2 microglobulin between 3.5 and 5.5mg/dL 
 
 
Stage III 
 
 
β2 microglobulin > 5.5mg/dL 
 
 
 
R-Stage I 
 
All of the following criteria must be met: 
• ISS stage I 
• No high-risk chromosomal abnormalities present 
• Normal LDH 
 
 
R-Stage II 
 
Neither R-ISS stage I or III 
 
 
 
R-Stage III 
 
All of the following criteria must be met: 
• ISS stage III 
• Presence of high-risk chromosomal abnormalities 
• High LDH 
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Studies comparing the original and updated systems have found that patients stratified 
using Durie-Salmon PLUS are commonly upstaged if the original Durie-Salmon staging 
system is used instead.  Fechtner et al. (2010) observed that only 45% of a cohort of 
MGUS and MM patients remained in the same staging category when analysed using 
both systems.  This was thought to be due to the removal of important clinical data 
(haemoglobin, serum calcium and paraprotein concentrations) in the Durie-Salmon 
PLUS system which is known to hold significant prognostic information.  However, a 
small number of patients would also have been upstaged when using Durie-Salmon 
PLUS due to the greater sensitivity of MR imaging in detecting bone lesions when 
compared to X-rays.     
 
1.5.6.2 The International Staging System for MM 
The international myeloma working group, a collection of IMF scientific advisors, devised 
the ISS in 2005.  It is more cost-effective than the Durie-Salmon staging system, relying 
on two blood tests to measure the concentration of serum β2 microglobulin and albumin.  
β2 microglobulin is a component of the MHC class I molecule, with higher concentrations 
reflecting a larger tumour mass and a greater impairment of renal function.  Meanwhile 
a reduction in the concentration of serum albumin is caused by cytokine release from the 
myeloma microenvironment.  Again, patients are categorised as either stage I, II or III 
(see Table 1.4).   
 
Median overall survival for each stage was found to be 62 months, 44 months and 29 
months respectfully (Greipp et al. 2005).  A revision to the ISS in 2015 sought to include 
chromosomal abnormalities in the staging criteria, as well as measurements of serum 
lactate dehydrogenase (LDH).  High-risk chromosomal abnormalities included the 
presence of del(17p), translocation t(4;14) or translocation t(14;16).  The revised ISS 
patients were also categorised as either R-stage I, II or III (see Table 1.5). 5-year overall 
survival rates for R-stage I, II and III patients were 82%, 62% and 40% respectfully.  The 
revised ISS also resulted in a significant number of patients being reclassified as higher-
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risk, with 26% of patients being given a better prognosis when compared to the original 
ISS staging system (Palumbo et al. 2015).  No matter which system is used, it must be 
recognised that both the ISS and revised ISS can lack accuracy for individual patients.  
Some patients may do better/worse than their ISS stage would suggest.  Therefore, there 
still remains significant unpredictability.   
 
 
1.5.7 Genetic Aberrations in MM 
Translocations involving the immunoglobulin heavy locus (IgH), located on chromosome 
14, are thought to be some of the earliest initiating events in the development of plasma 
cell disorders (see figure 1.6).  These translocations most commonly occur during class 
switch recombination, with oncogenes being placed under the influence of the IgH 
enhancer.  Studies have suggested that IgH translocations involving chromosome 14q32 
exist in around 47% of MGUS and 73% of symptomatic MM patients, reaching as high 
as 84% in patients with plasma cell leukaemia (Nishida et al. 1997; Avet-Loiseau et al. 
2002).  This can result in the IgH enhancers Eμ, Eα1 and Eα2 being placed into the 
proximity of oncogenes (Bergsagel and Kuehl 2001).  One such set of genes, commonly 
overexpressed in the early stages of MGUS, are the cyclin D proteins.  These act to drive 
cells though the G1/S phase by forming a complex with cyclin-dependent kinases 
(CDKs), resulting in the phosphorylation and inactivation of the retinoblastoma protein 
(Musgrove et al. 2011).  The upregulation of cyclin D1 or cyclin D3, caused by 
t(11;14)(q13;q32) and t(6;14)(p21;q32) translocations respectively, is thought to occur in 
around 20% of MM cases (Zhan et al. 2006).   
 
IgH translocations are also involved in each of the high-risk chromosomal abnormalities 
outlined in the revised ISS for MM (Palumbo et al. 2015).  A t(4;14)(p16;q32) 
translocation is thought to be present in around 15% of MM patients, resulting in 
overexpression of the FGFR3 and MMSET genes.  This event is known to indirectly lead 
to the upregulation of cyclin D2 (Kuehl and Bergsagel 2005).  Meanwhile, around 10% 
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of patients are thought to express a t(14;16)(q32;q23) translocation which results in the 
upregulation of the c-MAF proto-oncogene (Zhan et al. 2006).   
 
Hyperdiploidy is also a common initiating event in MM, with around 50% of all MGUS 
and MM patients thought to present with multiple copies of chromosomes 3, 5, 7, 9, 11, 
15, 19 and/or 21 (Smadja et al. 2001).  Again, cyclin D1 expression can be upregulated 
due to an increased copy number of chromosome 11.  However, it has been suggested 
that hyperdiploidy of some chromosomes may confer a significantly better prognosis than 
others.  One study identified patients with trisomy 3 and 5 as having an improved overall 
survival, even in patients with the high-risk t(4;14) translocation.  Conversely, trisomy 21 
and gain of the 1q arm significantly worsened overall survival (Chretien et al. 2015).   
 
Chromosome 13 deletions, arising either from loss of the q arm or monosomy, are further 
events that are thought to be present in around 50% of MM patients (Chiecchio et al. 
2006).  Recent studies have suggested that loss of chromosome 13 confers a 
significantly reduced overall survival (Shaughnessy et al. 2003; Chiecchio et al. 2006).  
One possible explanation for this is that the loss of the q arm also results in the loss of 
the gene encoding the retinoblastoma protein.  However, chromosome 13 encodes a 
significant number of other genes and so this is unlikely to be to only reason (Walker et 
al. 2010).  Deletion of the 17p arm is also a significant event in MM, leading to its inclusion 
in the revised ISS as a high-risk abnormality.  This deletion is thought to be present in 
around 11% of MM patients, resulting in loss of the TP53 gene and disruption to apoptotic 
and senescent pathways (Avet-Loiseau et al. 2007). 
 
Further secondary genetic events include the dysregulation of the genes encoding MYC 
and RAS-family proteins.  In one study, the c-myc locus was shown to be rearranged in 
3% of MGUS, 4% of smouldering MM, and 15% of symptomatic MM patients (Avet-
Loiseau et al. 2001).  Around 10% of these rearrangements are thought to occur via a 
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t(8;14) translocation, again involving the IgH locus on chromosome 14 (Bergsagel and 
Kuehl 2003).  Meanwhile, Chng et al. (2008) demonstrated that 7% of MGUS patients 
analysed during their study had mutations in RAS-family genes (RAS, KRAS and HRAS).  
This increased to 25% for patients with newly diagnosed MM and 45% of patients with 
relapsed MM.  Those patients in which a RAS mutation was identified had a significantly 
reduced overall survival when compared to those without.   
 
Telomeric shortening is also known to occur in the CD138+ plasma cells of MM patients, 
acting as a possible explanation for the genetic instability that drives disease 
progression.  Wu et al. (2003) used TRF analysis to compare the mean telomere lengths 
of abnormal plasma cells with normal leukocytes isolated from the same patient.  They 
not only observed that mean telomere length was significantly reduced in the abnormal 
plasma cells, relative to the leukocyte population, but that the mean telomere lengths of 
those plasma cells were also reduced when compared to normal CD138+ plasma cells 
isolated from healthy patients.  Cottliar et al. (2003) appeared to verify this discovery, 
demonstrating that the mean telomere lengths of MM patient whole bone marrow 
aspirates were significantly shorter than normal controls.  They also showed that a 
negative correlation exists between mean telomere length and the percentage of plasma 
cells within the bone marrow.  
 
1.5.8 Treating MM 
MM is an incurable disease, with treatments focusing on the relief of symptoms and 
reducing the population of abnormal plasma cells.  As well as the treatment of individual 
symptoms mentioned earlier, a significant number of drugs have been devolved which 
are prescribed in the case of symptomatic MM.  However, treatments vary depending on 
the current health of the patient and whether the disease has relapsed.  Treatment is 
normally initiated either when myeloma-defining events are detected or if the 
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concentration of paraprotein in the blood increases significantly during several clinic 
visits.   
 
1.5.8.1 Current Treatments  
After being diagnosed, MGUS and smouldering MM are rarely treated.  It is not until 
symptoms begin to appear that treatment is initiated.  The national institute for health 
and care excellence (NICE) currently recommends bortezomib (marketed as Velcade), 
thalidomide and dexamethasone as an induction treatment for previously untreated 
patients.  This is also known as VTD (NICE, 2016).  Bortezomib is a proteasome inhibitor 
that causes cellular apoptosis by preventing the degradation of misfolded proteins, 
thalidomide is an immunomodulatory drug which prevents angiogenesis, and 
dexamethasone is a corticosteroid (Richardson et al. 2005; Palumbo et al. 2008).  This 
combination is known to be more effective as an induction therapy than thalidomide and 
dexamethasone (VD) alone, or bortezomib-cyclophosphamide-dexamethasone (VCD).  
Instead, the use of cyclophosphamide is usually reserved for the treatment of relapsed 
MM (Cavo et al. 2010; Cavo et al. 2015).   
 
If a patient is healthy and suitable enough, autologous stem cell transplantation can be 
considered.  This involves first reducing the number of abnormal plasma cells in bone 
marrow by prescribing several cycles of VTD induction therapy.  Stem cells are then 
harvested from the patient’s bone marrow, at which point treatment with high-dose 
chemotherapy (and sometimes radiation) is used to kill most of the plasma cells.  The 
harvested bone marrow is then infused back into the patient (Kyle and Rajkumar 2008).  
A second autologous stem cell transplantation can be performed once the patient 
relapses, with one phase III study suggesting that this can improve progression free 
survival and overall survival when compared to cyclophosphamide alone (Cook et al. 
2014).   
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A small number of patients may benefit from myeloablative allogenic stem cell 
transplants, whereby the patient is given donor stem cells after high-dose chemotherapy.  
This method remains the only potential cure for MM, possibly due to the anti-MM effects 
of the immune cells within the allograft (Lokhorst et al. 2010).  However, a high 
transplant-related mortality has been recorded, with around 29% of patients in one study 
eventually succumbing to either infection or graft versus host disease (Vekemans et al. 
2014).  Outcomes can be improved by having a patient undergo a reduced-intensity 
allograft, with less chemotherapy being administered.  This does not suppress the 
patient’s immune system to the same extent, but still allows the donor cells to mount an 
immune response against the cancer.  Although Crawley et al. (2007) demonstrated that 
reduced-intensity allografts result in a reduced mortality when compared to 
myeloablative allografts (24% vs 37% at two years respectively), progression-free 
survival was also reduced (18.9% vs 34.5% at 2 years).   
 
Autologous and allogenic stem cell transplants are unsuitable for frail patients who would 
not be expected to survive the high-risk procedure.  Instead, NICE recommends treating 
with a combination of bortezomib and an alkylating agent such as melphalan (NICE, 
2016).  Facon et al. (2007) also recommend combining this treatment option with 
thalidomide to further increase overall survival.  Regardless of how MM is treated, almost 
all cases will inevitably relapse.  This is due to subclonal evolution, with the genetic 
landscape of the various plasma cell clones becoming more heterogeneous during 
disease progression and treatment (Bolli et al., 2014).  At this point, NICE recommends 
bortezomib and dexamethasone, followed by the second autologous stem cell transplant 
where possible.  After two or more relapses, lenalidomide should be administered in 
combination with dexamethasone and cyclophosphamide (NICE, 2016).   
 
As well as direct treatment of the cancer, patients will also require their symptoms to be 
addressed and managed as the myeloma develops.  For example, bisphosphonates are 
commonly administered to slow osteoclast-mediated bone resorption and prevent 
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hypercalcemia (Papapoulos, 2008).  Dialysis may also be used to when renal impairment 
or failure occurs.  As a chronic disease, supportive management is critical and involves 
focussing on preventing anaemia (blood transfusion) and thrombosis formation (plasma 
exchange), an impaired immune system, managing neuropathy, reducing pain and 
fatigue, and dealing with the psychologic effects of cancer formation and chemotherapy 
(NICE, 2016).   
 
1.5.8.2 Future Treatments  
Although the next generation of immunomodulators (Pomalidomide) and proteasome 
inhibitors (Carfilzomib and Ixazomib) have now been approved for treatment in cases of 
MM, novel treatments are also beginning to show promise (San Miguel et al. 2013; 
Stewart et al. 2015; Moreau et al. 2016).  The histone deacetylase (HDAC) inhibitor 
panobinostat has recently been approved for use in cases of relapsed MM, with the 
clinical trials performed by San-Miguel et al. (2014) suggesting that panobinostat-
bortezomib-dexamethasone results in a significantly increased progression-free survival 
when compared to bortezomib-dexamethasone alone (median 11.99 months against 
8.08 months respectfully).  Meanwhile, a HDAC-6 inhibitor called riclinostat has recently 
completed phase I clinical trials in refractory MM and has been shown to enhance the 
effects of carfilzomib in vitro (Yee et al. 2016; Mishima et al. 2015).   
 
In patients where current therapeutic options have been exhausted, monoclonal 
antibodies (mAb) have emerged as a novel and effective treatment.  One of the 
advantages of this therapy is its ability to selectively target the abnormal plasma cells in 
MM.  Daratumumab is one such anti-CD38 mAb which induces cell death via antibody-
dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and 
complement-dependent cytotoxicity (Lonial et al. 2016).  Palumbo et al. (2016) 
demonstrated during phase III clinical trials that the use of daratumumab-bortezomib-
dexamethasone in relapsed MM patients improves progression-free survival when 
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compared to bortezomib-dexamethasone alone (60.7% vs 26.9% after 12 months 
respectfully).   
 
Elotuzumab is another mAb which was recently approved for the treatment of relapsed 
MM.  It targets the SLAMF7 (otherwise known as CD319) surface antigen on normal and 
abnormal plasma cells, inducing cell death by antibody-dependent cell-mediated 
cytotoxicity, as well as inhibition of the SLAMF7-mediated adhesion of MM cells to bone 
marrow stromal cells (Lonial et al., 2016).  Phase III clinical trials by Lonial et al. (2015) 
demonstrated that elotuzumab-lenalidomide-dexamethasone treatment in relapsed MM 
resulted in an increased progression-free survival when compared to lenalidomide-
dexamethasone alone (41% vs 27% after 24 months).   
 
Novel treatments which target abnormal signalling pathways have also been proposed, 
with cyclin-dependent kinase (CDK) inhibitors currently being explored as an option to 
overcome the upregulation of cyclin D family proteins that have commonly been identified 
in MM.  Dinaciclib is one such CDK inhibitor which has recently undergone successful 
phase II clinical trials in relapsed MM as a single agent (Kumar et al. 2015).  It has also 
been demonstrated that dinaciclib is capable of sensitising MM cell lines to the effects of 
PARP inhibition (Alagpulinsa et al. 2016).  However, PARP inhibitors are not currently 
recommended as a treatment for MM and little work has been carried out to explore their 
role in preventing a telomere-driven crisis within abnormal plasma cells.   
 
1.6 DNA Repair and PARP Inhibition 
Critical telomeric shortening may not always trigger senescence.  Genetic abnormalities, 
such as the loss of functional retinoblastoma or p53 proteins described in MM, 
sometimes permit a cell to continue dividing beyond the Hayflick limit which eliminates 
the protective capacity of the telomere.  In these cases, chromosomal fusion is thought 
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to drive the genomic rearrangement and instability that underpins a significant number 
of cancers (Lin et al. 2014; Roger et al. 2013; Gisselsson et al. 2001).  As a method of 
identifying novel cancer treatments, it is necessary to understand and target the DNA 
damage repair mechanisms which play a role in the aberrant repair of telomere-deficient 
chromosomal ends.  One such target is the poly(ADP-ribose) polymerase (PARP) family.  
Comprised of 17 members, each uses NAD+ as a substrate with which to catalyse the 
addition of ADP-ribose to target proteins.  PARP1 and PARP2 are both known to play 
various roles in the repair of DNA damage, making them attractive targets in the 
treatment of genetically-unstable cancers (Vyas and Chang 2014).  PARP inhibitors have 
already been approved for use in BRCA-mutated breast and ovarian cancers, but little is 
known about their capacity to treat MM (Kaufman et al. 2015).    
 
1.6.1 Single-Strand DNA Breaks  
Common causes of single-strand DNA breaks include oxidative attack by endogenous 
reactive oxygen species (ROS), external factors such as UV light and cigarette smoke, 
and even aborted DNA repair mechanisms (Mello Filho and Meneghini 1984; Nelson and 
Kastan 1994; Caldecott 2008).  The result is an inability to replicate DNA during S-phase, 
with replication forks becoming blocked or collapsing.  Because of this, an inevitable 
consequence is that any unrepaired single-strand DNA breaks will eventually become 
double-strand breaks.  Cells therefore require the ability to delay cell cycle progression 
whilst the damage is repaired by one of several mechanisms (Cimprich and Cortez 2008) 
 
The process of cell cycle arrest is initiated by an ATR-mediated pathway.  Replicative 
stress causes replication protein A (RPA) to bind at the site of single-strand DNA damage 
(Unsal-Kacmaz and Sancar 2004).  RPA is a complex of three proteins (RPA14, RPA32 
and RPA70) which are responsible for recruiting ATR via the ATR-interactive protein 
(ATRIP).  It has been observed that the loss of ATRIP activity prevents ATR binding at 
the single-strand break, thus inhibiting the initiation of cell cycle arrest (Cortez et al. 
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2001).  Once bound to DNA, ATR is activated by topoisomerase 2-binding protein 1 
(TOPBP1) and the Rad9-Hus1-Rad1 (9-1-1) complex (Kumagai et al. 2006).  This 
activation results in the phosphorylation of several signalling proteins, most notably 
checkpoint kinase 1 (CHK-1).  CHK-1 then targets the cell division cycle (CDC) proteins 
CDC25a and CDC25b for ubiquitin-mediated degradation, preventing the cells from 
transitioning thought the S-phase or G2-M checkpoints (Mailand et al. 2000; Nam and 
Cortez 2011; Zhou and Bartek 2004).  However, this pathway only seeks to prevent cell 
cycle progression.  The repair of a single-strand DNA break is carried out by one of 
several different mechanisms. 
 
1.6.1.1 Base Excision Repair 
Base excision repair (BER) is primarily responsible for correcting base lesions which do 
not significantly distort the helical DNA structure (see figure 1.7).  This mostly includes 
deaminated bases and abasic (AP) sites.  The removal of the damaged base is carried 
out by a glycosylase enzyme, leaving behind an empty deoxyribose residue.  An AP-
endonuclease (APE1) then cleaves the deoxyribose residue, generating 5′-deoxyribose 
phosphate and 3′-hydroxyl ends at the site (Hegde, Hazra, and Mitra 2008).  Before the 
repair of this single nucleotide-free gap, otherwise known as short-patch repair, PARP1 
and PARP2 homo- and heterodimers bind to the site of the break.  Their activity recruits 
XRCC1, a protein which ensures efficient gap-filling and nucleotide ligation by 
polymerase β and DNA ligase III (Schreiber et al. 2002).  It has been demonstrated that 
inhibition of PARP1 and PARP2 prevents the recruitment of XRCC1, leading to elevated 
frequencies of genetic damage (Reynolds et al. 2015; Breslin et al. 2015).   
 
A variation of this process exists whereby several nucleotides are removed from the area 
downstream of the base lesion.  Known as long-patch repair, this still requires the 
damaged base to be removed by the action of a glycosylase and an AP-endonuclease.  
At this point, polymerase δ is recruited to synthesise a sequence of 2-10 nucleotides 
downstream of the DNA damage site (Pascucci et al. 1999).  This acts to displace the 
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original nucleotide sequence, creating a flap which is then cleaved by flap endonuclease 
1 (FEN1).  At this point, the nick is sealed by DNA ligase I (Krokan and Bjoras 2013). 
Mutated forms of FEN1 have been identified in cancer, whereby their presence 
correlated with a reduction in long-patch repair activity and greater frequencies of genetic 
damage (Sun et al. 2017). 
 
1.6.1.2 Nucleotide Excision Repair  
Nucleotide excision repair (NER) is primarily responsible for correcting base lesions 
which significantly distort the helical DNA structure.  An example of this would be the 
pyrimidine dimers formed as a result of expose to UV radiation (Fitch et al. 2003).  This 
mechanism can initiate via one of two pathways; global genome repair (GGR) or 
transcript coupled repair (TCR).  Either way, the pathways merge once the transcription 
factor IIH (TFIIH) complex binds at the site of DNA damage. 
 
During GGR, base lesions are sensed by the UV-damaged DNA-binding (UV-DDB) 
protein.  This stimulates the recruitment of XPC-RAD23B-CENT2, a protein complex 
which continuously scans the genome.  After binding to the site of DNA damage, the 
RAD23B subunit dissociates and the TFIIH complex is recruited (Kamileri, Karakasilioti, 
and Garinis 2012).  Meanwhile, the TCR pathway is initiated by the stalled translation of 
an RNA polymerase II molecule.  Unable to dissociate, RNA polymerase II instead 
colocalises with the DNA-dependent ATPase cockayne syndrome B (CSB) protein.  This 
acts to recruit an E3-ubiquitin ligase complex which forces RNA polymerase II to 
backtrack, allowing TFIIH to access the site of DNA damage (Marteijn et al. 2014).  
 
In the case of either GGR or TCR, a subunit of the TFIIH protein complex then unwinds 
the double-stranded DNA surrounding the site of damage.  Another subunit with 
endonuclease activity cleaves approximately 27 nucleotides from the single-stranded 
DNA surrounding the site (Friedberg 2001).  DNA polymerase δ and DNA ligase III are 
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then responsible for filling the resulting nucleotide gap.  However, the role that PARP1 
and PARP2 play in this mechanism is not well characterised.  It has been suggested that 
PARP1 acts during GGR to modify the XPC-RAD23-CENT2 complex, regulating its 
ability to bind DNA (Maltseva et al. 2015).  Meanwhile, XRCC1 is known to increase the 
efficiency of DNA polymerase δ and DNA ligase I activity during NER (Moser et al. 2007).  
Whether PARP1 or PARP2 play a role in the recruitment of XRCC1, as is the case with 
the BER mechanism, remains to be known.     
 
1.6.1.3 Mismatch Repair 
DNA mismatch repair is responsible for correcting the abnormal pairing of nucleotides in 
a double-stranded DNA sequence.  These errors mainly occur during DNA replication, 
with examples including the alignment of guanine-thymine or adenine-cytosine bases.  
Defects in the ability of a cell to perform mismatch repair have been associated with a 
high incidence of cancer, most commonly colorectal and endometrial (Barnetson et al. 
2006; Win et al. 2012).   
 
The mechanism is initiated when heterodimers of the DNA mismatch repair (MSH) 
proteins MSH2, MSH3 or MSH6 bind to the site of damage in an ATP-dependent 
manner.  A second heterodimer, comprised of the MutL homolog 1 (MLH1) and post-
meiotic segregation protein-2 (PMS2) proteins, then binds to form a complex.  This 
complex diffuses upstream of the mismatch site, eventually encountering the 
proliferating cell nuclear antigen (PCNA) protein and the replication factor C (RFC) 
protein complex.  RFC is displaced from the DNA, at which point exonuclease 1 (EXO1) 
associates.  EXO1 then degrades the strand of nucleotides up to and including the site 
of mismatch repair.  RPA is recruited to the remaining single-stranded DNA, stabilising 
it until polymerase δ and DNA ligase I can synthesis and join a new complementary 
sequence (Jiricny 2006; Modrich 2006; Hombauer et al. 2011).   
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1.6.2 Double-Strand DNA Breaks  
Although double-strand DNA breaks may be formed by a failure to repair single-strand 
DNA breaks, they can also result from direct exposure to ionising radiation or ROS.  
Either way, the cell is required to halt cell cycle progression until the damage is repaired 
by one of several mechanisms (Shrivastav, De Haro, and Nickoloff 2008).  The process 
of cell cycle arrest is initiated by an ATM-mediated pathway, not to be confused with the 
ATR-mediated pathway that is triggered in response to single-strand DNA damage.  It 
begins when multiple copies of the MRE11-RAD50-NBS1 (MRN) complex bind to the 
damaged DNA ends and to each other, acting to bridge the gap and bring the DNA 
strands closer together (Williams et al. 2008).  The complex also recruits inactive ATM 
homodimers which then dissociate into active monomers (Bakkenist and Kastan 2003).  
 
ATM continues the signalling pathway by interacting with a series of mediator proteins; 
MDC1, 53BP1, MRN and BRCA1.  Their binding, particularly that of MDC1, allows ATM 
to directly phosphorylate any nearby histone H2AX proteins.  This step is crucial for the 
recruitment of those proteins which are involved in the repair of double-strand DNA 
breaks (Jazayeri et al. 2006).  ATM also phosphorylates CHK-2 and p53, leading to the 
inhibition of the CDK2-cyclin E complex and preventing the cell from transitioning through 
the S-phase or G2-M checkpoints (Lobrich and Jeggo 2007; Lee and Paull 2007).     
 
1.6.2.1 Homologous Recombination  
Homologous recombination (HR) requires that the ends of each damaged DNA strand 
undergo resectioning (see figure 1.8).  This is initiated when exonuclease 1, CtIP and 
BRCA1 bind to the MRN complex.  Together, these remove nucleotides in a 5′ to 3′ 
direction on each DNA strand to leave behind a single-stranded overhang (Chen et al. 
2008; Chen et al. 2017).  This overhang is stabilised by the addition of replication protein 
A (RPA).  The breast cancer type 2 susceptibility (BRCA2) protein then mediates the 
removal of RPA from the single-stranded DNA, as well as the addition of RAD51.  RAD51 
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is necessary for strand invasion, a process whereby each single-stranded overhang 
binds to its complementary sequence on a homologous chromosome (Krejci et al. 2012).  
This undamaged chromosome is then used as a template by polymerase δ with which 
to synthesise the correct nucleotide sequence (Maloisel, Fabre, and Gangloff 2008).   
 
At this point, HR can undertake one of two alternative pathways.  The first of these, 
synthesis-dependent strand annealing (SDSA), ends with the newly synthesised strand 
of DNA dissociating from the template strand.  It then anneals with the other half of the 
original chromosome, without any DNA being permanently exchanged between the 
homologous chromosomes (Moynahan and Jasin 2010).  This is not the case for the 
second HR pathway, double-strand break repair (DSBR).  Here, each single-stranded 
DNA overhang from the damaged chromosome binds to its complementary sequence 
on the homologous template chromosome at the same time.  This forms a structure 
known as a Holliday junction.  The BLM/TopoIIIα/RMI1/RMI2 protein complex is then 
responsible for orchestrating the exchange of single-stranded nucleotide sequences 
between the homologous chromosomes (Mimitou and Symington 2009).  Regardless of 
which pathway is used, the result is a repaired double-strand DNA break without any 
loss of nucleotide sequence. 
 
Mutations in either BRCA1 or BRCA2 are known to result in a compromised HR pathway, 
significantly increasing the risk of cancer development (Antoniou et al. 2008).  It is 
thought that BRCA1 and BRCA2 mutations confer a 65% and 45% chance of developing 
breast cancer by age 70 (Antoniou et al. 2003).  BRCA-mutated breast and ovarian 
cancers are commonly treated using the PARP inhibitors Rucaparib or Olaparib (see 
section 1.6.3 – PARP Inhibition).  These drugs act to prevent the repair of single-strand 
DNA breaks, which eventually become double-strand DNA breaks (Knepper, Saller, and 
Walko 2017; Kim et al. 2015).  In the presence of compromised HR pathway, cells must 
rely on the error-prone non-homologous end joining pathways to repair the increased 
frequency of DNA damage.  The resulting genetic instability can prove catastrophic,  
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triggering apoptosis specifically in the HR-deficient cancer cells (Farmer et al. 2005; 
Javle and Curtin 2011).   
 
1.6.2.2 Non-Homologous End Joining 
Non-homologous end joining (NHEJ) is thought to be the most common mechanism used 
to repair double-strand DNA breaks in vertebrates (Liang et al. 1998; Rothkamm et al. 
2003).  Unlike the homology-directed repair observed in HR, NHEJ is simply used to 
ligate two broken DNA ends together (see figure 1.9a).  The mechanism is initiated by 
the Ku70/Ku80 heterodimer.  This binds to one of the DNA ends in a double-strand break, 
acting to recruit the DNA-dependent protein kinase catalytic subunit (DNA-PKcs).  The 
resulting protein complex then binds to an identical complex on the corresponding DNA 
end, acting to bridge the gaps in the break and bring the DNA ends into proximity with 
each other (Weterings and Chen 2008).  This occurs in conjunction with ligase IV, an 
enzyme which joins the DNA ends together with the help of the accessory proteins 
XRCC4 and XLF (Chen et al. 2000).  PARP3 also accelerate the repair of double-strand 
DNA breaks by recruiting the aprataxin-and-PNK-like factor (APLF) protein.  This 
promotes retention of the XRCC4/ligase IV complex at the break site (Rulten et al. 2011).  
However, a second mechanism is known to take over if the classical NHEJ pathway 
becomes compromised. 
 
Known as alternative non-homologous end joining (alt-NHEJ), this pathway utilises a 
short homologous sequence at the broken DNA ends to guide their alignment 
(Pannunzio et al. 2014).  It is from this that the alternative name of microhomology-
mediated end joining is derived (see figure 1.9b).  The switch from the classical pathway 
to this alt-NHEJ pathway is thought to be driven by the loss of either Ku70/Ku80 or ligase 
IV (Riballo et al. 2004).  Alt-NHEJ is also thought to be promoted by PARP1 which 
competes with Ku70/80 for binding at the site of double-strand DNA breaks (Wang et al., 
2006).  It has been observed that inhibition of PARP1 function impairs the repair of 
double-strand DNA breaks (Audebert, Salles, and Calsou 2004).  In the case of repair 
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by the alt-NHEJ pathway, damaged DNA ends are trimmed to create the microhomology 
that facilitates their ligation.  Like HR, this is performed by the exonuclease1, CtIP and 
BRCA1 proteins which bind to the MRN complex at the DNA ends.  After aligning the 
ends based on the newly created homologous sequences, ligation is performed by ligase 
III (Zhang and Jasin 2011; Truong et al. 2013).  However, alt-NHEJ is thought to be more 
error-prone than either the HR or the classical NHEJ pathways.  This is due to the loss 
of nucleotides that occurs during resectioning of the DNA ends, a process which can 
result in the disruption of genetic sequences (Rai et al. 2010).  It has also been 
demonstrated that the expression of ligase III is necessary for the escape of cells from a 
telomere driven crisis, while the expression of ligase IV is not (Jones et al. 2014).  This 
suggests that the alt-NHEJ pathway is responsible for the genetic rearrangements that 
take place at the ends of critically shortened telomeres, acting to drive cancer 
progression.   
 
1.6.3 PARP Inhibition 
From the descriptions of each repair pathway, it may appear that PARP1 and PARP2 
play only minor roles in the repair of single-strand DNA damage.  However, PARP 
inhibitors are now routinely used in the treatment of BRCA-mutated breast and ovarian 
cancers.  This discrepancy comes from the fact that PARP1 and PARP2 directly bind to 
sites of DNA damage during BER.  Their activity not only acts to recruit proteins involved 
in single-strand DNA repair, but also to promote their own dissociation from DNA.  In the 
presence of a PARP inhibitor, PARP1 and PARP2 are trapped at the site of DNA 
damage.  This blocks any further repair and eventually results in the formation of a 
double-strand DNA break during S-phase (Murai et al. 2012).  In normal cells, this 
damage would simply be repaired by the HR pathway.  However, BRCA-mutations in 
cancer prevent this pathway from functioning.  It therefore becomes necessary for the 
cell to rely on the more error-prone NHEJ pathways, producing catastrophic DNA 
damage and rearrangements that inevitably lead to apoptosis (Javle and Curtin 2011).   
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A sensitivity to PARP inhibition can be induced by co-treating cells with molecules that 
interfere with HR.  In one study, inhibition of RAD51 (a crucial component of the HR 
pathway) improved the effectiveness of PARP inhibition in cells with no prior defects in 
the HR pathway (Wang et al. 2012).  More commonly, PARP inhibition has been 
examined in combination with either radiation or DNA damaging agents.  It is thought 
that excessive single-strand DNA breaks are produced in this way, with PARP inhibitors 
preventing their repair via BER.  This results in an overwhelming frequency of double-
strand DNA breaks which inevitably leads to apoptosis (Calabrese et al. 2004; Tentori et 
al. 2006; Donawho et al. 2007).   
 
Although most articles discussing PARP inhibition focus on PARP1 and PARP2, 
inhibitors rarely target a single member of the PARP family.  This is because the catalytic 
sites of most PARP proteins share a significant homology (Smith 2001).   For example, 
Wahlberg et al. (2012) demonstrated that Veliparib binds to the catalytic sites of PARP1, 
PARP2, PARP3 and PARP4.  Meanwhile, Rucaparib and Olaparib bind to nine and 
seven different PARP family proteins respectively.  A bias in the understanding of PARP 
protein function exists because PARP1 and PARP2 are some of the most abundant 
members of this family expressed in cells.  They are also the most well-characterised 
due to their early discovery (Vyas and Chang 2014).  Although the inhibition of PARP1 
and PARP2 certainly plays an invaluable role during the treatment of BRCA-mutated 
cancer, the fact that little is known about the effects of PARP inhibition on the remaining 
PARP family members may be a cause for concern (Rouleau et al. 2010).   
 
Rucaparib and Olaparib are examples of PARP inhibitors which are both promiscuous 
and only partially understood.  Like many inhibitors, their effects on PARP1 and PARP2 
are well documented (Murai et al. 2014).  However, little has been done to identify their 
effects on pathways that utilise the other PARP family proteins inhibited by these drugs.  
Regardless, both Rucaparib and Olaparib have now received accelerated approval for 
the treatment of BRCA-mutated cancers (Syed 2017; Kim et al. 2015).  In both cases, 
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phase III clinical trials are still ongoing.  Phase II clinical trials have shown an improved 
progression-free survival in the case of both Rucaparib and Olaparib when used to treat 
BRCA-mutated breast and ovarian cancers (Drew et al. 2016; Swisher et al. 2017; Tutt 
et al. 2010; Ledermann et al. 2014). 
 
1.7 Aims of the Project 
Short dysfunctional telomeres have previously been identified as a driving force in 
cancer, resulting in chromosomal fusion and rearrangement that acts to facilitate 
progression of the malignancy.  Studies into the telomere dynamics of breast cancer and 
chronic lymphocytic leukaemia have managed to identify a correlation between telomere 
length and patient outcome, demonstrating the potential for telomere length 
measurements to be used as a prognostic indicator.  We therefore sought to understand 
the role that telomeres play in the progression of MM, as well as the use of telomere 
length measurements in predicting patient outcome.  We also sought to use PARP 
inhibition as a method of combating the ability of MM cell lines to escape from a telomere-
driven crisis.  
 
The aims of this project can be discerned from the aims of each individual chapter: 
Chapter 3 - Here, we aim to identify the prognostic value of telomere length 
measurement in patients with MM.  We will then attempt to consider whether these 
measurements can be used to refine existing staging systems, with an emphasis placed 
on the ISS.  Also, we will examine the bone marrow aspirates of MM patients for evidence 
of chromosomal end-end fusion. 
Chapter 4 -  It has previously been demonstrated in chronic lymphocytic leukaemia that 
a relationship exists between telomere length and the frequency of chromosomal end-
end fusion.  We therefore aim to determine if a similar relationship exists in MM, using 
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MM cell lines that we will drive into a state of telomere-driven crisis.  We will also examine 
this relationship within the context of the p53 status of each cell line.   
Chapter 5 - Little is known about the role that PARP inhibitors might play in treating MM.  
Even less is known about the effect that these drugs would have on the escape of cells 
from a telomere-driven crisis.  We will therefore seek to explore the use of Rucaparib 
and Olaparib as novel treatments for MM, analysing their ability to promote apoptosis in 
combination with critical telomeric erosion.   
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Chapter 2 
Materials and Methods 
 
2.1 Equipment and Reagents 
Unless stated otherwise, the following basic equipment was used.  Manufacturers and 
models are listed where possible: Biological Safety Cabinet – Herasafe ks (Thermo 
Fisher Scientific); Centrifuge (large) – Centaur 2 (MSE); Centrifuge (small) -  Fresco 
21 Centrifuge (Haraeus) and Biofuge Pico (Heraeus); Glassware and Plastics – 
Various types (Ambion, Azlon, Becton Dickenson, Costar, Eppendorf, Fisher, 
SARSTEDT, Schott Duran, Sigma and Thermo Scientific); Hot Block – Dri-Block DB2A 
(Teche) and Grant QBTP (Grant Instruments); Hybridisation Oven – Hybaid Maxi 14 
(Thermo Scientific); Incubator – Heracell 150 (Heraeus); Thermal Cyclers – Tetrad 2 
(Bio-Rad) and SimpleAmp (Life Technologies); Tube Rotor - Stuart SB1 Blood Tube 
Rotator (Stuart Scientific) and Roller Mixer SRT2 (Stuart Scientific); UV 
Transilluminator – Flowgen Transilluminator (Flowgen); Water Bath – Jab 18 (Grant 
Instruments). 
 
Unless otherwise stated, the following basic chemicals were used.  Manufacturers are 
listed where possible:  Acetic Acid (Fisher); bovine serum albumin (BSA) (2mg/ml – 
Thermo Fisher); dimethyl sulfoxide (DMSO) (Sigma); foetal calf serum (FCS) (Life 
Technologies); Glycene (Fisher); Glycerol (Sigma); hydrochloric acid (HCl) (Fisher); 
sodium chloride (NaCl) (Fisher); sodium hydroxide (NaOH) (Fisher); phosphate-
buffered saline (PBS) (10x – Thermo Fisher Scientific); sodium dodecyl sulfate (SDS) 
(Fisher); Tris-HCl (Fisher); Tween20 (Sigma); phenylmethylsulfonyl fluoride (PMSF) 
(Sigma); 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) 
(Calbiochem). 
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2.2 Patient Samples and Tissue Culture 
 
2.2.1 Obtaining Patient Bone Marrow Aspirates and DNA Samples 
DNA samples, extracted from the whole bone marrow aspirates of MGUS and MM 
patients, were provided by Professor James Allen, Newcastle University.  Patient 
samples were collected at diagnosis, prior to treatment, through treating centres within 
the Heart of England NHS Foundation Trust and the Newcastle upon Tyne NHS 
Foundation Trust between 1990 and 2005, with ethical approval from the Newcastle 
Haematology Biobank (07/H0906/109+5) in accordance with the declaration of Helsinki.  
In total, 202 patient DNA samples were gathered in this manner.   
 
Whole bone marrow aspirates were obtained locally, from patients at the University 
Hospital of Wales with written informed consent (research ethics committee number: 
13/WA/0383).  Samples were obtained with help from Professor Chris Fegan, Cardiff 
University.  In total, 19 patient whole bone marrow aspirates were gathered in this 
manner.   
 
2.2.2 Isolation of Mononuclear Cells from Patient Bone Marrow Samples 
Mononuclear cells were first separated from the whole bone marrow aspirate by density 
gradient centrifugation.  5ml of bone marrow were carefully layered onto 6ml of 
Histopaque-1077 (Sigma-Aldrich) that had been added to a 15ml Falcon tube.  This was 
centrifuged at 300g for 20 minutes with the break off.  The mononuclear cell layer was 
then removed from the tube and added to 10ml of PBS (1x).  
 
2.2.3 Isolation of CD138+ Cells from Patient Mononuclear Cell Samples 
After centrifugation at 300g for 5 minutes, the supernatant was removed and the cells 
were suspended in 80µl of autoMACS running buffer (1x PBS, BSA 500mg/ml, EDTA 
20mM – Miltenyi Biotech) and 20µl of CD138 MicroBeads (Miltenyi Biotec).  This 
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suspension was mixed thoroughly, before being incubated at 4oC for 15 minutes.  10µl 
of human CD138-APC antibody (Miltenyi Biotec) was then added and the cells were 
incubated at 4oC for a further 5 minutes.  2ml of autoMACS running buffer was added 
and the cells were centrifuged at 300g for 5 minutes, with the resulting cell pellet being 
resuspended in 500µl of autoMACS running buffer.  CD138+ selection was achieved 
using the autoMACS Pro Separator (Miltenyi Biotec) as per the manufacturer’s 
guidelines using the ‘Possel’ software setting.   
 
The purity of the CD138+ and CD138- fractions was determined using flow cytometry.  A 
sample of the unsorted marrow cells, sorted CD138- cell fraction and sorted CD138+ cell 
fraction was centrifuged at 300g for 5 minutes.  The supernatant was removed and the 
resulting cell pellet was washed in PBS.  Again, the cells were centrifuged at 300g for 5 
minutes and the supernatant removed.  The cell pellet was suspended in 100µl of PBS 
before being analysed using an Accuri C6 flow cytometer equipped with CFlow software 
(BD Biosciences).  A sample of unsorted marrow cells that had not been exposed to 
human CD138-APC antibody was used as a control. 
 
In total, 10,000 events were recorded, per sample, using flow cytometry.  Cells were first 
analysed using forward scatter-area (FSC-A) against side scatter-area (SSC-A), with 
appropriate gating being used to exclude cell debris and dead cells from the analysis.  
Further analysis was performed on these gated cells to identify the CD138- and CD138+ 
fractions, using FL4-A against FL1-A to detect Allophycocyanin (APC)-bound cells with 
denoted CD138+ plasma cells.  Each sample demonstrated >80% purity in the positively 
selected and negatively selected fractions.  An example of this analysis can be seen in 
Supplementary Figure 18.   
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2.2.4 Cell Lines and Growth Conditions 
The NCI-H929, RPMI-8226 and U266B1 cell lines were purchased from Sigma-Aldrich.  
Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 media (Life 
Technologies) supplemented with Penicillin (100 Units/ml - Sigma), Streptomycin 
(0.1mg/ml - Sigma), FCS (10% v/v - Thermo Fisher Scientific) and L-glutamine (2mM - 
Sigma).  Cells were incubated at 37oC in 5% CO2. 
 
The JJN-3 cell line was gifted by Professor Chris Pepper, Cardiff University.  Cells were 
cultured in Dulbecco's Modified Eagle Medium (DMEM - Life Technologies) 
supplemented with Sodium Pyruvate (1mM - Invitrogen), Penicillin (100 Units/ml - 
Sigma), Streptomycin (0.1mg/ml - Sigma), non-essential amino acids (1x - Sigma), FCS 
(20% v/v - Thermo Fisher Scientific) and L-glutamine (2mM - Sigma).  Cells were 
incubated at 37oC in 5% CO2. 
 
The HEK-293 cell line was gifted by Dr Rhiannon Robinson, Cardiff University.  Cells 
were cultured in Dulbecco's Modified Eagle Medium (DMEM - Life Technologies) 
supplemented with Penicillin (100 Units/ml - Sigma), Streptomycin (0.1mg/ml - Sigma), 
FCS (10% v/v - Thermo Fisher Scientific) and L-glutamine (2mM - Sigma).  Cells were 
incubated at 37oC in 5% CO2. 
 
2.2.5 Trypsinisation and Cell Counting 
For the HEK-293 adherent cell line, trypsin was used to detach cells from the culture 
flasks.  Media was removed from the flasks and the adherent cells were washed using 
PBS (1x).  For a 75cm2 flask, 2ml of trypsin (1x – Thermo Fisher Scientific) was washed 
over the cells and the flask was incubated at 37oC for 5 minutes.  10ml of fresh 
Dulbecco's Modified Eagle’s Medium (DMEM - Life Technologies) was then added to 
inactivate the Trypsin and the cells were harvested and centrifuged (175g for 5 minutes) 
prior to resuspension in fresh culture media.    
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As a method of counting and assessing the viability of each of the cell lines, 2.5µl of 
solution 13 (Acridine Orange 80µg/ml and DAPI 40µg/ml - Chemometic) was added to a 
50µl suspension of cells.  Cells were counted using the NucleoCounter NC-250 
(Chemometec) as per the manufacturer’s guidelines.  
 
2.2.6 Viral Infection of Cell Lines – Reducing Telomerase Activity 
2x106 cells were suspended in 2ml of media (DMEM, 10% v/v FCS, 2mM L-Glutamine, 
8µg/ml Hexadimethrine bromide) containing a recombinant retrovirus that was grown 
using the ΨCRIP cell line (gifted by Richard Mulligan, Whitehead Institute, Cambridge).  
The retrovirus carried the pBABE-Puro vector (Addgene) which contained the gene 
encoding a dominant-negative human-TERT protein.  Cells were incubated at 37oC with 
5% CO2 for 4 hours, after which 2ml of supplementary media were added.   
 
4-10 days after transfection, cells that had successfully integrated the pBABE-Puro 
vector into their genome were selected for using puromycin.  The addition of puromycin 
was gradual, with JJN-3 and U266B1 cells initially being exposed to 0.75µg/ml of 
puromycin for 48 hours; 1.5µg/ml for 48 hours; and then maintained under constant 
selection (2µg/ml).  NCI-H929 cells were initially exposed to 0.25µg/ml puromycin for 48 
hours and then maintained under constant selection (0.5µg/ml).  
 
2.2.7 Cell Cloning  
Appropriate growth media was used to dilute either the JJN-3 or U266B1 cell lines to a 
concentration of 20 cells per ml.  100µl of this was then added to each well of a 96-well 
plate.  Cells were incubated at 37oC and 5% CO2 until a population of cells could be 
observed in each well (approximately 1.5x104 cells).  At this point, the cells were 
transferred to a 24-well plate containing 500µl of appropriate growth media.  Again, the 
cells were visualised by microscopy and transferred to a 6-well plate containing 2ml of 
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appropriate growth media once the population was considered to be large enough 
(approximately 5x105 cells). 
 
2.2.8 Freezing Cells in Liquid Nitrogen and Thawing Procedure 
Approximately 1x105 – 1x107 cells were centrifuged at 3421g for 5 minutes before being 
resuspended in 1ml of freezing media (50% appropriate growth media, 25% DMEM, 15% 
FCS and 10% DMSO).  Cells were stored in a freezing ampoule (Thermo Scientific) 
which was then placed into a freezing container (Mr. Frosty) that was filled with isopropyl 
alcohol to promote a controlled rate of freezing of the samples.  Containers were stored 
at -80oC for up to a week before being stored in liquid nitrogen.  
When needed, cells were removed from liquid nitrogen and thawed at 37oC using a water 
bath.  DMSO-containing freezing media was removed by adding 9ml of the appropriate 
growth media to cells, dropwise.  Cells were then centrifuged (300g for 5 minutes) and 
the supernatant was removed.  Cell pellets were suspended in a suitable volume of the 
appropriate growth media.   
 
2.3  DNA/Protein Extraction and Quantification 
 
2.3.1 DNA Extraction (Phenol – Chloroform) 
Genomic DNA was extracted from cell pellets that contained more than 1x105 cells.  Cell 
pellets were re-suspended in 300µl of lysis buffer (100mM NaCl, 10mM Tris.HCl pH 8, 
5mM EDTA pH 8 and 0.5% SDS) containing RNase (300ng/µl - Sigma) and Proteinase 
K (400ng/µl - Sigma).  The cell-lysis mixture was incubated at 45oC for around 18 hours.  
At this point, 300µl of phenol/chloroform (Sigma) were added to the cell lysate.  The 
resulting mixture was placed into a tube rotator and spun for 30 minutes at room 
temperature.  Cell lysates were then centrifuged for 5 minutes at 16,060g.  The aqueous 
phase was transferred to a new tube containing 300µl phenol/chloroform.  This was spun 
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for a further 20 minutes using a tube rotator, before being centrifuged for 5 minutes at 
16,060g.   
 
The resulting aqueous phase was transferred to a new tube and 30µl of Sodium Acetate 
(3M, pH 5.2) and 900µl of Ethanol (absolute, -20oC - Fisher) were then added.  The 
resulting mixture was left at -20oC for a minimum of 20 minutes, allowing the DNA to 
precipitate.  Precipitated DNA was then centrifuged for 5 minutes at 16,060g, with the 
resulting DNA pellet being washed in 70% ethanol (-20oC - Fisher).  Residual ethanol 
was then removed and the DNA was allowed to air dry.  DNA was re-suspended in Tris-
HCl (10mM, pH 8 - Sigma). 
 
2.3.2 DNA Extraction (QIAamp DNA Micro Kit) 
Genomic DNA was extracted from cell pellets that contained less than 1x105 cells.  The 
protocol was performed as outlined in the QIAamp DNA Micro Handbook (Protocol: 
Isolation of Genomic DNA from Small Volumes of Blood).  DNA was eluted into a final 
volume of 50µl using buffer AE.   
 
2.3.3 DNA Quantification 
For concentrations of DNA greater than 20ng/µl, Hoechst 33258 fluorometry was used 
to quantify the DNA with a QuantiFluor-ST Fluorometer (Promega).  2µl of DNA were 
added to 2ml of TEN buffer (1x, 1µg/ml Hoechst – Bio-Rad) and mixed thoroughly before 
being quantified according to the manufacturer’s instructions.    
 
Where the concentration of DNA in a sample was less than 20ng/µl, an assay was 
performed using PicoGreen Dye (Life Technologies) and the Nanodrop 3300 
Fluorospectrometer (Thermo Scientific).  DNA was first diluted 1:100 with Tris-HCl 
(10mM, pH 8 – Sigma).  The 20x stock of PicoGreen Dye was diluted to 1x using TE 
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buffer (10mM Tris-HCl, 1mM EDTA, pH 7.5).  DNA was then further diluted 1:1 with a 1x 
solution of PicoGreen.  The solution was left to incubate at room temperature for 5 
minutes before being quantified.  Regardless of the method used to quantify DNA, 
standard curves were developed using calf thymus DNA (Bio-Rad) and all quantification 
was performed in triplicate. 
 
2.3.4 Protein Extraction (Western Blot) 
Cells were washed twice in PBS (4oC), before being centrifuged at 100g (4oC) for 5 
minutes.  The supernatant was removed and the cells were suspended in 2.5x their 
volume of lysis buffer (150mM NaCl, 50mM Tris-HCl, 5mM EDTA, 1% NP40) that also 
contained 3% v/v PMSF (100mM - Sigma), 1% v/v Protease Inhibitor Cocktail III (100mM 
AEBSF Hydrochloride, 80µM Bovine Lung Aprotinin, 5mM Bestatin, 1.5mM E-64 
Protease Inhibitor, 2mM Leupeptin Hemisulfate, 1mM Pepstatin A  – Calbiochem) and 
1% v/v Phosphatase Inhibitor Cocktail II (200mM Imidazole, 100mM Sodium Fluoride, 
115mM Sodium Molybdate, 100mM Sodium Orthovanadate, 400mM Sodium Tartrate 
Dihydrate - Calbiochem).  The cells were then left on ice for 5 minutes before being 
centrifuged at 20,000g (4oC) for 30 minutes.  The protein-containing supernatant was 
removed and stored at -80oC until required.   
 
2.3.5 Protein Quantification (Western Blot) 
Using lysis buffer, BSA (2mg/ml) was diluted to 0, 100, 200, 300 and 400µg/ml 
concentrations.  The protein samples to be quantified were diluted 1/10 in water.  40µl 
of either a BSA standard or a protein sample were added to a 1.6ml semi-micro cuvette 
(Fisher Brand) and mixed thoroughly with 1ml of coomassie blue reagent (Thermo 
Scientific).  An Ultrospec 3100 Pro (Amersham Biosciences) spectrophotometer was 
used to measure the absorbance at a wavelength of 595nm.  A 1/10 dilution of lysis 
buffer in water was used as a reference.  Protein concentration was calculated by 
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comparing the absorbance recorded for each sample against the absorbance recorded 
for the BSA standard curve.   
 
2.3.6 Protein Extraction (Telomerase Assay) 
Approximately 1x106 cells were suspended in PBS before being centrifuged at 300g for 
5 minutes.  The supernatant was removed and the cell pellet was suspended in 200µl of 
CHAPS lysis buffer (1x - Millipore) and incubated for 30 minutes on ice.  Cell lysates 
were spun at 12,000g (4oC) for 20 minutes. The protein-containing supernatant was then 
removed. 
 
2.3.7 Protein Quantification (Telomerase Assay) 
Protein quantification was performed using the Coomassie Plus Assay Kit (Thermo 
Scientific) and BSA (2mg/ml) as a standard.  10µl of each standard or supernatant 
sample were combined with 300µl of Coomassie Plus Protein Assay Reagent and 
allowed to incubate at room temperature for 10 minutes.  Absorbance at 595nm was then 
measured using the FLUOstar Optima Microplate Reader (BMG Labtech).  Standards 
were measured in duplicate while supernatant samples were measured in triplicate.  
Protein concentration was calculated by comparing the absorbance recorded for each 
sample against the absorbance recorded for the BSA standard curve.    
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2.4  Oligonucleotides 
A list of primers that were used can be found in Table 2.1.  All primers were synthesised 
by MWG-Biotech. 
 
Application Primer Name Primer Sequence (5′ to 3′) 
 
STELA 
 
XpYpE2 
17pSeq1rev 
Teltail 
Tel2 
 
 
TTGTCTCAGGGTCCTAGTG 
GAATCCACGGATTGCTTTGTGTAC 
TGCTCCGTGCATCTGGCATC 
TGCTCCGTGCATCTGGCATCTAACCCT 
 
Fusion 
 
17p6 
XpYpM 
16p1 
21q1 
 
 
GGCTGAACTATAGCCTCTGC 
ACCAGGTTTTCCAGTGTGTT 
TGGACTTCTCACTTCTAGGGCAG 
CTTGGTGTCGAGAGAGGTAG 
 
Fusion 
Reamplification 
 
17p7 
XpYpO 
16p2 
21qSeq1 
 
 
CCTGGCATGGTATTGACATG 
CCTGTAACGCT GTTAGGTAC 
TCACTGCTGTATCTCCCAGTG 
TGGTCTTATACACTGTGTTCCACTG 
 
Fusion 
Sequencing 
 
17p2 
17pSeqR1 
17pSeq1 
17pFries 
17pSeqR3 
17pSeqR2 
17pSeq3 
 
16pSeq4 
16p2SeqB 
16p6 
16pRev8 
16pSeq3 
16p5 
 
10q3 
21qSeq2 
8p1 
10q2 
21q3 
10q1 
21qC 
 
GCTAGGAATGGAATCATTGACTCA 
GAATCCACGGATTGCTTTGTGTAC 
AAGCAGGTTGAGAGGCTGAGG 
CCCTCATCTAAGTCTTGTCGTTTCAT 
TTATAAGCTTTACTGTCTCTCCAC 
CCATTAGCCTGTGGGGTCTGAT 
ACTTGTTGAGGACAGGATTCT 
 
TGGGTCCTGGCAACACTCTG 
GCTCCAGATGACATCACAGGG 
CTCCACTCCAGTGCTCAGCTTG 
ACACATGAAGAGAAAGAAGAGGTCAAAG 
TCCAGGGCTTCACCTGCTAG 
TAGCATGTGTCTCTGCGCCTG 
 
AGACACAGGATAGTGGGCTCTG 
TGCCCCAATCATCATTCACTCTGC 
TGCACAGGACTCTTAGGCTG 
TGCAATGTCCCTAGCTGCCAG 
CTGCAGTTGTCCTAGTCGC 
AGGTTCCACTCGTCTCTGCG 
AGAGTTCTTCTCAGGTCAGACCTG 
 
Table 2.1 – A complete list of all primers used during the study 
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2.5  Polymerase Chain Reaction 
 
2.5.1 STELA PCR 
Tris-HCl (10mM, pH 8 - Sigma) was used to dilute genomic DNA to 250pg/µl.  Tel2 linker 
was then added to a final concentration of 250nM.  A PCR mixture was produced which 
contained Taq buffer (75mM Tris-HCl (pH 8.8), 20mM (NH4)2SO4, 0.01% Tween 20 – 
Thermo Scientific); MgCl2 (2mM – Thermo Scientific); NTPs (1.2mM); telomere-adjacent 
(0.5µM) and teltail (0.5µM) primers; 0.05 Units/µl of a 10:1 mixture of Taq:Pwo 
Polymerase (Thermo Scientific : Roche); and the DNA/Tel2 mixture (25pg/µl and 25mM 
respectively).  Reactions were made up to 10µl using double distilled water and a total 
of six repeats were carried out per DNA sample.  The reactions were cycled using a 
Tetrad thermal cycler (Bio-Rad) under the following conditions: 22 cycles of 94oC for 20 
seconds, 59oC (17pSeq1rev STELA Primer) or 65oC (XpYpE2 STELA Primer) for 30 
seconds and 68oC for 8 minutes. 
 
2.5.2 Fusion PCR 
A PCR mixture was produced which contained Taq buffer (75mM Tris-HCl (pH 8.8), 
20mM (NH4)2SO4, 0.01% Tween 20); MgCl2 (2mM); NTPs (1.2mM); 17p6 (0.5µM), 
XpYpM (0.5µM), 16p1 (0.5µM) and 21q1 (0.5µM) primers; 0.05 Units/µl of a 10:1 mixture 
of Taq: Pwo Polymerase; and 10ng/µl of the DNA to be amplified.  Reactions were made 
up to 10µl using double distilled water and a total of nine repeats were carried our per 
DNA sample.  The reactions were cycled using a Tetrad thermal cycler (Bio-Rad) under 
the following conditions: 25 cycles of 94oC for 20 seconds, 62oC for 30 seconds and 68oC 
for 8 minutes.   
 
2.5.3 Fusion Reamplification PCR 
Successfully amplified Fusion PCR products were diluted 1:40 using double distilled 
water.  A PCR mixture was then produced that contained Taq buffer (75mM Tris-HCl (pH 
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8.8), 20mM (NH4)2SO4, 0.01% Tween 20); MgCl2 (2mM); NTPs (1.2mM); telomere 
adjacent primers (0.5µM); and 0.05 Units/µl of a 10:1 mixture of Taq: Pwo Polymerase.  
3µl of the diluted fusion PCR product were added before the mixture was made up to 
30µl using double distilled water.  The reactions were cycled using a Tetrad thermal 
cycler (Bio-Rad) under the following conditions: 33 cycles of 94oC for 20 seconds, 62oC 
for 30 seconds and 68oC for 8 minutes. 
 
2.5.4 Sanger Sequencing 
4.4µl of the purified fusion reamplification PCR product were combined with BigDye 
Terminator Cycle Sequencing Mix 3.0 or 3.1 (Applied Biosystems) and an appropriate 
sequencing primer (0.16µM) up to a total reaction volume of 10µl.  The reactions were 
cycled using a Tetrad thermal cycler (Bio-Rad) under the following conditions: 26 cycles 
of 96oC for 10 seconds, 50oC for 5 seconds and 60oC for 4 minutes.   
 
2.6  Gel Electrophoresis 
 
2.6.1 STELA and Fusion PCR Products  
DNA fragments were resolved using a 0.5% agarose (Roche) gel produced using Tris-
acetate-EDTA (TAE) buffer (40mM Tris base, 20mM acetic acid, 1mM EDTA) and 
ethidium bromide (1µg/ml – Fisher Scientific).  Gels were submerged in 4oC TAE buffer 
that was cooled using a refrigerated circulating bath (Grant).  5µl of the STELA or fusion 
PCR product were mixed with 1µl of a 6x loading dye (5% bromophenol blue, 5% xylene, 
15% ficol) before being loaded into the gel.  STELA PCR products were run at 120 volts 
for 17 hours.  Fusion PCR products were run at 45 volts for 17 hours.  DNA bands were 
visualised using a UV-transilluminator (Flowgen).   
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2.6.2 Fusion Reamplification PCR Products 
DNA fragments were resolved using a 0.8% agarose (Geneflow) gel produced using 
Tris-acetate-EDTA buffer (40mM Tris base, 20mM acetic acid, 1mM EDTA) and ethidium 
bromide (1µg/ml – Fisher Scientific).  Gels were submerged at room temperature in TAE 
buffer and run at 120 volts for 2 hours. 
 
2.6.3 Proteins (Western Blot) 
3µl of 3x loading buffer (0.5M Tris-HCl, 30% Glycerol, 10% SDS, 3% 2-mercaptoethanol, 
1% bromophenol blue) was added to 10µg of protein in a volume of 12µl.  Protein 
samples and molecular weight markers were then boiled at 100oC for 5 minutes.  
Proteins were resolved using a 10% Mini-Protean TGX Precast Gel (Bio-Rad), 
submerged in running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH8.3), and run 
at 100 volts for 1-2 hours.     
 
2.7  Southern Blot and Radiolabelling 
 
2.7.1 Southern Blot 
Agarose gels, containing resolved STELA or fusion products, were washed twice in 
depurination buffer (0.25M HCl) for 6 minutes per wash.  Gels were then washed in 
denaturation buffer (1.5M NaCl, 0.5M NaOH) for 15 minutes, before the DNA was 
transferred to a positively charged nylon membrane (GE Healthcare) by southern blotting 
for 4 hours.  
 
2.7.2 Radiolabelling DNA Probe 
A 45µl solution of TE buffer, containing 25ng of a DNA probe (Table 2.1), was heated to 
96oC for 5 minutes.  The solution was then cooled on ice for a further 5 minutes before 
being added to an Amersham Rediprime II Random Prime Labelling Bead (GE 
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Healthcare).  4µl of [33P]dCTP (3000Ci/mmol - PerkinElmer) was then added and the 
reaction mixture was heated at 37oC in a water bath.  After 1 hour, 50µl of water and 1µl 
of a [33P]dCTP-labelled DNA ladder (1:1 of 1Kb and 2.5Kb) were added.  Radiolabelled 
probes were stored at 4oC for up to two weeks.     
 
2.7.3 Hybridisation 
Membranes were washed using water and placed into a hybridisation bottle that had 
been warmed to 56oC.  15ml of church buffer (7% SDS, 0.5M sodium phosphate buffer 
(1M disodium hydrogen phosphate and 1M sodium dihydrogen phosphate), 1mM EDTA, 
1% BSA, pH 7.2), also warmed to 56oC, was added to the bottle.  The radiolabelled probe 
was heated to 96oC for 5 minutes before 25µl was then added to the bottle.  Bottles were 
hybridised at 56oC overnight in a rotating hybridisation oven.  Excess probe was then 
removed by washing the membranes in 56oC washing buffer (0.1% sodium chloride 
sodium citrate and 0.1% sodium dodecyl sulphate) six times over the course of an hour.  
Membranes were then dried by placing them at 56oC for 25 minutes.   
 
2.7.4 Visualising Radiolabelled Membranes 
Membranes were placed into a cassette (Amersham) with a phosphoimaging screen 
(Amersham) for 24 hours.  The screen was then scanned using a Typhoon FLA 9500 
biomolecular imager (GE Healthcare).  For STELA, TotalLab TL120 software was used 
to identify the molecular weights of each telomere in a sample.  The distance between 
the STELA primer binding site and the telomere repeating region was then subtracted: 
408bp for the XpYpE2 primer and 311bp for the 17pSeq1rev primer. 
 
2.7.5 Stripping Membranes for Fusion Analysis 
Radiolabelled probes were removed by washing the membrane in a boiling solution of 
0.2% SDS for one hour, three times.  Membranes were then re-probed using the same 
method outlined previously (see 2.7.3 Hybridisation).   
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2.8  Western Blot 
 
2.8.1 Transfer 
A polyvinylidene fluoride transfer membrane (Immobilon-P - Millipore) was submerged 
in methanol (Fisher), before being washed in water for 2 minutes and then transfer buffer 
(25 mM Tris, 192 mM glycine, 20% methanol, pH8.3) for 1 minute.  Resolved proteins 
were transferred from the 10% Mini-Protean TGX Precast Gel (Bio-Rad) to the 
nitrocellulose membrane by western blotting in transfer buffer for 2 hours at 100 volts 
(4oC).   
 
2.8.2 Immunoprobing 
Membranes were blocked in 0.2% Tween/5% milk/PBS for 1 hour.  The membranes 
were then placed into a 15ml falcon tube containing the appropriate antibody solution 
and the appropriate concentration of primary antibody (see Table 2.2).  Tubes were left 
on a roller at 4oC overnight.  Membranes were washed using 1% Tween/PBS for 25 
minutes (with the 1% Tween/PBS being changed after each 5-minute period).  The 
membranes were added to a second 15ml falcon tube which contained the appropriate 
antibody solution and the appropriate concentration of secondary antibody (see Table 
2.2).  Tubes were left on a roller at room temperature for 1 hour.  Again, membranes 
were washed using 1% Tween/PBS for 25 minutes (with the 1% Tween/PBS being 
changed after each 5-minute period).   
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Table 2.2 – A list of the primary and secondary antibodies used for the 
immunoprobing procedure, the concentrations used and the appropriate 
immunoprobing solution. All secondary antibodies were conjugated to 
horseradish peroxidase (HRP).  All antibodies were purchased from Trevigene. 
 
 
 
 
Primary Antibody 
(Dilution) 
Primary Antibody 
(Solution) 
Secondary 
Antibody 
(Dilution) 
Secondary 
Antibody 
(Solution) 
 
Mouse Polyclonal 
Anti-PAR  
(2µl in 2ml) 
 
 
0.2% Tween/5% 
Milk/PBS 
 
Anti-Mouse  
HRP 
(1µl in 2ml) 
 
0.2% Tween/5% 
Milk/TBS 
 
Rabbit Polyclonal 
Anti-Rb  
(8µl in 2ml) 
 
 
0.2% Tween/5% 
Milk/PBS 
 
Anti-Rabbit  
HRP  
(1µl in 2ml) 
 
0.2% Tween/5% 
Milk/TBS 
 
Rabbit Polyclonal  
Anti-Chk-1  
(2µl in 2ml) 
 
 
0.2% Tween/5% 
BSA/TBS 
 
Anti-Rabbit  
HRP  
(1µl in 2ml) 
 
0.2% Tween/5% 
Milk/TBS 
 
Rabbit Polyclonal 
Anti-Actin  
(2.7µl in 2ml) 
 
 
0.2% Tween/1% 
BSA/5% Milk/PBS 
 
Anti-Rabbit  
HRP  
(1µl in 2ml) 
 
0.2% Tween/1% 
BSA/5% Milk/PBS 
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2.8.3 Visualisation with Luminescent Substrates 
Visualisation was performed using the ECL Plus kit (Thermo Scientific).  50µl of reagent 
A were added to 2ml of reagent B.  This solution was then poured over the membrane 
and left at room temperature for 5 minutes.  Excess ECL reagent was poured off and the 
membrane was wrapped in Saran wrap.  In a dark room, Chemiluminescence Hyperfilm 
ECK (Amersham) was exposed to the membrane before being developed and fixed 
using the SRX-101A Medical Film Processor (Konica Minolta Medical and Graphic Inc.).  
Proteins were identified by their molecular weight, using molecular weight markers of 
known size for comparison.   
 
2.8.4 Stripping Antibody from Membrane 
Membranes were washed for 5 minutes in water, 5 minutes with NaOH (0.2M) and 5 
minutes with water.  The membranes were then ready to undergo immunoprobing with 
a different antibody (see 2.8.2 Immunoprobing). 
 
2.9  Telomerase Assay 
 
The telomerase activity of each supernatant sample was measured using the TRAPeze 
XL Telomerase Detection Kit (Millipore).  50µl reaction volumes were produced by 
combining sterile water, TRAPeze XL Reaction Mixture (1x), Taq Polymerase (5 Units) 
and 2µl of each sample.  The reactions were cycled using a Tetrad thermal cycler (Bio-
Rad) under the following conditions: 30oC for 30 minutes; 36 cycles of 94oC for 30 
seconds, 59oC for 30 seconds and 72oC for 60 seconds; and 72oC for 3 minutes.   
 
The 50µl reaction mixture was then combined with 150µl of TRAPeze buffer (10mM Tris-
HCl pH 7.4, 0.15M NaCl and 2mM MgCl2) in a black 96-well microplate (ThermoFisher 
Scientific).  The fluorescence of fluorescein and sulforhodamine were measured using 
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the FLUOstar Omega Microplate Reader (BMG Labtech): fluorescein using an excitation 
wavelength of 485nm and emission was detected at 584nm, sulforhodamine using an 
excitation at 585nm and an emission at 612nm.  Telomerase activity was then calculated 
as per the manufacturers guideline’s.    
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Chapter 3 
Using the Mean XpYp Telomere Length of Whole Bone Marrow Aspirates 
as a Prognostic Indicator in Multiple Myeloma 
 
3.1 Abstract 
Short dysfunctional telomeres have previously been identified as a driving force in 
cancer, resulting in chromosomal fusion and rearrangement that acts to facilitate 
progression of the malignancy.  As it has recently been demonstrated that telomere 
length is an accurate predictor of clinical outcome in patients with chronic lymphocytic 
leukaemia (CLL), we aimed to determine whether a similar relationship existed in 
monoclonal gammopathy of undetermined significance (MGUS) and Multiple Myeloma 
(MM).  We used single telomere length analysis (STELA) to measure XpYp telomeres in 
the whole bone marrow aspirates of 61 MGUS and 141 MM patients.  From this, we 
identified a mean XpYp telomere length threshold of 3.92kb which could be used to 
stratify MM patients as either low- or high-risk.  Multivariate analysis was then employed 
to establish the most significant factors enabling prognostication of the MM cohort.  This 
concluded that the international staging system (ISS) for MM was the most important, 
followed by age at diagnosis and then mean XpYp telomere length.  We therefore sought 
to incorporate this threshold into the ISS for MM, allowing each prognostic subset to be 
further risk-stratified.  Consequently, we argue for the inclusion of telomere length data 
in the ISS, with the aim of increasing the prognostic resolution of this staging system. 
 
The inferior prognosis that often accompanies patients with critically shortened 
telomeres has previously been attributed to chromosomal end-end fusion that drives the 
genomic rearrangement underpinning cancer progression.  We therefore sought to 
determine whether these fusion events were present within the whole bone marrow 
aspirates of MM patients.  Of the 16 samples analysed, each showed evidence of 
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chromosomal end-end fusion.  However, we were unable to demonstrate that the 
presence of these fusion events was directly linked to mean XpYp telomere length.  
Instead, we identified a significant relationship between the standard deviation of each 
STELA profile and the frequency of fusion, suggesting that a subset of critically 
shortened telomeres may be responsible for the genomic instability and chromosomal 
rearrangements that define MM.   
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3.2 Introduction  
Multiple myeloma (MM) is a plasma cell disorder, characterised by osteolytic bone 
lesions, renal failure and anaemia (International Myeloma Working 2003).  It is caused 
by an uncontrolled growth of abnormal plasma cells within the bone marrow, resulting in 
the release of large quantities of paraprotein into the blood (Rajkumar et al. 2014).  MM 
is often preceded by monoclonal gammopathy of undetermined significance (MGUS), an 
asymptomatic disorder from which the risk of developing symptomatic MM is 1% per year 
for each patient (Kyle et al. 2002).  Rates of survival for MM patients can range from 
months to years, resulting in a disease which is characterised by its heterogeneous 
clinical course (Jimenez-Zepeda et al. 2016).  Reliable prognostic markers are therefore 
necessary to provide accurate risk stratification and aid in clinical decision making.   
 
Developed in 1975, the Durie-Salmon staging system was one of the earliest methods 
used to stratify MM patients.  Its intention was to estimate the risk of disease progression 
based upon some of the most common clinical features of MM (Durie and Salmon 1975).  
One such feature is an increased concentration of serum calcium, a product of the bone 
resorption that occurs when abnormal plasma cells activate osteoclasts within the bone 
marrow.  The resulting loss of bone density also produces lesions, manifesting as 
weakened bones or painful fractures (Tanaka et al. 2007; Terpos, Moulopoulos, and 
Dimopoulos 2011).  A further feature of MM is the presence of circulating paraprotein, 
with increasing concentrations in the blood pointing towards a greater number of 
abnormal plasma cells within the bone marrow.  These cells cause a loss of bone marrow 
homeostasis resulting in, for example, impaired red blood cell production and anaemia 
(Maes et al. 2010).  Together, these four features (reduced serum calcium, evidence of 
bone lesions, increased paraprotein concentration and reduced haemoglobin 
concentration) are used by the Durie-Salmon staging system to gauge the clinical stage 
of each MM patient. 
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However, a new staging system was developed in 2005 by the International Myeloma 
Working Group.  This is known as the international staging system (ISS) and primarily 
utilises the concentration of serum β2 microglobulin to stratify patients (Greipp et al. 
2005).  As a component of the MHC class I molecule, β2 microglobulin is present on the 
surface of all nucleated cells.  Free β2 microglobulin is normally filtered from the blood 
by the kidneys, but the impaired renal function that often accompanies MM can result in 
its accumulation (Rossi et al. 2010).  For this reason, β2 microglobulin concentrations 
are thought to act as an indirect measurement of both tumour mass and renal function.  
Serum albumin, the main component of blood plasma, is also used to stratify low- and 
intermediate-risk MM patients when β2 microglobulin concentrations are below 3.5mg/L.  
It is thought that reduced concentrations of serum albumin are the result of increased IL-
6 production by the myeloma microenvironment (Jacobson et al. 2003).   
 
In 2015, the ISS was revised to incorporate chromosomal abnormalities and serum 
lactate dehydrogenase (LDH) concentrations (Palumbo et al. 2015).  The presence of 
del(17p), t(4;14) or t(14;16) was now enough to classify a patient as high-risk.  This was 
due to the loss of TP53 conferred by del(17p), resulting in disruption to apoptotic and 
senescent pathways (Avet-Loiseau et al. 2007).  Meanwhile, t(4;14) and t(14;16) are 
known to enhance the survival of malignant plasma cells by upregulating cyclin D2 and 
c-MAF expression (Bergsagel and Kuehl 2005; Zhan et al. 2006).  Increased 
concentrations of LDH also indicate higher tumour burden, with intermediate- and high-
risk patients being identified based on abnormal serum LDH levels (Terpos et al. 2010).   
 
However, performing four separate tests in line with the revised ISS guidelines increases 
both the cost and time required for prognostication.  Meanwhile, the original ISS relies 
too heavily on the concentration of serum β2 microglobulin to accurately stratify 
intermediate- and high-risk patients.  For these reasons, a new cost-effective prognostic 
indicator is necessary which can increase the prognostic resolution of the ISS for MM.   
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It has recently been demonstrated that telomere length holds significant prognostic value 
in chronic lymphocytic leukaemia (CLL), breast cancer and myelodysplasia (Lin et al. 
2014; Simpson et al. 2015; Williams et al. 2017).  In the case of CLL, the mean XpYp 
telomere length threshold of 3.81kb was identified, below which chromosomal end-end 
fusion events were detected.  Of those patients in which fusion events were detected, 
the mean XpYp telomere length was 2.26kb.  Using both 3.81kb and 2.26kb to stratify 
CLL patients proved to be highly prognostic, although 2.26kb was shown to hold the 
greatest prognostic significance (Lin et al. 2014).  This 2.26kb threshold also held the 
greatest prognostic significance when used to stratify breast cancer patients (Simpson 
et al. 2015).   
 
However, these are not the only studies linking telomere length to prognosis.  Shorter 
mean telomere length has also been shown to correlate with poor survival in bladder, 
prostate and lung cancer (Russo et al. 2014; Heaphy et al. 2013; Jeon et al. 2014).  A 
meta-analysis by Zhang et al. (2015) concluded that shorter mean telomere length was 
significantly associated with poor cancer survival across forty-five independent studies.  
The reason for this prognostic significance is likely to be the relationship between 
critically shortened telomeres and genomic instability.  If the DNA damage signalling 
pathways in a cell are compromised, then cell division may continue beyond the Hayflick 
limit.  Once the protective function of the telomere is lost, chromosomal ends can be 
recognised as double-strand DNA breaks and may be subject to fusion with other 
unprotected ends.  The resulting genomic instability is known as a telomere-driven crisis 
and is thought to drive cancer progression (Lin et al. 2010; Roger et al. 2013; Gisselsson 
et al. 2001).   
 
A small-scale study has already established that the bone marrow aspirates of MM 
patients demonstrate a shorter mean telomere length than the aspirates of healthy 
individuals (Cottliar et al. 2003).  The mean telomere length of plasma cells from MM 
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patients are also known to be shorter than those of leukocytes isolated from the same 
patient (Wu et al. 2003).  However, little is known about the prognostic value of these 
telomere length measurements.  We therefore sought to assess whether a relationship 
existed between mean XpYp telomere length and overall survival in cohorts of MGUS (n 
= 61) and MM (n = 141) patients.  This involved measuring mean telomere length in the 
whole bone marrow aspirates of these patients using STELA.   
 
We used a mean XpYp telomere length threshold of 3.92kb to stratify low- and high-risk 
MM patients.  Multivariate analysis was then employed to establish the most significant 
factors enabling prognostication of the MM cohort.  This concluded that the international 
staging system (ISS) for MM was the most important, followed by age at diagnosis and 
then mean XpYp telomere length (Hyatt et al. 2017).  Inclusion of this telomere length 
threshold within the ISS criteria increased prognostic resolution, resulting in the further 
stratification of stage I/II and stage III patients.  We then attempted to identify the 
underlying mechanism for the prognostic significance of telomere length measurements 
in MM, seeking to explore the relationship between telomere shortening and genomic 
instability.  Utilising a small cohort of 16 MM patients, we observed that the frequency of 
chromosomal end-end fusion events was not directly linked to mean XpYp telomere 
length in this study, but was significantly linked to the standard deviation of the STELA 
profile.  
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3.3 Aims of the Chapter 
We hypothesised that telomere length measurements held prognostic value within the 
context of MM.  The aim of this chapter was therefore to identify whether STELA could 
be used to isolate low- and high-risk patients within a MM cohort.  We then considered 
whether telomere length measurements could be used to refine the prognostic resolution 
of the ISS.  We also aimed to determine whether chromosomal end-end fusion events 
could be detected in the bone marrow aspirates of MM patients, as well as whether a 
relationship existed between telomere length and the frequency of these fusion events.  
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3.4 Results 
3.4.1 Characteristics of the MGUS and MM Cohorts 
Bone marrow aspirates were obtained from 61 MGUS and 141 MM patients.  Clinical 
data was also available for the majority of patients in each cohort.  This included the 
patient’s serum β2 microglobulin, haemoglobin, albumin and calcium levels (Table 3.1).  
When compared to the cohort of patients used to outline the original ISS guidelines 
(Greipp et al. 2005), our MM cohort had almost identical mean β2 microglobulin (3.8mg/L 
versus 4.0mg/L) and albumin (3.6g/dL versus 3.6g/dL) levels.  The gender composition 
of the Greipp et al. (2005) cohort was 57% male and 43% female; our MM cohort was 
54% male and 46% female.  Average age at diagnosis for the Greipp et al. (2005) cohort 
was 66 years, against our MM cohort which was 72 years.  From this, we concluded that 
our patient cohort was directly comparable to that of the original ISS cohort.  It is 
important to note that mean and median values for the serum haemoglobin and calcium 
concentrations of our cohort could not be established due to the presence of non-
numerical values.  Calcium concentrations were defined as being either ‘normal’ or ‘high’, 
preventing a comparison with other studies from being made. 
 
By combining this data with the outcomes for each patient, we could plot Kaplan-Meier 
survival curves for our MM cohort (Figure 3.1).  In each case, the thresholds used to 
stratify patients were the same as those used in the ISS (β2 microglobulin </>5.5mg/L 
and albumin </>3.5g/dL) or Durie-Salmon staging system (haemoglobin </>10g/dL).  
From this, it was observed that β2 microglobulin levels held the greatest prognostic value 
(HR = 3.6), followed by haemoglobin (HR = 3.1), age at diagnosis (HR = 2.5) and serum 
albumin concentration (HR = 2.0).  Meanwhile, stratification of patients based on serum 
calcium concentration (HR = 1.3) and gender (HR = 0.83) proved to hold little prognostic 
value.  Again, this observation closely mirrored the results of the original ISS cohort 
(Greipp et al. 2005).  In this case, β2 microglobulin was shown to have the greatest 
prognostic value, followed by age at diagnosis, haemoglobin, serum albumin, serum  
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MGUS 
 Patient Data 
Available 
for… 
Mean Median Range 
Age at Diagnosis 
(Years) 
49 66.31 69 33 - 90 
Survival 
(Months) 
41 31.78 19 1 - 200 
β2 microglobulin 
(mg/L) 
50 5.16 4.85 1.3 - 22 
Albumin  
(g/dL) 
45 4.18 4.2 3.5 – 4.7 
Haemoglobin 
(g/dL) 
48 - - - 
Calcium 
(Normal vs High) 
46 
(46 vs 0) 
- - - 
Gender  
(Male vs Female) 
52 
(22 vs 30) 
- 
 
- - 
XpYp Telomere 
Length (kb) 
61 5.33 5.41 1.00 - 7.61 
Telomere Length 
Standard deviation 
(kb) 
61 2.23 2.23 0.82 – 3.77 
 
 
Multiple Myeloma 
 Patient Data 
Available 
for… 
Mean Median Range 
Age at Diagnosis 
(Years) 
129 64.31 66 34 - 87 
Survival 
 (Months) 
131 50.89 48 1 - 192 
β2 microglobulin 
(mg/L) 
95 7.26 4 1.6 – 53.2 
Albumin  
(g/dL) 
73 3.55 3.6 2.2-4.8 
Haemoglobin 
(g/dL) 
111 - - - 
Calcium 
(Normal vs High) 
115 
(74 vs 41) 
- - - 
Gender  
(Male vs Female) 
137 
(74 vs 63) 
- - - 
XpYp Telomere 
Length (kb) 
141 4.84 4.96 1.26-7.51 
Telomere Length 
Standard Deviation 
(kb) 
141 2.12 2.08 0.60 – 4.20 
Table 3.1 – Characteristics of the MGUS and MM Cohorts 
Mean XpYp telomere length was measured in the whole bone marrow aspirates of 202 MGUS 
and MM patients.  This table lists the characteristics of each cohort.  
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calcium and patient gender.  The major difference was that Greipp et al. (2005) still found 
serum calcium concentrations to hold significant prognostic value, whereas we did not.  
This was likely due to the limited size of our MM cohort (n = 141) against the larger cohort 
size used to define the ISS (n = 10,750).   
 
3.4.2 MGUS and MM Exhibit Heterogeneous Telomere Length Distributions 
Single telomere length analysis (STELA) is a single-molecule PCR-based technique 
which allows individual telomeres from specific chromosomal ends to be measured 
(Baird et al. 2003).  We used STELA to measure the mean XpYp telomere length in 61 
MGUS and 141 MM patients.  Figure 3.2a is an example of the STELA profiles that were 
produced for each of these patients.  Every band represents a single XpYp telomere, 
with the mean telomere length of a patient being calculated from this profile.  The mean 
XpYp telomere length across the MGUS and MM cohorts were 5.33kb and 4.84kb 
respectively.  Comparisons with Cottliar et al. (2003) suggested that these values were 
shorter than the average telomere length of healthy control bone marrow aspirates 
(8.50kb), but similar to those of MM bone marrow aspirates (5.20kb) calculated using 
TRF analysis.   
 
Standard deviation was used as a measurement of telomere length heterogeneity within 
an individual STELA profile.  The mean of the standard deviations across the MGUS and 
MM cohorts were 2.23kb and 2.12kb respectively.  These values were much greater than 
that of the clonal fibroblast populations (~0.85kb) or purified B cell populations (~1.00kb) 
identified by Lin et al. (2010).  Although MM is characterised by the growth of clonal 
plasma cell populations, the DNA samples analysed here were isolated from unsorted 
bone marrow aspirates.  This means that the XpYp telomeres of multiple cell types were 
being measured, unlike that of a clonal population whereby a single cell type is being 
measured.  Therefore, the heterogeneous telomere length profiles observed may have 
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been caused by the diverse cellular composition of each DNA sample and/or the 
replicative history of each cell type.     
 
A number of STELA profiles also displayed multimodal distributions (Figure 3.2b and 
3.2c).  These are distinct distributions of telomere lengths within a single STELA profile, 
with each distribution having a unique mean telomere length.  Again, their presence 
reflects the different replicative histories of the various cell types that compose the bone 
marrow microenvironment.  Given that the mean telomere lengths of plasma cells 
isolated from MM patients are known to be significantly shorter than those of healthy 
controls (Wu et al. 2003), we next sought to determine whether plasma cells were 
responsible for the presence of these shortened telomere length distributions within the 
STELA profiles of MM patients.  
 
Isolation of CD138+ cells from the whole bone marrow aspirates of three MM patients, 
followed by STELA of both the CD138- and CD138+ fractions, revealed that CD138+ cells 
often had significantly shortened telomeres when compared to the rest of the aspirate 
(Figure 3.3).  In the case of each patient, mean XpYp telomere length of the whole 
aspirate lay above the 3.81kb fusogenic threshold identified in CLL.  However, mean 
XpYp telomere length of the CD138+ fraction fell below this threshold in each case, with 
the CD138+ cells of patient J also falling below the CLL fusogenic mean threshold of 
2.26kb (Lin et al. 2014).  The mean XpYp telomere length of the CD138+ fractions from 
these three patients was 2.40kb.   
 
Plotting the mean XpYp telomere lengths of MGUS and MM patients revealed that a 
significant difference existed (p = 0.01) between the two cohorts (Figure 3.4a).  MGUS 
patients often had longer telomeres (mean = 5.33kb) than MM patients (mean = 4.84kb).  
Also, a much greater proportion of MM patients had a mean XpYp telomere length that 
fell below the CLL fusogenic threshold of 3.81kb (5 MGUS against 26 MM).  A significant 
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difference was also observed between the mean XpYp telomere lengths of ISS I and ISS 
II MM patients (p = 0.05), as well as ISS I and ISS III MM patients (p = 0.03).  However, 
a significant difference did not appear to exist between the mean XpYp telomere lengths 
of ISS II and ISS III MM patients (p = 0.8).   
 
Plotting the mean XpYp telomere length of whole bone marrow aspirates against the 
patient’s age at diagnosis (Figure 3.4b) demonstrated that a statistically significant 
relationship existed (p = 0.009).  Mean XpYp telomere length of the cohort was shown 
to decrease by an average of 22 base pairs per year, consistent with the average 
telomeric erosion rates observed in the leukocytes (-26bp per year), muscle (-24bp per 
year) and skin (-23bp per year) of healthy adults (Daniali et al. 2013).   
 
3.4.3 Telomere Length is Highly Prognostic in MM 
To determine whether the mean telomere length of whole bone marrow aspirates held 
prognostic significance in MM, we attempted to stratify patients as either low- or high-
risk based on an XpYp telomere length threshold.  It is important to note that data 
regarding overall survival was only available for 131 of the 141 MM patients.  Recursive 
partitioning was used to test a range of telomere-length thresholds between 2kb and 6kb 
(Figure 3.5a).  The optimum threshold in the 131-patient cohort that provided the most 
prognostic significance (HR = 3.6; P < 0.0001) was found to be 3.93kb.  A Kaplan-Meier 
survival curve was then plotted using this threshold (Figure 3.5b), showing that patients 
with a mean XpYp telomere length greater than 3.92kb had a significantly increased 
median survival (85 months) when compared to patients with a mean XpYp telomere 
length less than 3.92kb (16 months).  For comparison, a second threshold of 4.96kb was 
plotted as this was the median value of the 131 mean XpYp telomere lengths (Figure 
3.5c).  This threshold was shown to hold prognostic significance (HR = 1.7; P = 0.02), 
but did not confer the same level of significance as the 3.92kb threshold.   
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A survival curve was then plotted using the 3.81kb fusogenic threshold identified in CLL 
(Figure 3.5d).  Due to the proximity of this threshold to our 3.92kb threshold, only four 
patients were recategorised.  Unsurprisingly, this also held prognostic significance and 
had an almost identical hazard ratio (HR = 3.4; P < 0.0001) to that of the 3.92kb 
threshold.  Although the 2.26kb fusogenic mean threshold identified in CLL was also 
plotted for our 131-patient MM cohort, the small number of patients (n = 5) whose mean 
XpYp telomere length fell below 2.26kb rendered this result insignificant (Figure 3.5e).  
An insufficient number of patients was also the reason why this analysis was not 
conducted in the MGUS cohort.  Data regarding overall survival was only available for 
41 MGUS patients, with each having a mean XpYp telomere length greater than 3.92kb.  
There was therefore limited merit in undertaking univariate analysis in this cohort.   
 
3.4.4 Incorporating Telomere Length Measurements into the ISS  
Although mean XpYp telomere length measurements held significant prognostic value in 
our MM cohort, they did not provide the same level of stratification as the ISS.  Even as 
an isolated marker, serum β2 microglobulin concentrations held greater prognostic 
significance than the 3.92kb telomere length threshold.  Multivariate analysis, carried out 
by Professor Robert Hills of Cardiff University, was employed to establish the most 
significant factors enabling prognostication of the MM cohort.  This concluded that the 
international staging system (ISS) for MM was the most important, followed by age at 
diagnosis and then a mean XpYp telomere length below 3.81kb.  Even after adjusting 
for ISS and age, patients with a telomere length below 3.81kb had a significantly shorter 
survival (Hyatt et al. 2017).  We therefore sought to combine ISS grouping and telomere 
length measurements, with a view to increasing the prognostic resolution of the ISS.   
 
Of the 131 MM patients for which survival data was available, serum β2 microglobulin 
concentrations were known for 95 of these.  However, data regarding serum albumin 
concentration was only available for 66 patients.  For this reason, as well as the fact that 
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serum albumin only plays a minor role in stratifying low- and intermediate-risk patients, 
we sought to combine stage I and stage II patients into a single cohort.  Using this data, 
we aimed to use mean XpYp telomere length measurements as a way to improve the 
prognostic resolution of the ISS with regard to intermediate- (stage I/II, <5.5mg/L β2 
microglobulin) and high-risk (stage III, >5.5mg/L β2 microglobulin) patients.   
 
Kaplan-Meier survival curves were plotted based on either the mean XpYp telomere 
length of the 95-patient cohort (Figure 3.6a), or their staging within the ISS (Figure 
3.6b).  Strikingly, the two curves appeared to plot a similar result for median survival, 
with <3.92kb mean XpYp telomere length patients and stage III patients having a median 
overall survival of 13 months and 14 months respectively.  Combining the mean XpYp 
telomere length threshold of 3.92kb with the ISS scoring for each patient resulted in 
further stratification of the stage I/II and stage III patients (Figure 3.6c).  ISS I/II patients 
with a mean XpYp telomere length below the 3.92kb threshold had a significantly 
reduced survival, while ISS III patients with a mean telomere length above the 3.92kb 
threshold had a significantly increased survival.  Combining these two new subgroups 
resulted in the formation of an intermediate subgroup, increasing prognostic resolution 
when compared to serum β2 microglobulin concentrations alone (Figure 3.6d).  For 
comparison, this analysis was repeated using the 3.81kb CLL fusogenic threshold 
(Supplementary Figure 1).  However, little difference was observed between this 
threshold and the 3.92kb threshold.   
 
3.4.5 Identifying Chromosomal Fusion Events in the Bone Marrow Aspirates 
of MM Patients 
Although we had demonstrated that mean XpYp telomere length measurements held 
significant prognostic value within the context of MM, an explanation for this observation 
had yet to be established.  Previous studies in CLL and colorectal cancer had identified 
a relationship between critically shortened telomeres and genomic instability 
  Chapter 3 - Results 
106 
 
 
  Chapter 3 - Results 
107 
 
(Lin et al. 2010; Roger et al. 2013).  It was thought that chromosomal end-end fusion 
events, which can occur after significant telomeric erosion, drove genomic 
rearrangement and cancer progression.  We therefore set out to determine whether 
these fusion events could be detected within the bone marrow aspirates of MM patients, 
as well as if the frequency of fusion was in some way linked to the mean XpYp telomere 
length of the whole bone marrow aspirate.   
 
Aspirates were obtained from 16 MM patients attending the haematology outpatient clinic 
at the University Hospital of Wales.  Patients were analysed for chromosomal end-end 
fusion events involving the 17p, XpYp, 16p family and 21q family of chromosomal ends 
(Figure 3.7a).  In each case, multiple fusion events were identified (Figure 3.7a; 
Supplementary Figures 2, 3, 4, 5, 6 and 7).  Of these, we were able to sequence three 
fusion events as a way of observing the extent of genomic erosion and the different types 
of events that can present (Figure 3.7b).  At five of these chromosomal ends, between 
1096 and 2770 base pairs of genomic DNA had been lost.  Only a single 17p 
chromosomal end showed any evidence of telomeric repeats, with fifty-seven TTAGGG 
repeats or variant repeats identified.  It could also be seen that fusion 3 contained 
extensive microhomology at the fusion site, with both chromosomes sharing an 
overlapping sequence of eight base pairs.   
 
Subsequent STELA of the 16 whole bone marrow aspirates identified a heterogeneous 
range of mean XpYp telomere lengths (Figure 3.8).  Simply plotting the frequency of 
chromosomal fusion observed for each patient against their respective mean XpYp 
telomere length (Figure 3.9a) was shown to hold little significance (p = 0.3).  However, 
plotting fusion frequency against the standard deviation for each STELA profile (Figure 
3.9b) resulted in the identification of a significant relationship (p = 0.04).   
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As we had previously demonstrated that the CD138+ plasma cells of MM patient bone 
marrow aspirates had significantly shorter telomeres than the CD138- cells, we used the 
mean of the 25th percentile of XpYp telomere lengths as an estimation of plasma cell 
telomere length in this 16-patient cohort.  Unfortunately, plotting the frequency of 
chromosomal fusion events against the telomere length of the 25th percentile (Figure 
3.9c) failed to demonstrate any significant correlation (p = 0.8).  However, plotting the 
frequency of chromosomal fusion events against the difference between the mean of the 
whole STELA profile and the 25th percentile (Figure 3.9d) resulted in significance (p = 
0.02).  It was thought that the different between the mean XpYp telomere length and the 
25th percentile was similar to that of the standard deviation of the STELA profiles, 
estimating the extent to which the telomere length of the plasma cell population differed 
from that of the remaining bone marrow stromal cells.   
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3.5 Discussion 
3.5.1 Telomeric Shortening in MM 
It has been well documented that a shorter mean telomere length is associated with a 
poorer outcome in specific cancers (Zhang et al. 2015).  With regard to CLL and breast 
cancer, telomere length measurements are known to hold significant prognostic value 
(Lin et al. 2014; Simpson et al. 2015).  We therefore hypothesised that this relationship 
may extend to MM, whereby telomere length measurements could be used to stratify 
patients based on their risk of disease progression.  Using a high-resolution telomere 
length analysis technique (STELA) on the whole bone marrow aspirates of 61 MGUS 
and 141 MM patients, we sought to identify whether mean XpYp telomere length 
measurements held prognostic value within the context of these disorders. 
 
Comparing the mean XpYp telomere length of the cohorts demonstrated that MGUS 
patients had a significantly longer telomere length than that of MM patients.  The mean 
XpYp telomere length of ISS I patients was also significantly longer than that of ISS II 
and ISS III patients.  This result is supported by Cottliar et al. (2003), a small-scale study 
which demonstrated that the whole bone marrow aspirates of MM patients had a shorter 
mean telomere length than those of healthy controls.  This relationship is mirrored in 
CLL, whereby a shorter mean XpYp telomere length is associated with an increased 
Binet staging classification (Lin et al. 2010).  But although malignant B-cells were 
identified as the cause of this telomeric shortening in CLL, we had yet to establish a 
similar cause in MM (Lin et al. 2010).   
 
As it is unlikely that telomere length is dynamically regulated throughout the course of 
the disease, due in part to the observation that telomerase activity also increases during 
the progression of MM (Xu, Zheng, et al. 2001; Shiratsuchi et al. 2002), it could be argued 
that the telomeric erosion originates from a single cell which will eventually give rise to a 
clonal population.  This idea was explored by Roger et al. (2013) using polyps and 
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carcinoma samples from patients with colorectal cancer.  It was demonstrated that 
telomere length was extremely variable between different colorectal polyps obtained 
from the same individual.  Also, mean telomere length did not significantly differ between 
a patient’s polyp and carcinoma samples, suggesting that telomere length was 
established before the progression of the cancer.  It was therefore thought that cells with 
shorter telomeres gave rise to tumours with shorter telomeres which were genetically 
unstable, rather than the mean telomere length of an individual cell decreasing as the 
disease progressed.     
 
As a way of identifying the source of the telomeric shortening observed in MM patients, 
we next isolated CD138+ plasma cells from the whole bone marrow aspirates of three 
MM patients. Mean XpYp telomere length was then calculated for both the CD138+ and 
CD138- cell fractions, demonstrating that plasma cells had a significantly reduced 
telomere length when compared to other non-malignant marrow cells.  This was 
consistent with the idea that these plasma cells exhibited an extensive replicative history 
when compared to the CD138- cells of the bone marrow.  These results were 
corroborated by Wu et al. (2003), whereby the CD138+ cells of MM patients were shown 
to have significantly shorter mean telomere lengths than those of leukocytes extracted 
from the same patient.  Given these findings, it could be argued that mean XpYp telomere 
length measurements in MGUS and MM patients reflect the tumour mass within the bone 
marrow.  As the disease progresses and the plasma cell population increases, mean 
XpYp telomere length of the whole bone marrow aspirate would decrease.  This would 
appear to concur with Cottliar et al. (2003), who demonstrated that the mean telomere 
length of MM patient whole bone marrow aspirates decreased as plasma cell infiltration 
increased.   
 
Although an estimation of the percentage of plasma cells within the bone marrow is used 
during the diagnosis of MGUS and MM, it is not used to stage the disease (Rajkumar et 
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al. 2014; Palumbo et al. 2015).  This is partially because quantifying plasma cell 
infiltration can be open to interpretation, reducing the accuracy of risk stratification (Al-
Quran et al. 2007).  Instead, clinical features such as serum β2 microglobulin 
concentration are used as a precise and consistent reflection of tumour mass (Greipp et 
al. 2005).  However, the original ISS relies heavily on serum β2 microglobulin 
concentrations to stratify patients.  Serum albumin concentrations are only considered 
when β2 microglobulin is <3.5g/dL, differentiating between ISS I and certain ISS II 
patients.  The remaining intermediate- and high-risk patients are stratified based solely 
on whether β2 microglobulin is >3.5g/dL or >5.5g/dL.  The next step was therefore to 
identify whether telomere length measurements held significant prognostic value with 
regard to MM, as well as to explore whether mean telomere length measurements might 
refine the staging criteria of the ISS.   
 
3.5.2 Telomere Length as a Prognostic Indicator in MM 
Taken as isolated prognostic factors, the mean XpYp telomere length threshold of 3.92kb 
was found to be one of the most significant methods used to stratify our MM cohort.  Only 
serum β2 microglobulin concentrations held greater prognostic value.  Although not as 
significant as measuring mean XpYp telomere length, serum albumin (</>3.5g/dL) and 
haemoglobin (</>10g/dL) concentrations also held prognostic value.  In line with the 
current literature, age (</>65 years) was shown to be a significant prognostic indicator, 
while gender was not (Kim et al. 2010; Palumbo et al. 2015).   
 
However, calcium concentration was found to hold little significance when used to stratify 
our MM cohort.  This is not a view shared by other studies, whereby a serum calcium 
concentration >10mg/dL led to a poorer patient outcome (Kim et al. 2010; Greipp et al. 
2005).  Although we also demonstrated that a higher serum calcium concentration 
resulted in a poorer patient outcome, this was not shown to be a significant result.  One 
possible explanation for this discrepancy could be that the patient numbers used in our 
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study were too low.   While we had access to the serum calcium concentrations and 
survival data of 115 MM patients, Kim et al. (2010) and Greipp et al. (2005) had access 
to 372 and 10,750 patients respectively.   
 
Regardless, including the 3.92kb mean XpYp telomere length threshold within the ISS 
significantly increased prognostic resolution when compared to serum β2 microglobulin 
concentrations alone.  It could be argued that a limitation of this study was the lack of 
data regarding patient serum albumin concentrations, thus requiring ISS I and ISS II 
patients to be combined.  However, albumin is only necessary to stratify low- and 
intermediate-risk MM patients.  There is little need to develop a new staging criteria for 
these patients when albumin concentrations already suffice.  Our focus was therefore on 
increasing the prognostic resolution of those intermediate- and high-risk patients for 
which β2 microglobulin concentrations are the only staging criteria.   
 
In this sense, we were successful in further risk-stratifying the ISS III patient cohort.  We 
therefore suggest that the stratification of patients based on tumour burden alone, as 
measured by serum β2 microglobulin concentration, is insufficient as it fails to account 
for highly aggressive and genetically unstable tumour subtypes.  Telomere length 
measurements may not only reflect the tumour mass within the bone marrow, but might 
also account for those plasma cell populations that have short dysfunctional telomeres 
and may be more prone to fusion and genomic rearrangement (Capper et al. 2007).  
Furthermore, the ability of telomere length measurements to sub-stratify ISS I/II patients 
calls into question the value of measuring serum albumin concentrations.  Further work 
needs to focus on identifying whether telomere length measurements could replace 
albumin in the ISS, or whether telomere length measurements should be used alongside 
serum β2 microglobulin and albumin concentrations to develop a four-stage ISS.   
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However, it is also worth noting that the ISS has recently been updated to include the 
presence of genetic abnormalities and serum lactate dehydrogenase (LDH) 
concentrations.  Known as the revised ISS, patients can be classified as high-risk if 
del(17p), t(4;14) or t(14;16) abnormalities are detected within the plasma cells.  
Unfortunately, this data was not available for our cohort and so we were unable to 
incorporate telomere length measurements into this updated staging system.  Future 
work may therefore require a new MM cohort to be establish for which genetic 
information is known.  This would allow the prognostic value of telomere length 
measurements to be examined within the context of the revised ISS.   
 
In any case, the identification of a 3.92kb prognostic threshold in MM was striking due to 
its proximity to the 3.81kb fusogenic threshold identified in CLL.  Hazard ratios for the 
3.92kb and 3.81kb telomere length thresholds in MM were 3.6 and 3.4 respectively, with 
this similarity likely caused by a difference of only four patients.  Lin et al. (2014) observed 
that chromosomal end-end fusion could only be detected in the isolated B-cells cells of 
CLL patients when mean XpYp telomere length fell below 3.81kb.  This genomic 
instability was thought to be driven by critically shortened telomeres, leading to a 
reduction in patient overall survival and accounting for the prognostic value of this 3.81kb 
threshold.  It could therefore be suggested that the prognostic value of the 3.92kb 
threshold in MM may have also been due to genomic instability.  This would most likely 
be driven by the shorter mean XpYp telomere lengths of the CD138+ plasma cell 
populations within the bone marrow. 
 
However, 3.81kb was not the most significant prognostic threshold identified in CLL.  This 
was 2.26kb, defined as the median XpYp telomere length of those patients whose 
isolated B-cells showed evidence of chromosomal end-end fusion.  Again, critically 
shortened telomeres were thought to be the cause of this genomic instability, resulting 
in the prognostic significance of the threshold (Lin et al. 2014).  Unfortunately, this 2.26kb 
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threshold could not be used to stratify our MM cohort as only four patients had a mean 
XpYp telomere length below 2.26kb.  This difference was thought to be due to cell types 
used in each study, with Lin et al. (2014) analysing the mean telomere length of CD19-
sorted B-cells and our study analysing the mean telomere length of unsorted bone 
marrow.  For this reason, we next sought to examine the mean XpYp telomere lengths 
of isolated CD138+ plasma cells in relation to a 2.26kb threshold. 
 
As described earlier, CD138+ plasma cells were shown to be the source of telomeric 
shortening in the whole bone marrow aspirates of three MM patients.  The average XpYp 
telomere length in the case of these three patients was 2.40kb, only marginally longer 
than the 2.26kb median fusogenic threshold identified in CLL (Lin et al. 2014).  This begs 
the question of whether the prognostic significance of XpYp telomere length 
measurements in MM could be improved by first isolating CD138+ cells from the whole 
bone marrow aspirate.  This method could potentially be used to recognise high-risk 
patients whose CD138+ cells contain shorter fusion-prone telomeres, even when plasma 
cell infiltration within the bone marrow is low.   
 
3.5.3 Chromosomal Fusion in MM 
Lin et al. (2014) observed that chromosomal end-end fusion events could only be 
detected in the isolated B-cells of CLL patients when mean XpYp telomere length fell 
below 3.81kb.  Not only did a significant number of MM patients within our cohort have 
a mean XpYp telomere length below this threshold, but these patients were also shown 
to have a poorer outcome.  We therefore attempted to detect chromosomal end-end 
fusion events in the whole bone marrow aspirates of sixteen MM patients, before trying 
to establish whether the extent of genomic instability correlated with telomere length.  It 
was expected that, as genomic instability was closely linked to mean telomere length 
and patient outcome in CLL, a similar relationship may exist in MM.   
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Of the sixteen MM patients analysed, each showed evidence of chromosomal end-end 
fusion.  We then sequenced three of these fusions to demonstrate that they were 
legitimate events.  Telomeres at five of the chromosomal ends involved had been 
completely lost, either due to erosion during cell division or deletion during breakage-
fusion-bridge cycles.  This was consistent with the results of Capper et al. (2007) who 
had attempted to define the critical telomere length at which fusion occurred in MRC5 
cells.  After sequencing seventy-nine chromosomal end-end fusion events, they 
determined that 47% contained no TTAGGG repeats immediately adjacent to the fusion 
site.  It was also observed that each fusion event analysed involved the deletion of one 
or both telomeres from the chromosomal ends involved, again consistent with our results. 
 
Although one of the fusion events isolated from our 16-patient MM cohort had fifty-seven 
telomeric repeats at the fusion site, those repeats immediately adjacent to the fusion site 
were telomere variant repeats.  It is known that these non-TTAGGG sequences do not 
confer telomeric function, offering an explanation as to why telomeric sequence was 
present within the fusion (Baumann and Cech 2001; Conomos et al. 2012).  However, 
the telomere does not need to have been completely eroded at both chromosomal ends 
for fusion to occur.  Capper et al. (2007) detected fusion events that contained up to 12.8 
TTAGGG repeats immediately adjacent to the fusion site, concluding that fusion events 
involving >13 TTAGGG repeats were rare and offering a definition of the critical telomere 
length necessary for fusion in human cells.   
 
A microhomology of 8 nucleotides was also recorded at the fusion site in one of the MM 
fusion events that we had managed to sequence.  This was much larger than the average 
microhomology (1.9 nucleotides) present within the fusion events of HCT116 cells (Jones 
et al. 2014).  It was also larger than the maximum microhomology identified in HCT116 
cells where the alt-NHEJ pathway had been disrupted (5 nucleotides), but not larger than 
the maximum microhomology identified when the c-NHEJ pathway had been disrupted 
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instead (10 nucleotides).  This may suggest that the processing and repair of the 
telomere-deficient chromosomal ends involved in this MM fusion event was orchestrated 
by the alt-NHEJ pathway.   
 
Although further work would be necessary to conclusively prove that this was the case, 
it would still be an important discovery as the alt-NHEJ pathway is known to be necessary 
for the escape of cells from a telomere-driven crisis (Jones et al. 2014).  Not only would 
we be able to conclude that the bone marrow cells of MM patients show evidence of 
chromosomal end-end fusion, but we would also be able to state that this genetic 
instability was driven by the same pathway that enable cells to escape crisis.  However, 
without sequencing a greater number of fusion events, it becomes impossible to make 
any convincing predictions about the nature of chromosomal fusion in MM.   
 
3.5.4 The Relationship Between Telomere Length and Fusion Frequency 
Having identified chromosomal end-end fusion events in each of the 16 whole bone 
marrow aspirates of MM patients, we next sought to compare the frequency of fusion 
observed to the mean XpYp telomere length of each patient.  From this, we failed to 
demonstrate that any significant relationship existed.  This was unsurprising given the 
relatively small size of the cohort, with this result likely being due to an insufficient number 
of patients studied.  It was also possible that, because we were using whole bone marrow 
aspirates rather than isolated plasma cells, the presence of healthy marrow cells with 
longer telomeres was obscuring any potential relationship between the shortened 
telomeres of CD138+ cells and genomic instability.  As we had previously demonstrated 
that CD138+ cells had a significantly shortened mean XpYp telomere length, relative to 
the remaining marrow cells, we used the mean of the 25th percentile of telomere lengths 
as an estimation of plasma cell telomere length.  However, comparing the 25th percentile 
to the frequency of fusion observed also failed to expose any significant relationship.   
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However, comparing the standard deviation of each STELA profile to the frequency of 
chromosomal end-end fusion resulted in the identification of a significant relationship.  It 
was thought that the standard deviation offered an estimation of the extent to which the 
telomere length of the plasma cell population differed from that of the remaining marrow 
cells.  As the population of abnormal plasma cells within the bone marrow increases, the 
frequency of critically shortened telomeres within the STELA profile would also increase.  
This would increase the standard deviation of the profile and would also lead to a greater 
frequency of chromosomal end-end fusion events.  Although a significant relationship 
was identified, this result carried a number of caveats that need to be carefully 
considered.   
 
As we had attempted to identify chromosomal end-end fusion events from the whole 
bone marrow aspirates of MM patients, we had no way of knowing if these events were 
observed in malignant plasma cells or normal marrow cells.  All we could conclude was 
that the whole bone marrow aspirates of these 16 MM patients showed evidence of 
genomic instability, manifesting as chromosomal end-end fusion.  Also, the standard 
deviation and 25th percentiles of each STELA profile may not accurately represent the 
difference between the telomere lengths of the plasma cell population and the remaining 
marrow cells.  It was simply an estimation based on fact that the CD138+ cells of three 
MM patients were previously shown to have a significantly shorter mean telomere length 
than that of the remaining marrow cells.     
 
This work should therefore form the basis for further experiments examining the 
relationship between telomere length and genomic instability in MM.  Although we have 
demonstrated that chromosomal end-end fusion can be observed in the whole bone 
marrow aspirates of MM patients, future work should focus on repeating these 
experiments using isolated CD138+ cells.  In this way, it would not only be possible to 
conclude that any fusion events recorded were from plasma cells only, but it would also 
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allow a direct comparison between plasma cells telomere length and the levels of 
genomic instability.   
 
3.5.5 Conclusions 
The aim of this chapter was to determine whether telomere length measurements held 
prognostic value within the context of MM.  Using a cohort of 61 MGUS and 141 MM 
patients, we demonstrated that a shorter mean XpYp telomere length was associated 
with a more advanced disease stage.  We then identified a 3.92kb telomere length 
threshold which held the greatest prognostic significance when used to stratify our cohort 
of MM patients, almost identical to the 3.81kb fusogenic threshold identified in CLL.  
Inclusion of this 3.92kb threshold within the ISS criteria allowed each prognostic subset 
to be further risk-stratified.  Further work should now focus on determining whether 
telomere length measurements could be used in place of serum albumin concentrations, 
or whether they could be used in conjunction with albumin data to develop a four-stage 
ISS.  Work should also be carried out to determine whether first isolating CD138+ plasma 
cells from the whole bone marrow aspirate would further improve the prognostic value of 
telomere length measurements in MM.   
 
We also aimed to determine whether chromosomal end-end fusion could be detected 
within the whole bone marrow aspirates of MM patients, and whether a relationship 
existed between this genomic instability and telomere length.  Although fusion events 
were recorded in each of the 16 MM patients analysed, we could not conclude that the 
frequency of fusion correlated with mean XpYp telomere length.  However, we could 
demonstrate that a significant relationship existed between the standard deviation of the 
STELA profile and the frequency of fusion.  Future work should focus on the detection of 
chromosomal end-end fusion events from isolated CD138+ plasma cells.  The 
relationship between mean telomere length and the frequency of fusion should then be 
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examined.  This would determine whether the shortened telomeres of CD138+ plasma 
cells are the source of genomic instability in MM. 
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Chapter 4 
The Role of a Telomere-Driven Crisis in Generating Chromosomal 
Instability in Multiple Myeloma 
 
4.1 Abstract 
Chromosomal abnormalities are a common feature of multiple myeloma (MM), with the 
presence of del(17p), t(4;14) or t(14;16) now being used as prognostic indicators 
(Palumbo et al. 2015).  Although the cause of this genetic instability has yet to be fully 
elucidated, previous studies of another B-cell neoplasm, chronic lymphocytic leukaemia, 
have demonstrated that a shorter mean XpYp telomere length is closely linked to a 
greater frequency of chromosomal end-end fusion (Lin et al. 2010).  Here, we have used 
DN-hTERT expression to significantly reduce the telomerase activity in three MM cell 
lines as a method of examining the telomere dynamics of these cells as they enter a 
telomere-driven crisis.  As each cell line had a different p53 expression profile (Hurt et 
al. 2006; Surget et al. 2014; Landau et al. 2012), it was also possible to analyse their 
response to critical telomere shortening in the context of a compromised tumour 
suppressive pathway. 
 
Each cell line behaved differently when faced with a significant reduction in telomerase 
activity.  The JJN-3 cell line (p53neg) exhibited telomere erosion and entered a telomere-
driven crisis, but was capable of escaping crisis.  This escape was marked by the 
recovery of growth and viability within the JJN-3 population, as well as an increased 
mean XpYp telomere length.  The NCI-H929 cell line (p53wt) also underwent crisis after 
mean XpYp telomere length fell from 1.32kb to 1.00kb, but this cell line was not capable 
of escaping.  While a reduced telomerase activity had little effect on either the mean 
XpYp telomere length or viability of the U266B1 cell line (p53mut).   
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The ability of the JJN-3 cells to avoid senescence was probed further, with three clonal 
populations of DN-hTERT cells being monitored during a telomere-driven crisis.  Before 
crisis, it was observed that a reduction in telomerase activity caused mean XpYp 
telomere length to fall as low as 0.76kb.  During this period, the frequency of observable 
chromosomal fusion events increased in line with telomere shortening.  After crisis, 
telomerase activity was shown to be significantly increased.  This was followed by a 
gradual increase in mean XpYp telomere length, as well as a decrease in the frequency 
of fusion events recorded.  We therefore argue that critical telomere shortening, 
especially in cells with damaged tumour suppressive pathways, increases the risk of 
chromosomal end-end fusion.  This may result in genomic instability which is thought to 
drive the progression of multiple myeloma. 
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4.2 Introduction 
Replicative senescence is a process by which cells lose the ability to divide, but remain 
viable and metabolically active.  This phenomenon is primarily regulated by telomeres, 
with telomere length acting to limit the replicative capacity of normal cells (Munoz-Espin 
and Serrano 2014).  Telomere erosion is considered to act as a tumour suppressive 
mechanism, limiting the growth capacity of cells which have acquired genetic 
abnormalities (Campisi 2001).  When a telomere becomes critically shortened in a 
normal cell, a DNA damage response is initiated.  This results in a G1/S cell-cycle arrest 
which is established primarily via the TP53 tumour suppressive pathway (Campisi and 
d'Adda di Fagagna 2007).  However, TP53 abnormalities are common in haematological 
malignancies, occurring in approximately 14% of acute myeloid leukaemia (AML), 13% 
of chronic lymphocytic leukaemia (CLL) and 13% of multiple myeloma (MM) patients 
(Haferlach et al. 2008; Dicker et al. 2009; Chng et al. 2007).  Without functional TP53, 
cells may continue to divide beyond their Hayflick limit (Chin et al. 1999). 
 
As well as limiting the replicative potential of a cell, telomeres also act to prevent the 
ends of chromosomes from being recognised as a double-strand DNA break (Doksani 
and de Lange 2014).  If a telomere erodes completely, and the cell is unable to trigger 
senescence due to abnormalities within the DNA damage signalling pathways, then this 
chromosomal end may be subject to fusion with other unprotected chromosomal ends.  
The result is a dicentric chromosome, an inherently unstable structure which may 
undergo breakage-fusion-bridge cycles.  Aneuploidy, loss of heterozygosity, 
chromosomal translocation and gene amplification can follow, acting as drivers of cancer 
progression.  This state of widespread genomic instability and rearrangement is known 
as a telomere-driven crisis (Maciejowski and de Lange 2017).   
 
It is possible for a cell to escape from crisis by reactivating telomerase, leading to the 
survival and proliferation of a clonal cancer cell with a significantly rearranged genome.  
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This ability is dependent on intrachromosomal fusion events which are products of the 
alternative nonhomologous end-joining (alt-NHEJ) pathway (Jones et al. 2014).  Sister 
chromatid fusion is thought to be responsible for the amplification or deletion of specific 
chromosomal arms that typifies almost every type of cancer.  Interchromosomal fusion 
events, products of the classical nonhomologous end-joining (C-NHEJ) pathway, are 
also frequent but are not sufficient to trigger an escape from a telomere driven crisis 
(Jones et al. 2014).  Chromosomal abnormalities and rearrangements are a common 
feature of MM, with specific types now being used as prognostic indicators.  The revised 
international staging system for MM lists the presence of del(17p), t(4;14) or t(14;16) 
abnormalities as indicators of high risk disease (Palumbo et al. 2015).  The deletion of 
the 17p chromosomal end is particularly striking given the presence of the TP53 gene 
on this arm, the loss of which could prevent the activation of a DNA damage response 
after critical telomere shortening (Lode et al. 2010).   
 
However, a mechanistic link between telomere dysfunction and genomic instability has 
yet to be established in MM.   Evidence for this relationship already exists in CLL (Lin et 
al. 2010) and colorectal cancer (Roger et al. 2013), with shorter mean telomere length 
being associated with an increased frequency of chromosomal end-end fusion and large-
scale genetic rearrangement.  As the previous chapter demonstrated that high-risk MM 
patients are more likely to have a mean XpYp telomere length below 3.92kb, we next 
examined the hypothesis that critical telomere shortening in MM may result in the 
genomic instability which drives cancer progression. 
 
To do this, we used a dominant-negative form of the human TERT subunit (DN-hTERT) 
that effectively abrogates telomerase activity, resulting in telomeric erosion, as a 
consequence of cell division, and the eventual onset of a telomere-driven crisis.  The 
influence of TP53 on this process was examined by utilising MM cell lines that varied in 
their p53 expression, allowing the response of the JJN-3 cell line (p53neg) to be assessed 
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alongside the NCI-H929 (p53wt) and U266B1 (p53mut) cell lines.  From this, we 
demonstrated that critical telomeric shortening resulted in the initiation of a telomere-
driven crisis, with only the JJN-3 cell line showing evidence of being able to escape.  It 
was also observed, using clonal populations of JJN-3 cells, that the frequency of inter- 
and intrachromosomal fusion events directly correlated with telomere length.   
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4.3 Aims of the Chapter 
We hypothesised that a causal relationship existed in MM between telomere length, the 
frequency of chromosomal fusion events and the onset of crisis.  In this chapter, we 
aimed to determine whether p53 expression was necessary for the escape of cells from 
a telomere-driven crisis in MM.  We then examined the idea that critically shortened 
telomeres in a p53neg MM cell line can result in an increased frequency of chromosomal 
end-end fusion and the escape of cells from crisis.   
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4.4 Results 
 
4.4.1 Characteristics of the Four Myeloma Cell Lines 
The MM cell lines JJN-3, NCI-H929, RPMI-8226 and U266B1 were chosen due to their 
varying TP53 status.  While JJN-3 cells do not express p53, NCI-H929 cells express a 
functional p53 protein that elicits a corresponding p21 response following DNA damage 
(Hurt et al. 2006; Surget et al. 2014).  Having been exposed to radiation, both RPMI-
8226 and U266B1 cells produce a mutated p53 protein.  However, U266B1 cells remain 
capable of generating a p21 response (Landau et al. 2012).  Table 4.1 lists the 
characteristics of each cell line, along with information regarding their p53 status and cell 
surface marker expression. 
 
4.4.2 Mean XpYp and 17p Telomere Length in Four Myeloma Cell Lines 
As a method of observing any potential relationship between telomere length and the 
frequency of chromosomal end-end fusion events in MM, the mean length of the XpYp 
and 17p telomeres were calculated using STELA.  Of the four MM cell lines, NCI-H929 
and RPMI-8226 were identified as having the shortest mean XpYp telomere lengths at 
1.66kb and 1.62kb respectively (Figure 4.1a).  The mean XpYp telomere length of the 
JJN-3 cell line was shown to be longer at 3.05kb, but still shorter than that of the U266B1 
cell line whose mean XpYp telomere length was calculated as 4.38kb.  Standard 
deviation was used as a measurement of telomere length heterogeneity within each 
STELA profile, with smaller values indicating a more clonal population of cells.  Standard 
deviation for the four cell lines varied greatly, with NCI-H929 and RPMI-8226 having 
homogeneous telomere length distributions (0.52kb and 0.42kb respectively) relative to 
the more heterogeneous telomere length distributions of JJN-3 and U266B1 (1.31kb and 
2.83kb respectively).   
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Table 4.1: The Characteristics of the four MM cell lines (Gooding et al. 1999) 
 
 
 
 
 JJN-3 NCI-H929 RPMI-8226 U266B1 
ORIGIN OF 
CELL LINE 
Female 
52 Years 
Female 
62 Years 
Male 
61 Years 
Male 
53 Years 
 
DISEASE 
TYPE 
Plasma Cell 
Leukaemia 
(evolved from MM) 
 
Multiple 
Myeloma 
 
Multiple 
Myeloma 
 
Multiple 
Myeloma 
 
ISOTYPE 
 
 
IgA k 
 
IgA k 
 
IgG λ  
 
IgE λ 
 
CELL 
SURFACE 
MARKERS 
 
CD138+ 
CD38+ 
CD19- 
CD56+ 
CD20- 
CD138+ 
CD38+ 
CD19- 
CD56+ 
CD20- 
CD138+ 
CD38+ 
CD19- 
CD56+ 
CD20- 
CD138+ 
CD38+ 
CD19- 
CD56- 
CD20- 
 
KARYOTYPE 
 
Hypotriploid 
with 9% Polyploidy 
Near-
Tetraploid 
(8q+) 
Hypotriploid 
with 7.5% 
Polyploidy 
 
Unknown 
 
TP53 
 
Homozygous 
Deletion 
(Not Functional) 
 
Wild Type 
(Functional) 
Homozygous 
Mutation 
(Not Functional) 
Homozygous 
Mutation 
(Functional) 
POPULATION 
DOUBLING 
TIME 
 
20-35 hours 
 
~70 hours 
 
~60-70 hours 
 
~55 hours 
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Measuring the mean 17p telomere length for the same four cell lines allowed 
comparisons to be drawn between the two telomere ends (Figure 4.1b).  At 2.99kb, the 
mean 17p telomere length of the JJN-3 cell line was almost identical to that of the mean 
XpYp telomere length of 3.05kb.  Standard deviation at the 17p telomere end, calculated 
as 1.51kb, was similar to that observed at the XpYp telomere (1.31kb).   
 
However, mean XpYp and 17p telomere length measurements varied greatly within the 
NCI-H929 cell line.  Compared to the mean length of the XpYp telomere end (1.66kb) 
and homogeneous telomere length distribution (standard deviation 0.52kb), the mean 
length of the 17p telomere end was much longer (2.84kb) and showed greater 
heterogeneity (standard deviation 1.66kb).  A multimodal distribution within the 17p 
telomere profile was also identified and may go towards explaining this difference.  
Multimodal distributions can reflect the presence of allelic variation in telomere length, 
clonal heterogeneity or the presence of additional copies of the telomere analysed.  In 
this case, gain of 17p has not been identified in the NCI-H929 cell line.  However, 
populations of these cells are known to be comprised of two subpopulations; CD138++ 
(95%) and CD138low (5%) (Paino et al. 2014).  While this might suggest that the 
multimodal distribution observed is due to clonal heterogeneity, rather than the presence 
of an additional 17p telomere, it is also impossible to rule out allelic variation as a cause 
without knowing the exact subtelomeric sequence of each individual chromosome.   
 
Like the JJN-3 cell line, the RPMI-8226 cell line also showed little difference between the 
mean telomere length at the XpYp and 17p telomere ends (1.62kb and 1.63kb 
respectively).  However, standard deviation at the 17p telomere end (1.59kb) was 
significantly increased when compared to the XpYp telomere end (0.42kb).  This is likely 
due to the presence of a small number of 17p telomere ends in the region of 8.7kb – 
14.7kb whose presence acted to skew the standard deviation.   
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It was not possible to calculate a mean 17p telomere length for the U266B1 cell line due 
to the limited number of bands present within the STELA profile.  This could either be 
due to the loss of the 17p chromosomal arm, or complete erosion of the 17p telomere.  
Either case would inhibit STELA by preventing the telorette primer from binding at the 
end of the 17p chromosomal arm.  However, it should be noted that the U266B1 17p 
STELA profile was not completely blank.  It contained a small number of bands which 
were each of varying size.   
 
4.4.3 The Frequency of Chromosomal Fusion in Four Myeloma Cell Lines 
Chromosomal fusion events were identified in the four MM cell lines using a single-
molecule telomere fusion assay with primers 17p6, XpYpM, 16p1 and 21q1.  It is 
important to note that, while the 17p6 and XpYpM primers were specific to their 
respective chromosomal ends, the 16p1 and 21q1 primers recognise several 
chromosomal ends; the 16p1 family primer binds at 16p, 1p, 9p, 12p, 15q, XqYq and the 
2q14 interstitial locus, while the 21q1 family primer binds at 21q, 1q, 2q, 5q, 6q, 6p, 8p, 
10q, 13q, 17q, 19p, 19q, 22q and the 2q13 interstitial telomeric locus.   
 
Although chromosomal fusion events were identified in each of the four myeloma cell 
lines (Figure 4.2a), the greatest frequency of fusion events were found within the RPMI-
8226 cell line (frequency of fusion = 115.56x10-6 events per cell).  A significant number 
of fusion events were also isolated from the NCI-H929 cell line (frequency of fusion = 
80x10-6/cell).  However, the U266B1 (frequency of fusion = 35.56x10-6/cell) and JJN-3 
(frequency of fusion = 8.89x10-6/cell) cell lines showed relatively few chromosomal fusion 
events.  
  
The true significance of this finding does not become apparent until the frequency of 
chromosomal fusion is viewed within the context of mean telomere length (Figure 4.3a 
and 4.3b).  The cell lines with the shortest mean XpYp telomere lengths, NCI-H929 and 
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RPMI-8226, also had the greatest number of identified chromosomal fusion events.  JJN-
3 and U266B1, each with a considerably longer mean XpYp telomere length, exhibited 
fewer detectable chromosomal fusion events.   
 
4.4.4 A Telomere-Driven Crisis in the JJN-3 Cell Line 
As the telomere length of the JJN-3, NCI-H929 and U266B1 cell lines are maintained by 
telomerase activity, we aimed to force these cells into a state of telomere-driven crisis 
by disrupting this enzyme via the incorporation of a dominant-negative (DN) TERT 
subunit.  DN-hTERT competitively inhibits the binding of wild-type TERT to the TERC 
subunit (Rahman, Mo, and Cui 2006).   It also forms dimers with wild-type TERT which 
are then actively degraded in the cytoplasm (Nguyen, Elmore, and Holt 2009).  The gene 
encoding the DN-hTERT subunit was packaged within a pBABE-puro retroviral vector 
and was delivered into the cells using viral transduction.  The control cells were 
generated expressing only the pBABE-puro vector, thus conferring a level of resistance 
to the antibiotic puromycin without the associated disruption to telomerase activity.   
 
After transfecting a population of JJN-3 cells (day 0) with either the DN-hTERT construct 
or the empty pBABE-puro vector as a control, puromycin was used to select for those 
cells (day 10) which had successfully incorporated the vector.  During the 51 days 
following transduction, cell growth was monitored in each population, as well as in an 
additional un-transfected control population of JJN-3 cells.  After the addition of 
puromycin, the growth of each population initially stalled for a period between day 5 and 
day 15 (Figure 4.4a).  However, by day 20 the growth of the DN-hTERT and puromycin-
resistant control cells had returned to normal.  Only the un-transfected JJN-3 control cells 
failed to continue growing once puromycin was introduced.   
 
Cell viability was also monitored during this period using the Vi-Cell XR (Beckman 
Coulter) automated trypan blue dye-exclusion assay (Figure 4.4b).  Initially the viability  
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of each population decreased, with the normal JJN-3 control cells finally reaching 2.2% 
viability by day 24.  DN-hTERT cells reached a low of 36.4% viability by day 13, before 
recovering to 83.7% viability by day 20 and finishing with a viability of 91% by day 51.  
The viability of puromycin-resistant control cells also decreased, reaching a low of 51.9% 
at day 15 before recovering to 83.7% by day 20 and finishing with a viability of 87.3%.   
 
Telomerase activity was measured in DN-hTERT and puromycin-resistant control JJN-3 
populations to determine whether the DN-hTERT construct was successfully reducing 
the activity of the telomerase enzyme (Figures 4.4c and 4.4d).  On day 27, the total 
product generated (TPG) by telomerase enzymes isolated from DN-hTERT cells was 
significantly reduced when compared to day 0 (p = 0.03).  This was in contrast to the 
puromycin-resistant control cells, where telomerase activity was not significantly reduced 
(p = 0.07) when compared to day 0. 
 
To directly observe the effect of a reduced telomerase activity, telomere length was 
monitored using STELA of the XpYp telomere at 9 time points during the growth of the 
JJN-3 cells.  Over a period of 27 days, mean XpYp telomere length was reduced from 
an initial 3.10kb to a low of 2.09kb in DN-hTERT JJN-3 cells (p = 0.0003; Figure 4.5a).  
Although a lower mean telomere length of between 2.22kb and 2.19kb was maintained 
after this period, mean telomere length had eventually risen back to 2.53kb by day 48.  
In the puromycin-resistant control cells, mean XpYp telomere length initially rose from 
2.71kb at day 0 to 3.01kb at day 27 (p = 0.22; Figure 4.5b).  A mean XpYp telomere 
length of between 3.05kb and 2.66kb was then maintained up until day 48.   
 
In summary, forcing the expression of DN-hTERT in a population of JJN-3 cells 
significantly reduced telomerase activity.  This resulted in telomeric erosion which 
eventually stabilised at around 2.20kb.  The viability of the DN-hTERT population also 
decreased by a greater extent than the puromycin-resistant control population, which 
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may be indicative that the cells were forced into a telomere-driven crisis following the 
DN-hTERT-mediated reduction in telomerase activity.  Eventually, viability recovered to 
around 90% and mean XpYp telomere length began to increase suggesting that the cells 
had escaped crisis.   
 
4.4.5 A Telomere-Driven Crisis in the NCI-H929 Cell Line 
Using the same technique as for JJN-3 cells, DN-hTERT was introduced into the NCI-
H929 cell line (day 0) to disrupt telomerase activity and force the cells into a state of 
telomere-driven crisis.  Until the addition of puromycin at day 4, the DN-hTERT and un-
transfected control NCI-H929 populations continued to experience growth (Figure 4.6a).  
The control cells which expressed only the puromycin-resistance gene continued to grow 
until day 6.  Between day 4 and day 8 in the DN-hTERT and un-transfected control NCI-
H929 populations (day 6 and day 8 in the puromycin-resistant control population) cell 
growth appeared to stop and the number of population doublings recorded did not 
increase.  Between day 8 and day 20, growth of the puromycin-resistant control cells 
returned to normal.  However, neither the DN-hTERT or the un-transfected control NCI-
H929 cells recovered and remained at 0.70 and 0.62 population doublings respectively 
until the experiment was ended.   
 
Cell viability followed a similar pattern, with the puromycin-resistant control cells falling 
from 73.8% viability on day 0 to 37.7% viability by day 10 (Figure 4.6b).  Between day 8 
and day 20, cells recovered to 59.9% viability.  Un-transfected NCI-H929 cells 
experienced a reduction in viability immediately after the addition of puromycin, falling to 
11.7% viability between day 4 and day 8.  This did not recover and the cells remained at 
around 9% viability up to day 20.  DN-hTERT cells also experienced a loss of viability, 
although this occurred at day 6, slightly after the normal NCI-H929 cells.  However, 
viability then continued to drop and did not recover.  DN-hTERT cells reached a final 
viability of 7.8% by day 20.   The telomerase activity assay for NCI-H929 cells at day 0 
  Chapter 4 - Results 
140 
 
  Chapter 4 - Results 
141 
 
  Chapter 4 - Results 
142 
 
showed that telomerase activity could be recorded as 64.23 TPG.  In the DN-hTERT 
cells, this value dropped significantly (p = 0.005) to almost 0 TPG at day 20 (Figure 4.6c) 
but increased to 72.31 TPG (p = 0.5) in the puromycin-resistant control cells (Figure 
4.6d).   
 
STELA was performed to measure mean XpYp telomere length during the telomere-
driven crisis in the populations of NCI-H929 cells.  In the DN-hTERT cells, mean XpYp 
telomere length increased marginally between days 0 and 9 (figure 4.7a).  By day 19, 
mean XpYp telomere length had decreased to 1.17kb and then again to 1.00kb by day 
23 (p = 0.02).  At this point, cell viability fell below 10% and the experiment was ended.  
In the puromycin-resistant control cells, mean XpYp telomere length remained constant 
and never fell below 1.30kb (p = 0.7; figure 4.7b).   
 
In summary, forcing the expression of DN-hTERT in a population of NCI-H929 cells 
significantly reduced telomerase activity.  This resulted in telomeric erosion which 
caused the mean XpYp telomere length to fall to 1.00kb.  Unlike the puromycin-resistant 
control population, the viability of the DN-hTERT population quickly fell below 10% and 
did not recover.   
 
4.4.6 A Telomere-Driven Crisis in the U266B1 Cell Line 
Cell growth in the un-transfected control U266B1, DN-hTERT and puromycin-resistant 
control populations continued at a steady rate until puromycin was added on day 5 
(Figure 4.8a).  At this point, the un-transfected control U266B1 cells failed to 
demonstrate any further growth.  The puromycin-resistant control cells grew almost 
uninterrupted by the presence of puromycin until day 17.  At this point, and again at day 
24, cells experienced a period of stalled growth that was immediately corrected by the 
following time point.  However, the overall trend between day 0 and day 54 was that of 
growth.  
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The DN-hTERT cells experienced a period of stalled growth between day 4 and day 15, 
eventually returning to normal growth between day 17 and day 54.   
 
The viability of un-transfected control U266B1 cells during this period decreased from 
77.5% at day 4 to 10.6% by day 15 and did not recover (Figure 4.8b).  The viability of 
the puromycin-resistant control cells fell from 76.6% to 68.9% between day 0 and day 
10, but increased rapidly to 89.2% by day 22.  Between day 24 and day 54, viability 
remained between 73.2% and 88.7%.  The viability of the DN-hTERT population 
decreased from 76.6% at day 0 to 45.0% by day 10.  At this point, the viability increased 
rapidly between days 13 and 17.  Between days 20 and 54, viability remained between 
70.4% to 85.9%.   
 
Telomerase activity was measured at three time points in both the DN-hTERT and 
puromycin-resistant control populations.  In the DN-hTERT cells, telomerase activity 
decreased from 90.53 TPG at day 0 to 27.18 TPG at day 33 (p = 0.01) but this increased 
to 44.65 TPG by day 50 and was no longer significantly different from day 0 (p = 0.1).  In 
the puromycin-resistant control population, telomerase activity increased between day 0 
(90.53 TPG) and day 33 (108.32 TPG) and again by day 50 (112.12 TPG).  However, 
neither of these changes in telomerase activity were significant (p = 0.5 and p = 0.3).   
 
Using STELA, the mean XpYp telomere length was analysed during the 54 days 
immediately following viral transduction.  The mean XpYp telomere length showed no 
significant change between day 0 and day 29 in the DN-hTERT population (p = 0.743), 
increasing from 3.75kb to 3.84kb (Figure 4.9a).  Between day 29 and day 33, the mean 
XpYp telomere length decreased to 3.44kb (p = 0.299).  This contrasted with the 
puromycin-resistant control cells whose mean XpYp telomere length decreased from 
3.65kb to 3.39kb between day 0 and day 33 (Figure 4.9b).  The mean XpYp telomere 
length in the DN-hTERT population alternated between a high of 3.87kb and a low of 
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3.32kb (p = 0.1554).  While the mean XpYp telomere length of the puromycin-resistant 
control population never rose above 4.00kb or fell below 3.43kb (p = 0.3526).   
 
In summary, forcing the expression of DN-hTERT in a population of U266B1 cells 
significantly reduced telomerase activity.  However, the effect on telomere length was 
minimal.  The mean XpYp telomere length of the DN-hTERT population remained stable 
at between 3.84kb and 3.32kb.  Immediately after transfection, the viability of the DN-
hTERT population decreased by a greater extent than the puromycin-resistant control 
population, but this alone was not enough to indicate that the cells had been driven into 
a telomere-driven crisis.  Eventually, viability recovered to around 80% and telomerase 
activity showed a small but insignificant increase.   
 
4.4.7 The Extent of Chromosomal Fusion in Three Myeloma Cell Lines During 
a Period of Telomere-Driven Crisis 
The JJN-3, NCI-H929 and U266B1 cell lines were examined for changes in the frequency 
of chromosomal fusion events during the period of telomere-driven crisis induced 
following the expression of DN-hTERT.  Each measurement was performed at the same 
time points at which STELA was performed. The frequency of chromosomal fusion was 
examined in both the DN-hTERT and puromycin-resistant control populations to allow 
for comparison.  However, no significant difference (p = 0.2334; p = 0.8501; p = 0.4258) 
was observed between the frequency of fusion in the DN-hTERT and puromycin-
resistant control populations for each of the three cell lines (Figure 4.10). 
 
In the JJN-3 DN-hTERT population, the frequency of chromosomal fusion events 
increased between day 0 and day 20 from 40x10-6/cell to 80x10-6/cell.  However, this 
was also true for the JJN-3 puromycin-resistant control population whereby the 
frequency of fusion events was calculated as 47x10-6/cell on day 0 and 80x10-6/cell by 
day 20 (Figure 4.10a).  Overall, the number of fusion events totalled 78 for the DN- 
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hTERT population and 66 for the puromycin-resistant control population.  Using a 
Wilcoxon matched pairs test, treating identical days in the DN-hTERT and puromycin-
resistant control populations as pairs, the overall difference between the change in the 
frequency of fusion events for each population was found not to be significant (p = 
0.2334).   
 
For the NCI-H929 cells, the number of chromosomal fusion events identified increased 
marginally between day 0 and day 19 for both the DN-hTERT and puromycin-resistant 
control populations (Figure 4.10b).  However, fusion events were undetectable in the 
DN-hTERT population at day 23.  This is in contrast to the puromycin-resistant control 
population whereby the frequency of fusion events was calculated as 60x10-6/cell at the 
same time point.  However, this change was not significant when assessed using a 
Wilcoxon matched pairs test (p = 0.8501).   
 
The number of chromosomal fusion events identified in the U266B1 DN-hTERT 
population did not change significantly when compared with the puromycin-resistant 
counterpart (p = 0.4258; Figure 4.10c).  The largest number of fusion events identified 
occurred at day 40 (frequency of fusion = 93x10-6/cell) for the DN-hTERT population and 
day 44 for the puromycin-resistant control population (frequency of fusion = 87x10-6/cell).  
Overall, 70 events were recorded for the DN-hTERT population and 52 for the 
puromycin-resistant control population.  Again, these values were shown not to be 
significant using a Wilcoxon matched pairs test (p = 0.4258). 
 
In summary, chromosomal end-end fusion events were identified in the JJN-3, NCI-H929 
and U266B1 cell lines.  However, no significant change in the frequency of fusion was 
detected, relative to the puromycin-resistant controls, when DN-hTERT was expressed.  
This was perhaps unsurprising for the U266B1 cell line, as the insignificant change in 
fusion frequency was consistent with the insignificant change to mean XpYp telomere 
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length recorded previously.  However, an insignificant change to fusion frequency in the 
JJN-3 and NCI-H929 cell lines was unexpected as the viability and telomeric erosion 
recorded previously in DN-hTERT populations was consistent with a telomere-driven 
crisis.  One possible explanation for the lack of change in NCI-H929 fusion frequency 
was that the cells had been unable to undergo significant genomic rearrangement due 
to the expression of a functional p53 protein.  Having the capacity to successfully trigger 
apoptosis in this way may also explain why the cells were unable to escape from a 
telomere-driven crisis, with viability of the DN-hTERT population eventually falling below 
10% and never recovering.   
 
As for the JJN-3 cell line, true fusion frequency might have been masked by the 
heterogeneity of the telomere lengths within the population of cells.  JJN-3 cells that had 
a shorter telomere length would enter into a telomere-driven crisis at an earlier time point 
to those cells with longer telomeres, with any resulting change in fusion frequency being 
obscured by the bulk of pre-crisis cells.  To test this hypothesis, clonal populations of 
cells would need to be driven into a telomere-driven crisis through the expression of DN-
hTERT.  Populations of cells derived from a single clone commonly express a 
significantly homogeneous range of telomere lengths, thus allowing the entire population 
to be driven into crisis together.   
 
4.4.8 Clonal Growth and Telomerase Activity During Crisis in Three JJN-3 
Clonal Populations 
Telomere length distributions within a cell line are commonly heterogeneous, with DN-
hTERT expression driving each cell into a state of telomere-driven crisis at different time 
points.  This can result in a population of cells being in a state of crisis for days or weeks, 
with any change in the frequency of fusion within an individual cell being masked by the 
range of pre- and post-crisis cells within the population.  As the JJN-3 and U266B1 cell 
lines contained heterogeneous telomere length distributions, attempts were made to 
create clonal colonies of these cell lines which expressed the DN-hTERT construct and 
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contained a more homogeneous telomere length distribution.  Several attempts were 
also made using dilution cloning to isolate single cell clones from the NCI-H929 cell line, 
but no viable clones could be established.  It was considered that this may be attributable 
to the relatively short telomere lengths observed in NCI-H929 cells which provide 
insufficient replicative capacity for the clones to establish prior to the onset of crisis.  
Instead, a method of dilution cloning was carried out on both the JJN-3 and U266B1 cell 
lines, resulting in the successful formation of clonal colonies of JJN-3 cells.  Although 
multiple attempts were made to clone the U266B1 cell line, it was not possible using the 
method of dilution cloning employed. 
 
Three clonal populations of JJN-3 cells, each expressing DN-hTERT, were monitored 
over a period of months for signs of a telomere-induced crisis (highlighted in red - 
Figure 4.11a).  During the initial 30 to 40 days, each clone grew normally before entering 
a period of slowed or stalled growth which was thought to represent crisis.  This period 
occurred between day 37 and day 52 in clone A, between day 42 and day 59 in clone B, 
and between day 44 and day 62 in clone C.  After this, each clone returned to a steady 
rate of growth similar to that observed before the onset of crisis.  The same pattern was 
not observed in the control cells, a clonal population of JJN-3 cells which expressed only 
the empty pBABE-puro vector.   
 
Telomerase activity was measured before the onset of crisis and after crisis in the three 
clonal populations of JJN-3 DN-hTERT cells (Figure 4.11b).  The telomerase activity 
before crisis in each clonal DN-hTERT population was greatly reduced when compared 
to the control clone at a similar time point.  However, telomerase activity in each DN-
hTERT clone following a period of crisis had increased (Figure 4.11b). Instead of 
returning to the normal levels seen in the control clone (43.45 TPG) or remaining at pre-
crisis levels, each DN-hTERT clone had significantly increased telomerase expression.  
This included clone A whose telomerase activity was 2.26x greater (p = 0.007), clone B 
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whose telomerase activity was 3.14x greater (p = 0.002), and clone C whose telomerase 
activity was 2.59x greater (p = 0.002) than that of the control clone at a similar timepoint.   
 
4.4.9 The Change in the Frequency of Chromosomal Fusion Events During a 
Telomere-Driven Crisis in JJN-3 DN-hTERT Clone A 
STELA was used to measure the mean telomere length, at both the XpYp and 17p 
telomere ends, in three clonal JJN-3 DN-hTERT populations during a period of telomere-
driven crisis.  Clonal populations of cells are commonly identified by their homogeneous 
telomere length distributions, measured by the standard deviation within a STELA profile 
(Baird et al. 2003).  An example of this can be seen in the STELA profile of clone A which 
was recoded at population doubling (PD) 23.2 (Figure 4.12).  With a standard deviation 
of 0.27kb at the XpYp telomere, this is a significant decrease from the standard deviation 
of 1.31kb originally identified in the parental JJN-3 population (p = <0.0001; Figure 4.1a). 
 
Between PD 23.23 and PD 26.49, before the onset of a telomere-driven crisis, the 
standard deviation (clonality) of each STELA profile remained relatively small at between 
0.27 – 0.34kb.  It can also be clearly seen that mean telomere length decreased by 
around 115 base pairs per PD during this period, falling from 1.82kb at PD 23.2 to 1.44kb 
by PD 26.5.  This is consistent with the telomeric erosion rates of MRC5 fibroblast clonal 
populations (~112bp/PD) and WI-38 fibroblast bulk populations (~132bp/PD), but greater 
than that of HCA-2 fibroblast bulk populations (65bp/PD) and HCT116 colorectal 
carcinoma clonal populations (45bp/PD) which were monitored using STELA at the XpYp 
telomere (Britt-Compton et al. 2006; Jones et al. 2014).  Between PD 27.9 and PD 37.8, 
during and after the period of crisis, the standard deviation within the STELA profile 
increased from 0.89kb to 1.18kb.  This occurred alongside an increase in the mean XpYp 
telomere length from 1.87kb at PD 27.9 to 2.47kb at PD 37.8.  
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The 17p telomere length was also measured at the same time points, but the STELA 
profile was much more complex than that of the XpYp profile (Figure 4.13).  This was 
due to the presence of a multimodal distribution, with three distinct populations of 17p 
telomere lengths being identified.  One explanation for this may be that multiple 
independent clones exist within the population, with each clone having a significantly 
different 17p telomere length.  However, as a multimodal distribution could not be 
identified from the XpYp STELA profile of clone A, it became less likely that this was the 
case.  Instead, each copy of chromosome 17 within the cells (of which there could be 
more than two per cell) may have a significantly different telomere length.  This allelic 
variation, combined with gain of 17p, may explain the multimodal distribution.  For this 
reason, the standard deviation of the 17p profile (1.47kb at PD 23.2) was not as 
homogeneous as the XpYp profile (0.27kb at PD 23.2).  Regardless, mean 17p telomere 
length decreased from 1.81kb at PD 23.2 to 1.77kb at PD 26.5.  This was followed by a 
sudden increase in both mean 17p telomere length (2.73kb by PD 31.7) and standard 
deviation (1.66kb by PD 31.7) immediately after the onset of crisis. 
 
The mean value of the lowest 17p distribution was also recorded so that the extent of 
telomere erosion could be monitored.  Again, mean 17p telomere length decreased from 
1.04kb at PD 23.2 to 0.91kb at PD26.5.  This was followed by a change in the distribution 
of telomere lengths throughout the 17p profile such that the individual telomere length 
distributions that were apparent prior to crisis could no longer be distinguished.   
 
The extent of chromosomal fusion in clone A, during the period of telomere-driven crisis, 
was also identified (Figure 4.14).  As mean telomere length shortened between PD 23.2 
and PD 26.5, the number of chromosomal fusion events identified increased.  After 
reaching a peak frequency of fusion at 353x10-6 events per cell, the frequency of fusion 
decreased between PD 28.0 and PD 37.8.  Most fusion events involved either the 17p 
chromosomal end or the 21q-family of chromosomal ends, while the 16p-family of 
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chromosomal ends showed relatively little change in fusion frequency throughout crisis.  
However, only two fusion events involving the XpYp chromosomal end were identified.  
This is likely explained by the longer mean XpYp telomere length, relative to the mean 
telomere length of the lower distribution in the 17p STELA profile.  This may have 
resulted in a smaller number of critically shortened XpYp telomeres, when compared to 
the 17p telomere, that were able to undergo fusion before a telomere-driven crisis was 
triggered. 
 
In summary, this clonal population of JJN-3 cells exhibited a period of stalled growth that 
was consistent with the onset of crisis.  STELA was used to identify the homogeneous 
telomere length profile that is characteristic of a clonal population, as well as track the 
extent of telomeric erosion in response to DN-hTERT expression.  As the cells entered 
a state of telomere-driven crisis, the frequency of chromosomal end-end fusion increased 
in line with mean telomere length.  The clonal population was then able to escape from 
crisis, resulting from an increased telomerase activity.  During this time, mean telomere 
length and standard deviation increased and the frequency of fusion decreased.   
 
 
4.4.10 The Change in the Frequency of Chromosomal Fusion Events During a 
Telomere-Driven Crisis in JJN-3 DN-hTERT Clone B 
The clonality of JJN-3 DN-hTERT clone B was demonstrated by its standard deviation 
of 0.45kb at PD 25.5 (Figure 4.15).  In a similar pattern to that observed in clone A before 
crisis, mean XpYp telomere length decreased at a rate of 97bp/PD from 2.02kb at PD 
25.5 to 1.40kb at PD 31.9.  During this period, standard deviation remained almost 
constant and never increased beyond 0.48kb.  After escaping from a state of crisis, mean 
telomere length increased to 2.44kb and the telomere length profile became more 
heterogeneous with the standard deviation increasing to 1.07kb by PD 49.7.  
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The 17p STELA profile of this clone also exhibited a multimodal distribution which 
increased the standard deviation of the profile to 1.44kb at PD 25.5 (Figure 4.16).  This 
is again consistent with the presence of multiple copies of the 17p subtelomeric 
sequence.  However, the overall mean of the 17p telomere length decreased from 2.40kb 
at PD 25.5 to 2.27kb at PD 30.5.  The mean of the lower distribution also decreased from 
0.93kb at PD 25.5 to 0.57kb at PD 33.6, at which point this distribution could no longer 
be identified as the telomere may have been completely eroded.  This coincided with a 
significant increase in both the mean 17p telomere length and standard deviation 
between PD 34.7 and PD 49.7.  Again, this is consistent with the increase in telomere 
length and standard deviation observed at the XpYp telomere at the same time points.   
  
During this time, the frequency of chromosomal fusion events was also monitored for the 
17p, XpYp, 16p-family and 21q family of chromosomal ends (Figure 4.17).  Again, the 
frequency of chromosomal fusion events increased as mean telomere length decreased.  
This resulted in an increase from 60x10-6 fusion events per cell at PD 25.53 to 353x10-6 
fusion events per cell by PD 33.64.  As the cells began their escape from a telomere 
driven crisis, the frequency of chromosomal fusion events began to decrease which 
culminated in a reduction in fusion frequency (47x10-6/cell) at PD 39.77.  The fusion 
profile was again dominated by 17p and 21q-family chromosomal fusion events, with 
only a modest increase in 16p-family fusion events being seen during the period of crisis.  
However, fusion events involving the XpYp telomere end continued to remain elusive.   
 
In summary, JJN-3 clone B cells that expressed DN-hTERT exhibited a period of stalled 
growth that was consistent with the onset of a telomere-driven crisis.  As the telomeres 
were eroded during each PD, the frequency of chromosomal end-end fusion increased 
in line with telomeric shortening.  In an identical manor to clone A, the population was 
then able to escape from crisis, as evidenced by a return to a pre-crisis growth rate and 
increased telomerase activity.  During this time, mean telomere length and standard 
  Chapter 4 - Results 
162 
 
deviation increased and a corresponding decrease in the frequency of fusion was 
observed.     
 
4.4.11 The Change in the Frequency of Chromosomal Fusion Events During a 
Telomere-Driven Crisis in JJN-3 DN-hTERT Clone C 
The mean XpYp telomere length of JJN-3 DN-hTERT clone C decreased by 128bp/PD 
from PD 24.0 (1.12kb) to PD 26.8 (0.76kb), at which point the cells had already begun 
to enter a state of telomere-driven crisis (Figure 4.18).  After this, mean XpYp telomere 
length began to increase and reached a maximum of 2.02kb by PD 35.9.  The 
homogeneous telomere length distribution of 0.25kb, a mark of the clonality of a 
population of cells, was also lost as the standard deviation increased after crisis to 
0.97kb.  
 
A similar effect was recorded at the 17p telomere end, with mean telomere length falling 
from 2.83kb at PD 24.0 to 1.86kb by PD 26.8 (Figure 4.19).  As with clone A and clone 
B, multimodal distributions were present within the 17p STELA profile, increasing each 
measurement of the standard deviation relative to the XpYp profile.  The mean of the 
lower distribution fell by 142bp/PD between PD 24.0 (1.21kb) and PD 27.8 (0.67kb), after 
which the ability to detect specific telomere length distributions within the profile was lost.  
Again, this was likely the result of complete telomeric erosion.  At both the XpYp and 17p 
telomere ends, mean telomere length decreased between PD 24.0 and PD 26.8 and 
then increased until PD 35.9.  
 
The overall number of fusions in clone C, as well as the peak number of fusions as the 
cells entered crisis, were much smaller than in clone A or clone B (Figure 4.20).  
Between PD 24.0 and PD 27.8, the number of observable fusions increased from 67x10-
6/cell to 120x10-6/cell.  This eventually fell to a low of 40x10-6 fusion events per cell by PD 
33.8.  However, fusion events involving the XpYp and 16p-family of chromosome ends   
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were rarely detected.  Most fusion events involved either the 17p or 21q-family of 
chromosome ends.   
 
In summary, the telomere dynamics of JJN-3 clone C closely mirrored that of clones A 
and B.  The expression of DN-hTERT caused a period of stalled growth throughout the 
clonal population that was consistent with the onset of a telomere-driven crisis.  The 
homogeneous XpYp telomere length distribution was eroded at a rate of 142bp/PD, as 
opposed to the 115bp/PD and 97bp/PD for clone A and clone B respectively.  The 
frequency of chromosomal end-end fusion increased in line with telomeric shortening, 
although the peak fusion frequency (120x10-6/cell) was lower than that of either clone A 
(353x10-6/cell) or clone B (353x10-6/cell).  Eventually, clone C escaped from a telomere-
driven crisis, possibly driven by the corresponding increase in telomerase activity.  At 
this point, telomere length and standard deviation increased and a corresponding 
decrease in the frequency of fusion was observed.     
 
4.4.12 Chromosomal Fusion Events within the JJN-3 DN-hTERT Clonal 
Populations Predominantly Involve the 17p or 21q-Family of 
Chromosome Ends  
Although several chromosomal ends were analysed during this study, the 17p and 21q-
family of chromosome ends showed the greatest change in the frequency of fusion as a 
direct result of changes in mean telomere length.  This was analysed graphically (Figure 
4.12), with 17p and 21q-family interchromosomal fusion events being plotted separately.  
In each case, the frequency of fusion events detected increased as telomere length 
decreased. 
 
In summary, this work demonstrated that DN-hTERT expression significantly reduced 
the activity of telomerase in three clonal populations of the JJN-3 cell line.  The resulting 
telomeric erosion (XpYp - 115bp/PD, 97bp/PD and 142bp/PD; 17p lower distribution – 
39bp/PD, 44bp/PD and 142bp/PD for clones A, B and C respectively) forced the cells 
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into a state of telomere-driven crisis, with the frequency of chromosomal end-end fusion 
increasing in line with telomeric shortening.  Eventually, each clonal population managed 
to escape from crisis, an event which was marked by the reactivation of telomerase and 
increasing mean XpYp and 17p telomere lengths.  Standard deviations also increased 
immediately after crisis, with telomere length profiles becoming significantly more 
heterogeneous.  As mean telomere length increased, a corresponding decrease in the 
frequency of fusion events was observed.    
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4.5 Discussion 
4.5.1 Telomere Length and Chromosomal Fusion in Four MM Cell Lines 
In the previous chapter, we demonstrated that mean XpYp telomere length 
measurements held prognostic value within the context of MM.  Having measured the 
mean XpYp telomere length of 141 MM patient whole bone marrow aspirates, we 
demonstrated that shorter XpYp telomere length (< 3.92kb) correlated with a decrease 
in overall survival.  However, we were unable to identify a cause for this relationship from 
the patient data alone.  Here, we hypothesised that shorter mean telomere length led to 
an increase in the frequency of chromosomal fusion events in MM.  This was based on 
our findings in the previous chapter, combined with the extensive literature regarding 
shortened telomeres and genomic instability in other haematological neoplasms 
(O'Sullivan and Karlseder 2010; Lin et al. 2010).  We expected that the presence of 
fusion events would drive the genomic rearrangements that are a characteristic of MM 
(Rajkumar et al. 2013).   
 
We attempted to address our hypothesis using the JJN-3, NCI-H929, RPMI-8226 and 
U266B1 cell lines.  This was necessary due to the difficulty in culturing primary CD138+ 
MM cells derived from patient bone marrow.  Most primary plasma cells have a lifespan 
of only a few days (Oracki et al. 2010) making them unsuitable for the long-term 
experiments performed here.  While long-lived memory plasma cells have been 
successfully cultured, their presence in bone marrow can be as low as 0.25% (Jourdan 
et al. 2014).  This makes them an unsuitable model due to the quantities of bone marrow 
required and the time needed for sufficient CD138+ isolation.  Using well-characterised 
cells lines, rather than primary cells, also meant that the p53 expression profiles were 
known.  This allowed the response to critical telomere shortening to be examined within 
the context of a damaged tumour suppressive pathway.  
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Telomere Length: Characterisation of the XpYp chromosome ends within the four cell 
lines revealed that the mean telomere lengths of NCI-H929 and RPMI-8226 were 
relatively short.  This is in comparison to the longer XpYp telomere lengths of the JJN-3 
and U266B1 cell lines.  The difference in mean telomere length between the four cell 
lines is simply a result of their origin, with each cell line being derived from a separate 
individual.  As we demonstrated in the previous chapter, mean telomere length can 
depend on several factors. This includes the age of the individual, the type of cell being 
examined, and whether the cells under examination are healthy or diseased (Friedrich 
et al. 2000; Svenson et al. 2011).   
 
However, the mean telomere length at the XpYp chromosome end did not always 
correlate with the mean 17p telomere length.  Within the NCI-H929 cell line, this 
difference was caused by the presence of a multimodal distribution.  These distributions 
can occur because a cell may have multiple copies of the sub-telomeric sequence used 
for STELA, with each copy located at a different chromosomal end (Baird et al. 2003).  If 
the telomere length of these chromosomes is significantly different, then a gap can form 
between the two distributions which allows each of the multimodal distributions to be 
analysed separately.  However, this difference between telomere lengths may not always 
be enough for individual distributions to be identified. 
 
This was not the cause of the differences between the mean XpYp and 17p telomere 
lengths in the U266B1 cell line.  While a heterogeneous telomere length distribution could 
be identified at the XpYp chromosomal end, the 17p telomere was not detectable using 
STELA.  One explanation for this could be the deletion of the 17p arm of the chromosome 
in this cell line.  Del(17p) is thought to be present in around 11% of MM patients (Avet-
Loiseau et al. 2007), however there is nothing in the current literature to suggest that the 
U266B1 cell line has a del(17p) abnormality.  Alternatively, the 17p telomere and/or the 
subtelomeric region containing the telomere-specific primer binding site could have been 
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completely eroded in this cell line due to cell division beyond the Hayflick limit.  A 
chromosomal fusion event or de novo telomere seeding by telomerase would then 
stabilise the unprotected chromosomal end.  Either way, the result would be loss of one 
or both primer binding sites and the inhibition of STELA at 17p telomere.  
 
One further possibility is that a mutation exists at the 17pSeq1Rev primer binding site in 
U266B1 which reduces the efficiency of the PCR.  To test these theories, Quantitative 
Fluorescent in situ hybridization (Q-FISH) could be used to show whether a telomere 
exists at the 17p chromosome end in U266B1 cells.  If it does, then simply changing the 
subtelomeric telomere-specific primer that is used in the PCR could yield a STELA profile 
at the 17p chromosomal end.  If it does not, then it may be possible that U266B1 cells 
have either an eroded 17p telomere or subtelomeric primer binding site.     
 
Chromosomal Fusion: Having examined mean XpYp and 17p telomere length, 
chromosomal fusion events were then quantified for each cell line.  We observed that 
the two cell lines with the shortest mean XpYp telomere length, NCI-H929 and RPMI-
8226, also had the greatest number of detectable chromosomal fusion events.  This 
result was the first evidence that a shorter mean telomere length may correlate with an 
increase in the frequency of fusion events in MM.    
 
Although we could not produce a 17p STELA profile for the U266B1 cell line, comparing 
mean 17p telomere length against the frequency of chromosomal fusion in the remaining 
cell lines did not change our result.  RPMI-8226 had the shortest mean 17p telomere 
length and the greatest frequency of chromosomal fusion events, while JJN-3 had the 
longest mean 17p telomere length and the lowest frequency of chromosomal fusion 
events.   
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However, it is important to note that mean telomere length was measured using STELA 
at only 2 of the potential 46 chromosomal ends.  Because of this, it became impossible 
to know how the mean telomere length at other chromosomal ends impacted on genomic 
instability and the frequency of fusion events.  Unfortunately, calculating every mean 
telomere length would not have been possible due to the requirement for a unique 
telomere-adjacent primer at each chromosomal end.  Designing these telomere-specific 
primers would necessitate generating sequence information for the subtelomeric regions 
of every chromosome.  For this reason, as well as the presence of a multimodal 
distribution within some of the 17p STELA profiles, we used mean XpYp telomere length 
as a standard throughout the chapter.  
  
Problems also arise when comparing different cell lines, with the possibility that each cell 
line may have an inherent genomic instability that is independent of telomere length.  To 
truly demonstrate that telomere length was the direct cause of the frequency of 
chromosomal fusion in MM, it became necessary to artificially reduce mean telomere 
length in each cell line and measure any change in the frequency of chromosomal fusion 
events. 
 
4.5.2 Expression of DN-hTERT in Three MM Cell lines 
Immortalised cell lines commonly express the enzyme telomerase as a method of 
maintaining telomere length and avoiding senescence.  We have attempted to disrupt 
this mechanism by using DN-hTERT expression to reduce telomerase activity within 
three MM cell lines; JJN3, NCI-H929 and U266B1.  We expected that mean telomere 
length would then decrease, forcing the cells into a state of telomere-driven crisis.  Due 
to the differing p53 expression profiles of the three cell lines, it was also possible to 
examine the role that p53 expression played in telomere fusion and the escape from a 
telomere-driven crisis; JJN-3 (p53neg), NCI-H929 (p53wt) and U266B1 (p53mut).   
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JJN-3: In the 15 days immediately following retroviral transduction of the JJN-3 cell line, 
the number of viable cells in the DN-hTERT population was much lower than that of the 
puromycin-resistant control.  This may suggest that the resulting telomere shortening 
had a deleterious effect on cell viability, one that is not simply a result of the transduction 
procedure or puromycin selection.  It could be the case that a lack of telomerase resulted 
in critical telomere shortening, causing additional cell death that is not experienced by 
the puromycin-resistant population.  
 
However, it should also be noted that the retroviral titre was unknown before conducting 
the transduction procedure.  This could also explain the difference if the DN-hTERT 
retroviral titre was lower than that of the puromycin-resistant control retroviral titre.  If this 
were the case, fewer cells within the DN-hTERT population would contain the pBABE-
puro vector which would then lead to greater cell death during the puromycin selection 
stage.  Incorporating a fluorescent reporter gene within the viral vector may allow the 
relative expression of the puromycin resistance gene to be estimated in both the DN-
hTERT and puromycin-resistant control JJN-3 populations (Soboleski, Oaks, and Halford 
2005).  If the expression of the fluorescent reporter, and by extension the puromycin-
resistance gene, was equal in both the DN-hTERT and control cells, then it could be 
argued that any difference in cell viability after the addition of puromycin might be caused 
by the expression of DN-hTERT.   
 
After transduction, telomerase activity was shown to be significantly decreased within 
the DN-hTERT population.  This coincided with a decrease in mean XpYp telomere 
length from 3.10kb to 2.09kb by day 27.  Surprisingly, mean XpYp telomere length did 
not fall further and was instead maintained at around 2.20kb for several weeks.  Mean 
XpYp telomere length had even increased by the time the final sample was taken at day 
48.   
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One possible explanation for this was that reactivation of telomerase had occurred, with 
the cells finding a way to bypass or outcompete DN-hTERT expression.  Had telomerase 
activity been recorded again closer to day 48, it may have been possible to identify 
whether this mechanism was responsible for preventing further telomeric erosion.  
However, evidence to support this hypothesis was uncovered by Delhommeau et al. 
(2002) who managed to transduce the UT-7 and U937 leukaemia cell lines with a Mig-R 
vector which contained the DN-hTERT gene.  Clonal populations were then grown, with 
50% of these populations later being shown to have reactivated telomerase.   
 
The authors identified two distinct mechanisms by which telomerase reactivation took 
place.  In most of the clonal populations, the cause was identified as the loss of DN-
hTERT expression following genomic instability.  However, one clonal population had an 
increased hTERT expression which resulted in telomerase activity being maintained, 
despite continued DN-hTERT expression.  In our experiments, performing a further 
telomerase assay at day 48 may have answered the question of whether telomerase had 
been reactivated, but it would have failed to answer by which (if either) mechanism this 
occurred.   
 
Another possibility for overcoming a reduction in telomerase activation is that the cells 
are undergoing alternative lengthening of telomeres (ALT).  This is a process by which 
cells lengthen telomeres in the absence of telomerase (Bryan et al. 1997).  During ALT, 
telomeres are elongated using either a second telomere or extra-chromosomal telomeric 
DNA as a template for telomere synthesis.  This process is known to occur in 
approximately 10% of cancers (Henson et al. 2009) and is thought to be implicated in at 
least one type of haematological malignancy (Samassekou 2013).  Again, a 
measurement of telomerase activity towards the end of the experiment may have gone 
towards explaining whether this observed telomere elongation was telomerase-
independent.  However, ALT is an unlikely explanation for the telomere length 
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maintenance observed here.  This mechanism has never been shown to occur in MM 
and the JJN-3 STELA profile does not fit with the heterogeneous telomere length profile 
described in ALT-dependent cells (Bryan et al. 1995).    
  
NCI-H929: Unlike the JJN-3 cell line, NCI-H929 cells expressing the DN-hTERT 
construct appeared to die immediately after puromycin selection.  This was preceded by 
a reduction in telomere length during the three weeks immediately after transduction.  
Although it may be argued that the cells could be sensitive to the effects of puromycin 
selection, the puromycin-resistant control cells appeared to recover quickly and did not 
experience the associated reduction in mean XpYp telomere length.  There are also 
examples of other researchers successfully growing NCI-H929 cells in the presence of 
up to 2 μg/ml of puromycin following a transduction procedure (Amodio et al. 2012; Ling 
et al. 2012).  It is therefore likely that cell death was the result of a decrease in telomere 
length brought on by a reduction in telomerase activity. 
 
This result also shares similarities with a previous study involving the use of a drug which 
inhibits telomerase activity.  Brennan et al. (2010) sorted CD138neg cells from the NCI-
H929 cell line (CD138neg cells were thought to more closely resemble memory B cells) 
and grew them in the presence of Imetelstat.  This is a 13-mer oligonucleotide which 
binds to the TERC subunit and inhibits the reverse transcriptase activity of telomerase.  
The growth of colonies treated with Imetelstat remained suppressed after 5 weeks.  
When we inhibited telomerase activity in the NCI-H929 cell line using a DN-hTERT 
construct, we also observed suppressed growth for the 3 weeks until the experiment was 
ended.       
 
This is not the only example of crisis being triggered in a MM cell line using Imetelstat.  
Akiyama et al. (2003) managed to shorten telomere length and inhibit growth in the 
MM.1S myeloma cell line (also p53wt).  Shammas et al. (2008) used this same compound 
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to inhibit growth and induce cell death in the INA-6, ARP-1 and OPM-1 myeloma cell 
lines.  This suggests that telomerase-inhibiting drugs offer a novel approach to treating 
MM, triggering a telomere-driven crisis by critically shortening telomere length.     
 
U266B1: However, not all myeloma cell lines are affected by the activity of telomerase-
inhibiting drugs.  When treated with Imetelstat (Akiyama et al. 2003) the growth of 
U266B1 cells remained constant and the level of cell death was almost unchanged.  This 
remained true even after 56 days of treatment, a confirmed reduction in telomerase 
activity and a >1kb reduction in telomere length.  This result mirrored our own study, 
whereby U266B1 cells expressing the DN-hTERT construct did not experience inhibited 
growth.  Cells showed a reduction in telomerase activity and a minor reduction in 
telomere length, but no change in growth that could not be attributed to the puromycin 
selection procedure.   
 
By the end of our experiment, cell viability and growth had returned to pre-crisis levels 
and telomere length stabilised.  Telomerase activity in the U266B1 cell line also remained 
lower than before transduction.  This suggests that telomere length is being maintained, 
even with a significantly reduced telomerase activity.  However, this could simply mean 
that low levels of telomerase activity are sufficient to maintain telomere length in U266B1 
cells.  This cell line is slow-growing, relative to the JJN-3 cell line, which may allow the 
small number of active telomerase enzymes to elongate telomeres at a faster rate than 
cell division occurs.  One way to overcome this is to reduce telomerase activity further, 
possibly by combining DN-hTERT expression with a telomerase-inhibiting drug (e.g. 
Imetelstat).  In this way, it would be possible to identify whether telomere length is 
maintained by the action of telomerase, or by an alternative mechanism.   
 
ALT could also explain telomere length maintenance in the absence of telomerase 
activity.  One of the phenotypic hallmarks of ALT is a significantly heterogeneous 
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telomere length profile (Bryan et al. 1995).  The XpYp STELA profile of the U266B1 cell 
line appeared to meet this criterion, having a standard deviation that was much greater 
than that of the other MM cell lines examined here.  The findings of (Shammas et al. 
2003), whereby treatment with the drug Telomestatin reduced U266B1 telomere length 
and cell viability, could also be used to suggest an ALT mechanism.  Telomestatin has 
previously been shown to inhibit the growth of fibroblast and osteosarcoma cell lines 
which were known to maintain telomere length using the ALT pathway (Kim et al. 2003; 
Fujimori et al. 2011). 
 
However, it is important to note that Telomestatin works via several different 
mechanisms.  Although the drug is thought to organise the 3′ overhang in such a way as 
to block reverse transcription and inhibit lengthening via ALT, is it also known to be 
responsible for downregulating c-MYC expression which leads to decreasing hTERT 
expression and thus lower telomerase activity (Mergny and Helene 1998; Grand et al. 
2002).  As well as showing that Telomestatin reduced the viability of U266B1 
populations, Shammas et al. (2003) also demonstrated that the drug caused a ~98% 
reduction in telomerase activity.   
 
Given these findings, it is more likely that the mean XpYp telomere length of our U266B1 
population is being maintained by low level telomerase activity.  Future work should 
therefore focus on further reducing telomerase activity, possible by combining DN-
hTERT expression with telomerase inhibiting drugs.  It is in this way that we would hope 
to force the cells into a state of telomere-driven crisis and examine both the effect of 
telomeric erosion on the frequency of chromosomal end-end fusion, as well as the ability 
of U266B1 cells to escape from crisis.   
 
The Role of p53: JJN-3 cells do not express a functioning p53 protein (p53neg) and the 
population was able to escape from a telomere-driven crisis.  Meanwhile, NCI-H929 cells 
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express a functioning p53 protein (p53wt) and the population was unable to escape from 
a telomere-driven crisis.  From this data alone, it may seem that p53 has a prominent 
role in dictating whether cells can escape crisis.  This is an important line of enquiry as 
around 13% of newly diagnosed MM cases are thought to involve TP53 abnormalities 
(Chng et al. 2007).   
 
However, it is also important to consider the response of the U266B1 cell line.  While 
these cells carry a mutation within the TP53 gene, U266B1 has been shown to express 
a functional p53 protein which can elicit a p21 response following genotoxic stress 
(Landau et al. 2012).  As significant telomeric erosion did not take place following DN-
hTERT expression, and so the cells did not experience a telomere-driven crisis, it was 
difficult to comment on the role that p53 expression may play in triggering U266B1 
senescence. 
 
While we may have been unable to cause a reduction in telomerase activity which 
triggered crisis in the U266B1 cell line, the use of Telomestatin by Shammas et al. (2003) 
managed to reduce telomerase activity by 98%.  This telomerase inhibition caused 
telomeric shortening followed by cell death.  In a similar manner to the NCI-H929 cell 
line, it may appear that the a functional p53 response prevented U266B1 cells from 
escaping a telomere-driven crisis.  It is also worth remembering that (Akiyama et al. 
2003)used Imetelstat to reduce telomerase activity in the p53wt MM.1S myeloma cell line, 
causing cell death.     
 
While both examples within the literature backup our hypothesis, there are also examples 
that do not.  (Shammas et al. 2008) demonstrated that telomerase inhibition caused the 
death of the ARP-1 and OPM-1 myeloma cell lines, both of which were shown elsewhere 
to be p53neg and p53mut/p21neg respectively (Nardiello et al. 2011; Chauhan et al. 2007; 
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Gorgun et al. 2010).  This may rule out the idea that p53 alone is necessary to induce 
senescence.   
 
Chromosomal Fusion: Although we have described three different responses to the 
expression of DN-hTERT in three MM cell lines, the effect on the frequency of 
chromosomal fusion events was almost identical.  Chromosomal fusion events were 
present in the JJN-3, NCI-H929 and U266B1 cells lines, but their frequency was relatively 
unchanged when compared to a puromycin-resistant control.  Any minor changes 
between timepoints can be attributed to errors in the quantification of DNA samples or 
pipetting.  Only the DN-hTERT-expressing NCI-H929 population showed any real 
change, with chromosomal fusion events being undetectable by day 23.  However, this 
can simply be explained by the extent of cell death as viability decreased to 7.8%.   
 
In the U266B1 cell line, a lack of change in the frequency of fusion events could be 
attributed to the fact that the mean XpYp telomere length does not alter significantly.  
However, the JJN-3 cell line does experience a significant decrease in the mean XpYp 
telomere length, but without the corresponding change in the frequency of chromosomal 
fusion events.  One explanation for this is that the chromosomal ends under examination 
were simply not the ends undergoing fusion.  The fusion assay performed here only 
examined 21 of the potential 46 chromosomal ends.  It is therefore possible that the 
chromosomal ends which were not under examination have undergone a significantly 
greater level of erosion and fusion.  However, it is unlikely that we would not have 
observed some form of existing change in the frequency of chromosomal fusion events 
after examining 46% of all chromosomal ends. 
 
Another possible cause for this observation might have been the heterogeneity of the 
telomere length profiles in these cell lines.  The cells with the shortest telomere lengths 
would enter a state of crisis much sooner than those with longer telomeres (Allsopp et 
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al. 1992; Capper et al. 2007).  Although these cells then experience greater level of 
chromosomal fusion, this could be overshadowed by the bulk of the pre-crisis population.  
By the time the cells with the longest telomeres enter a state of telomere-driven crisis, 
those with shorter telomeres would have already escaped from crisis or undergone 
apoptosis.  It is in this way that a heterogeneous telomere length profile may disguise 
the change in the frequency of chromosomal fusion events, by constantly having a 
stream of cells that are entering and escaping crisis.  The easiest way to overcome this 
is to use a clonal population of cells.  Clonal populations typically exhibit more 
homogeneous telomere length profiles, as each cell is derived from the same parental 
cell.  In this way, all cells within a population will enter crisis at roughly the same time. 
 
4.5.3 Expression of DN-hTERT in Three Clonal Populations of JJN-3 Cells 
Telomerase Reactivation: Clonal populations of the JJN-3 cell line, each expressing 
DN-hTERT, were monitored during a telomere-driven crisis.  Telomerase assays, 
performed before this period of crisis, show that telomerase activity was significantly 
decreased in each population.  After crisis, telomerase activity had increased.  This 
suggests that reactivation of telomerase had occurred, but does not explain the 
mechanism by which it had been triggered.  Most surprising was the observation that 
telomerase activity had increased well beyond the base levels recorded in the clonal 
population of control JJN-3 cells.   
 
One possible explanation for the reactivation of telomerase is that genomic instability 
and rearrangement, brought about by critical telomeric shortening, caused the gene 
encoding the DN-hTERT construct to be damaged and rendered inactive.  Retroviral 
transduction works by integrating DNA into the host’s genome.  As telomere shortening 
led to chromosomal instability, it is possible that double-stranded DNA breaks caused 
the DN-hTERT gene to be interrupted and inactivated.  Only a single cell would need to 
undergo this process, which would then express functional telomerase, allowing it to 
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outgrow the remaining cells.  This mechanism was shown to occur preferentially in the 
Delhommeau et al. (2002) study mentioned previously.  However, this mechanism fails 
to explain why telomerase activity was increased beyond the levels recorded in the 
control population. DN-hTERT inactivation should simply lead to telomerase activity 
returning to normal levels.   
 
An alternative explanation is that hTERT expression was significantly increased, allowing 
functional hTERT to outcompete the inactivation caused by DN-hTERT expression.  
Although the signalling pathways connecting telomere length and telomerase activity are 
not fully understood, it is possible that critical telomere shortening results in an 
upregulation of the transcription factors responsible for synthesis of the telomerase 
subunits (De Boeck et al. 2009).  Amplification of the hTERT locus could also occur via 
genomic rearrangements which place the gene under the control of a strong promotor.  
Both mechanisms would go towards explaining the significantly increased telomerase 
activity, relative to the control JJN-3 population, which was observed post-crisis.   
 
Discerning which of these mechanisms are responsible for telomerase reactivation 
would first require identifying whether DN-hTERT expression had decreased or whether 
hTERT expression has increased.  Delhommeau et al. (2002) achieved this by utilising 
a Mig-R1 plasmid that contained a green fluorescent protein (GFP) reporter gene 
alongside the DN-hTERT gene.  It was concluded that loss of DN-hTERT expression 
also resulted in the loss of GFP expression.  By repeating our experiment under these 
conditions, we could identify whether DN-hTERT expression has been lost (loss of GFP 
expression) or hTERT expression was simply outcompeting DN-hTERT expression 
(continued expression of GFP).   
 
Demonstrating that telomerase activity increased significantly after crisis in clonal JJN-3 
populations may go some way towards explaining the behaviour of the JJN-3 bulk 
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population described earlier (see 4.5.2 – Expression of DN-hTERT in Three MM Cell 
Lines).  We previously recorded a decrease in telomerase activity immediately after DN-
hTERT expression, but then failed to measure telomerase activity again as telomere 
length began to stabilise and then increase.  Here, in a clonal JJN-3 population 
expressing DN-hTERT, we have demonstrated that telomerase activity eventually 
increased after a period of telomere-driven crisis.  This adds weight to the argument that 
telomerase reactivation is responsible for the increase in mean XpYp telomere length 
that was observed in the non-clonal JJN-3 population.   
 
Telomere Length: The effect on telomere length in the three clonal JJN-3 populations, 
caused by this increase in telomerase activity, was examined by measuring mean 
telomere length during a period of telomere-driven crisis.  We observed that an escape 
from crisis was marked by an increase in mean XpYp and 17p telomere length, as well 
as increased heterogeneity within the STELA profile of each clonal population.  These 
telomere dynamics closely mirrored the results observed when clonal populations of a 
colorectal carcinoma cell line were monitored though a telomere-driven crisis (Jones et 
al. 2014).  This increasing telomere length and heterogeneity could simply have been 
caused by the cells within each clonal population entering crisis at slightly different times, 
resulting in each JJN-3 cell being at a different stage of telomere elongation.  Continuing 
to monitor mean telomere length in the clonal population would have been the simplest 
way of proving this hypothesis, with the expectation that a homogeneous telomere length 
distribution would eventually reform (albeit with a longer mean telomere length) once 
each cell has undergone telomerase-dependent telomere elongation. 
 
However, it is also possible that the STELA profile would remain heterogeneous.  This 
could be caused by differing levels of telomerase activity within each post-crisis cell of 
the population, with greater telomerase activity in a cell leading to a longer telomere 
length.  The idea that greater telomerase activity leads to greater mean telomere length 
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was explored in Cristofari and Lingner (2006), whereby the telomerase activity of HeLa 
cells was increased artificially by transduction with a vector encoding hTERT.  This 
resulted in the transduced cells having a longer telomere length than control cells with a 
lower telomerase activity.  Although we could record the average telomerase activity 
across each of the JJN-3 clonal populations, we do not know the levels of telomerase 
activity in the individual cells.  As it is not possible to measure and compare the 
expression of telomerase between single cells, it would be necessary to sub-clone cells 
from the post-crisis JJN-3 DN-hTERT population and compare the relative telomerase 
activities of each new sub-clonal population.  This is the only way that we would be able 
to determine whether the heterogeneous telomere length distribution is caused by a 
significant difference in telomerase activity between the individual post-crisis cells. 
   
When comparing the three clonal populations, mean telomere length could not be used 
to predict when the cells would enter a state of telomere-driven crisis. As clone A entered 
crisis, it had a mean XpYp telomere length of 1.44kb.  This is in comparison to clone C 
which had a shorter mean XpYp telomere length of 0.76kb.  When 17p telomere length 
was measured instead, this order was reversed.  Clone C began crisis with a longer 
mean 17p telomere length of 2.41kb, while clone A had a shorter mean 17p telomere 
length of 1.77kb.  This suggests that measuring the mean telomere length of a single 
chromosomal end is not enough to accurately predict when crisis will occur.  The 
telomere lengths of each chromosome within a cell will differ, as will the telomere lengths 
between identical chromosomes in different cells. This leads to each clonal population 
having distinct telomere length profile, with different critically-shortened telomeres 
initiating crisis in each clone.  Predicting crisis therefore requires all chromosomal ends 
to measured, as well as each STELA profile to be considered as a whole.  This includes 
the presence of multimodal distributions and the number of critically shortened 
telomeres.   
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Frequency of Fusion: However, we could demonstrate that mean telomere length 
directly correlated with the frequency of chromosomal fusion events observed throughout 
the genome.  While we were unable to measure mean telomere length at any of the 
chromosomal ends targeted by the 16p-family or 21q-family of fusion primers, we were 
still able to compare the mean telomere length at the 17p and XpYp chromosomal ends 
with their respective frequency of fusion events.   
 
From this, it became clear that the XpYp chromosome was involved in relatively few 
fusion events throughout each of the three JJN-3 clonal populations.  This may be 
explained in clone A and clone B by the longer pre-crisis mean XpYp telomere length, 
relative to the mean of the 17p lower distribution at the same timepoint.  Lin et al. (2010) 
demonstrated that chromosomal fusion events, identified and sequenced from the 
peripheral blood mononuclear cells of CLL patients, contained an average of 5.8 
TTAGGG repeats.  More than 30% of the fusions identified in CLL patients did not contain 
a single TTAGGG repeat between the two chromosomal ends.  It is therefore unlikely 
that the mean XpYp telomere lengths recorded here, which in clone A and clone B never 
fell below 1.40kb, would be short enough for a detectable number of XpYp fusion events 
to occur.  The homogeneous XpYp STELA profiles recorded in all three JJN-3 clonal 
populations further explain the lack of fusion events, with no individual XpYp telomere 
falling below 350bp in length (about 58 TTAGGG repeats). 
 
By contrast, the mean of the lowest distribution of 17p telomere ends in each clone 
almost always fell below 1.00kb.  Also, due to the heterogeneous distribution of telomere 
lengths within the 17p STELA profiles, a significant proportion of individual telomere ends 
fell towards the bottom of the profile.  This suggest that a greater number of critically 
shortened 17p telomeres are present.  It is therefore more likely in these cells for a 17p 
chromosome to exist where the telomere has been eroded completely, when compared 
to an XpYp chromosome with >58 telomeric repeats.   
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When the total number of chromosomal fusion events were examined in each clonal 
population, it became clear that the 17p and 21q-family of chromosomal ends 
experienced the greatest frequency of fusion.  For the 21q-family primer, this may be 
explained by the large number of chromosomal targets (21q, 1q, 2q, 5q, 6q, 6p, 8p, 10q, 
13q, 17q, 19p, 19q, 22q and the 2q13 interstitial telomeric locus).  The greater the 
number of primer binding sites, the greater the chance of observing a fusion event.  
However, this does not remain true for the 16p-family primer which also has many 
chromosomal targets (16p, 1p, 9p, 12p, 15q, XqYq and the 2q14 interstitial locus).  Also, 
the 17p primer only binds at one chromosomal end, but the number of chromosomal 
fusion events are almost equal to the 21q-family primer.  In fact, most chromosomal 
fusion events observed were interchromosomal between the 17p and the 21q-family.   
 
This high frequency of fusion involving either the 17p or 21q-family of chromosomal ends 
may go some way towards explaining the incidence of certain chromosomal 
abnormalities in MM.  Walker et al. (2010) analysed 372 MM patient DNA samples and 
showed that several common abnormalities involve the 21q-family of chromosomal ends.  
Del(13q) was shown to occur in 59% of MM patients, resulting in the loss of the 
retinoblastoma protein (RB1).  Del(6p) was shown to occur in 33% of cases, resulting in 
a deregulation of cyclin D3.  And del(8p) was shown to occur in 25% of MM cases.  The 
frequency of del(17p) in MM is so significant that it is now listed by the revised ISS as a 
potential indicator of high-risk disease (Palumbo et al. 2015).  This is particularly relevant 
for the JJN-3 cell line, as these cells are known lack p53 expression (Hurt et al. 2006).   
 
This protein, which is necessary for triggering senescence after telomeric erosion, is 
located close to the end of the 17p chromosomal arm (Deng, Chan, and Chang 2008).  
Loss of p53 may explain why this cell line, unlike the NCI-H929 cell line which has normal 
p53 expression, can avoid the senescence that should be triggered by critical telomere 
shortening.  As around 11% of MM cases are thought to involve del(17p) (Avet-Loiseau 
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et al. 2007), disruption of p53 and the ability of MM cells to escape from a telomere-
driven crisis may be a significant event that requires further exploration. 
 
4.5.4 Conclusions 
The aim of this chapter was to determine whether myeloma cell lines had the capacity to 
avoid senescence after undergoing a telomere-induced crisis.  This was achieved 
through the expression of DN-hTERT which reduced the activity of telomerase, the 
enzyme responsible for adding telomeric repeats to the ends of chromosomes.  Although 
DN-hTERT expression had little effect on the viability and mean XpYp telomere length 
of the U266B1 cell line, reducing telomerase activity in the NCI-H929 cell line caused a 
reduction in both viability and mean XpYp telomere length.  It was concluded that NCI-
H929 cells were unable to escape from a telomere-driven crisis and underwent apoptosis 
after critical telomere shortening.  However, the JJN-3 cell line did not undergo apoptosis, 
even after a significant reduction in mean XpYp telomere length.  Instead, JJN-3 cells 
managed to escape from a telomere-driven crisis by reactivation of the telomerase 
enzyme.  Although the p53 expression profiles of each cell line may explain their different 
responses to critical telomere shortening, more works needs to be done in this area 
before a definitive conclusion can be established.    
 
We also used clonal populations of JJN-3 cells, each expressing DN-hTERT, to 
demonstrate that critically shortening telomeres results in an increased frequency of 
chromosomal end-end fusion.  We therefore conclude that, in the JJN-3 myeloma cell 
line, a causal relationship exists between mean XpYp or 17p telomere length and the 
frequency of chromosomal end-end fusion.  Our results also point towards a significant 
number of these events involving the 17p and 21q-family of chromosome ends.  Due to 
the high incidence of del(17p) and 21-family abnormalities in MM, we believe that critical 
telomere shortening may play a significant role in driving genomic instability and the 
progression of MM. 
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Chapter 5 
Using the PARP Inhibitors Rucaparib and Olaparib to Prevent Escape 
from a Telomere-Driven Crisis 
 
5.1  Abstract 
PARP inhibition is primarily used in the treatment of BRCA-deficient ovarian cancer, with 
preliminary results suggesting that it may also prove effective in treating other 
homologous recombination-deficient cancers.  PARP inhibitors are thought to work by 
interfering with the cells ability to repair DNA damage, specifically by preventing PARP 
family proteins from targeting single- and double-strand DNA breaks for repair.  Due to 
the increased frequency of chromosomal end-end fusion during a telomere-driven crisis, 
we attempted to use the PARP inhibitors Rucaparib and Olaparib as a method of 
restricting the erroneous repair of telomere-deficient chromosomal ends.  We 
hypothesised that PARP inhibition would interfere with the alt-NHEJ pathway, limiting the 
formation intrachromosomal fusion events which have previously been identified as 
necessary for facilitating an escape from a telomere-driven crisis. 
 
Clonal populations of JJN-3 cells were transfected with a DN-hTERT construct and 
grown in culture until they entered a state of telomere-driven crisis. The cells were then 
exposed to varying concentrations of either Rucaparib or Olaparib indefinitely.  We 
observed that treating this MM cell line with either 7.50μM Rucaparib or 3.75μM Olaparib 
prevented an escape from crisis, whilst having little effect on the growth of a control 
population of JJN-3 cells.  XpYp telomere length measurements, recorded immediately 
before the onset of crisis, showed that treating these cells with 3.75μM Olaparib resulted 
in a significantly longer mean XpYp telomere length when compared to untreated 
controls.  However, no significant difference in mean XpYp telomere length was recorded 
when cells were instead treated with 7.50μM Rucaparib.  Measuring the frequency of 
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chromosomal end-end fusion in Rucaparib- and Olaparib-treated JJN-3 subpopulations 
also failed to identify a significant change, relative to control subpopulations.  We 
therefore concluded that PARP inhibitors show promise as a novel treatment for MM, 
although attempts to identify the mechanism by which Rucaparib and Olaparib prevented 
an escape from crisis proved inconclusive.  We argue that PARP inhibition may hold 
particular therapeutic value when used to treat high-risk MM patients, previously 
identified as having a shorter mean XpYp telomere length, due to the increased genetic 
instability that might otherwise drive cancer progression.  
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5.2 Introduction 
DNA repair pathways play an important role in maintaining genomic stability by 
preventing single- and double-strand DNA breaks from inducing harmful mutations and 
rearrangements which may potentially result in the formation of cancer.  DNA damage 
can often prevent a cell from passing through the various cell cycle checkpoints that 
regulate eukaryotic cell division.  These checkpoints offer an opportunity to repair DNA 
damage, with failure to do so resulting in cell cycle arrest (Otto and Sicinski 2017).  
Single-strand DNA breaks are often identified for repair by PARP1 and PARP2, members 
of the poly (ADP-ribose) polymerase (PARP) family which use NAD+ as a substrate to 
modify target proteins (Caldecott 2014).  Depending on the PARP family member, these 
modifications can either result in the addition of individual ADP-ribose units called MAR 
(mono (ADP-ribose)) or branched chains of ADP-ribose units called PAR (poly (ADP-
ribose)).  In the case of PARP1 and PARP2, PAR modification is used to recruit several 
scaffold proteins to the site of a single-strand DNA break, most notably XRCC1 which is 
required for enlisting the enzymatic components of the base excision repair (BER) 
pathway (Hanzlikova et al. 2017). 
 
PARP1 has also been implicated in several double-strand DNA break repair pathways, 
although its roles within these pathways are not fully understood.  PARP1 is known to be 
active at stalled and collapsed replication forks, recruiting MRE11 which is necessary for 
initiating the homologous recombination (HR) pathway and restarting DNA replication 
(Yang et al. 2004; Bryant et al. 2009).  PARP1 is also thought to compete with Ku70/Ku80 
for binding at double-strand DNA breaks, shifting repair away from the classical non-
homologous end joining (NHEJ) pathway and towards a PARP1-driven alternative-NHEJ 
pathway (Mansour et al. 2013).  This is important as the alt-NHEJ pathway has been 
implicated in the escape of cells from a telomere-driven crisis (Jones et al. 2014).  
Meanwhile PARP3, another PARP family member which modifies target proteins through 
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the addition of PAR, is thought to recruit Ku80 to double-strand DNA breaks which then 
accelerates repair via the classical-NHEJ pathway (Rulten et al. 2011).   
 
However, only 3 of the 17 PARP family proteins have been shown to regulate DNA 
damage repair pathways.  The remaining members play a diverse array of roles, ranging 
from stress granule assembly to promotors of cell migration (Vyas and Chang 2014).  
PARP5a and PARP5b (also known as Tankyrase-1 and Tankyrase-2) are even known 
to positively regulate telomere length by modifying TRF1, a key member of the shelterin 
complex.  This activity inhibits the binding of TRF1 at the telomere, allowing telomere-
elongation by the enzyme telomerase (Smith and de Lange 2000; Cook et al. 2002).  The 
importance of each PARP protein also varies, with knockdown studies concluding that 
some PARP family members are more necessary than others for survival.  For example, 
Vyas et al. (2013) demonstrated that PARP4 and PARP6 knockdown barely impacted 
HeLa cell viability, while PARP8 knockdown almost completely inhibited cell growth.   
 
Due to the numerous functions carried out by the PARP family proteins, PARP inhibition 
continues to be investigated as a method of treating cancers.  However, PARP inhibition 
is currently used exclusively to treat those cancers which are BRCA1/BRCA2 deficient 
(Fong et al. 2009).  Breast cancer susceptibility (BRCA) proteins are an integral part of 
the HR pathway, recruiting RAD51 to sites of double-strand DNA breaks (Powell and 
Kachnic 2003).  This protein then forms a complex with MRE11 and NBS1, triggering 
cell cycle arrest and enabling the damaged DNA ends to be processed (Uziel et al. 2003).   
In the case of BRCA-deficiency, cells must rely on the more error-prone NHEJ pathways 
for repair of double-strand DNA breaks (Patel, Sarkaria, and Kaufmann 2011).  It is 
thought that inhibition of PARP prevents the modification and recruitment of target 
proteins to a single-strand DNA break, whilst still allowing PARP to bind DNA.  In this 
way, PARP becomes trapped at sites of DNA damage and prevents the repair of single-
strand DNA breaks.  An overwhelming number of double-strand DNA breaks then form 
which the cell, unable to undergo HR due to BRCA-deficiency, then incorrectly repairs 
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via NHEJ pathways.  The resulting genetic damage is overwhelming and is thought to 
promote apoptosis (Konecny and Kristeleit 2016; Patel, Sarkaria, and Kaufmann 2011). 
 
Attempts are now being made to treat HR-normal cancers by inhibiting both PARP family 
proteins and the HR pathway.  It has been demonstrated in vitro that supressing 
phosphoinositide 3-kinase (PI3K) expression induces BRCA1/BRCA2 downregulation, 
thus sensitising breast cancer cell lines to PARP inhibition (Ibrahim et al. 2012).  The use 
of bortezomib in multiple myeloma (MM) cell lines was also shown to suppress the HR 
pathway indirectly, resulting in apoptosis when these cells were exposed to the PARP 
inhibitor Veliparib (Neri et al. 2011).  However, in vivo studies which combine inhibitors 
of HR and PARP have never been attempted.  Instead, most clinical trials involving 
PARP inhibitors have focused on the treatment of those breast and ovarian cancers 
which are already HR-deficient (Tutt et al. 2010; Ledermann et al. 2014). 
 
The first PARP inhibitor to be approved for use in the treatment of cancer was Olaparib.  
Marketed as Lynparza, this PARP inhibitor is used to treat BRCA-deficient ovarian 
cancer (Kim et al. 2015).  However, several other PARP-inhibiting drugs are currently 
undergoing clinical trials.  One of these is Rucaparib which is currently undergoing phase 
III trials, as well as also having been granted accelerated approval by the USA FDA for 
use in BRCA-deficient ovarian cancer (Knepper, Saller, and Walko 2017).  Due to the 
homologous nature of the catalytic domains within the PARP family, PARP inhibitors 
such as Rucaparib and Olaparib very rarely bind to a single PARP protein (Ame, 
Spenlehauer, and de Murcia 2004).  As well as binding to PARP1, PARP2, PARP3, 
PARP4, PARP15 and PARP16 in vitro, Rucaparib and Olaparib also have their own 
individual targets.  Rucaparib has been shown to bind at the catalytic sites of PARP5a, 
PARP5b and PARP10.  While Olaparib also binds to PARP12 (Wahlberg et al. 2012).   
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In the previous chapter, we demonstrated that a telomere-driven crisis in the JJN-3 MM 
cell line caused a significant increase in the frequency of chromosomal end-end fusion 
events.  This eventually resulted in the reactivation of telomerase and the escape of 
these cells from crisis.  Here, we have attempted to reduce the frequency of fusion by 
employing the PARP inhibitors Rucaparib and Olaparib.  We hypothesised that the 
inhibition of PARP1, PARP2 and PARP3 would not only result in catastrophic genomic 
damage as single-strand DNA breaks went unrepaired, but also that the frequency of 
chromosomal end-end fusion would decrease as the efficiency of double-strand DNA 
break repair was reduced.  It was considered that this might change the types genomic 
rearrangements that occur in the context of telomere dysfunction, which in turn may 
modulate the ability of cells to escape from a telomere-driven crisis.   
 
We observed that clonal JJN-3 populations, each expressing DN-hTERT, were unable 
to escape from crisis when treated with either 7.50μM Rucaparib or 3.75μM Olaparib.  A 
change in the pre-crisis mean telomere length was also recorded, whereby those 
subpopulations treated with 3.75μM Olaparib had a longer mean XpYp telomere length 
than control subpopulations.  However, Rucaparib treatment had little effect on mean 
XpYp telomere length, and no significant change in the frequency of chromosomal end-
end fusion was observed for either PARP inhibitor.  We therefore concluded that 
Rucaparib and Olaparib could prevent the escape of JJN-3 cells from a telomere-driven 
crisis, possibly by impeding their progression through the cell cycle and by selectively 
killing those cells with critically shortened telomeres.  However, further work would be 
required to explain these results, especially given the wide range of PARP family proteins 
targeted by Rucaparib and Olaparib.   
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5.3 Aims of the Chapter 
We hypothesised that PARP inhibition may interfere with the ability of MM cells to identify 
and repair DNA damage, including those pathways which recognise telomere-deficient 
chromosomal ends as double-strand DNA breaks.  We anticipated that there might be a 
change in the types of telomere fusion detected, with the frequency of intrachromosomal 
fusion reduced as the alt-NHEJ pathway was disrupted.  It was thought that this would 
impact on the ability of MM cells to escape from a telomere-driven crisis.  In this chapter, 
clonal populations of JJN-3 DN-hTERT cells were exposed to the PARP inhibitors 
Rucaparib and Olaparib.  In this way, we aimed to drive the cells into a telomere-driven 
crisis, whilst simultaneously limiting their capacity to repair telomere-deficient 
chromosomal ends.  We expected that treatment with either Rucaparib or Olaparib would 
reduce the frequency of chromosomal end-end fusion and modulate the ability of cells to 
escape from a telomere-driven crisis.   
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5.4 Results 
5.4.1 Exposure of PARP Inhibitors to Clonal Populations of JJN-3 DN-hTERT 
Cells During a Telomere-Driven Crisis 
Three clonal populations of JJN-3 cells, each expressing DN-hTERT, were exposed to 
the PARP inhibitors Rucaparib or Olaparib during a telomere-driven crisis.  Although 
clone B and clone C were used in the previous chapter, clone A could not be used here 
due to an insufficient number of cells.  We therefore utilised a fourth clonal population of 
JJN-3 DN-hTERT cells (clone D), the characteristics of which matched those of the other 
DN-hTERT clonal populations used in these experiments (see Supplementary Figures 
8, 9, 10 and 11).  A clonal JJN-3 population expressing only the pBABE-puro vector 
(control clone) was also exposed to the same concentrations of Rucaparib and Olaparib.  
This control enabled the effects of the PARP inhibitors to be evaluated in a JJN-3 clonal 
population with longer, functional telomeres than those undergoing a telomere-driven 
crisis. 
 
Each clonal JJN-3 population was split into twelve subpopulations before the onset of 
crisis, allowing different concentrations of Rucaparib or Olaparib to be added.  Cells were 
grown in 1.00μM - 7.50μM of Rucaparib or 0.50μM - 3.75μM of Olaparib.  Controls for 
each DN-hTERT clone included an untreated subpopulation and a subpopulation which 
was exposed to 0.1% (v/v) DMSO.  The DMSO control was necessary as both Rucaparib 
and Olaparib were dissolved in DMSO, thereby allowing the effects of the PARP 
inhibitors to be distinguished from that of the solvent.  The growth of each subpopulation 
was statistically compared to that of the untreated control using one-way ANOVA with 
Dunnett’s post-hoc test.  This allowed the effects of Rucaparib and Olaparib on cell 
growth to be examined, comparing the growth of each treated subpopulation to that of 
the untreated controls.  Significance was defined as p < 0.05.   
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After following the clone B cells for a period of 84 days (Figure 5.1a), the untreated 
subpopulation escaped from a telomere-driven crisis and underwent a total of 53.0 
population doublings (PD) before being terminated.  Culturing the cells in either 1.00μM 
or 2.50μM Rucaparib did not prevent an escape from crisis, but did have a negative 
impact on the growth of the subpopulations.  Clone B cells which were grown in the 
presence of 1.00μM Rucaparib underwent a total of 50.9 PDs (p = 0.06), whereas those 
grown in 2.50μM Rucaparib underwent only 48.3 PD (p = 0.007) before being terminated.  
The subpopulations which were grown in either 5.00μM or 7.50μM Rucaparib failed to 
escape from a telomere-driven crisis.  Those grown in 5.00μM Rucaparib experienced 
32.5 PDs by day 84 (p = 0.01), while those grown in 7.50μM Rucaparib experienced only 
28.0 PDs (p = 0.002).   
 
Treating clone B subpopulations with Olaparib had a similar effect to that of Rucaparib, 
although Olaparib was used at half the concentration of Rucaparib (Figure 5.1b).  The 
untreated subpopulation managed to escape from crisis and was recorded as having 
undergone 48.3 PDs by day 95.  Culturing the cells in concentrations of either 0.50μM 
or 1.25μM Olaparib did not impact on their ability to escape from a telomere-driven crisis, 
but higher concentrations of Olaparib did have a negative impact on the growth of each 
subpopulation.  By day 95, cells treated with 0.50μM Olaparib had undergone 41.4 PDs 
(p = 0.001) while the 1.25μM Olaparib subpopulation had undergone 40.6 PDs (p = 
0.0002).  Those subpopulations which were grown in either 2.50μM or 3.75μM Olaparib 
did not manage to escape from a telomere-induced crisis.  The 2.50μM subpopulation 
underwent a total 29.78 PDs (p = 0.004), while the 3.75μM subpopulation underwent a 
total of 30.0 PDs (p = 0.0009).   
 
Clone C differed from clone B in the sense that 5.00μM Rucaparib did not prevent the 
cells escaping from a telomere-driven crisis, although it did delay the escape (Figure 
5.2a).  The final PD attained by the untreated clone C subpopulation was 38.4 by day 
99. Again, higher concentrations of Rucaparib had greater impacts on cell growth.  The 
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1.00μM Rucaparib subpopulation managed just 34.9 PDs by day 99 (p = 0.02), while the 
2.5μM and 5.00μM Rucaparib subpopulations managed just 34.6 PDs and 31.3 PDs 
respectively (p = 0.008; p = 0.005).  Regardless, all but the 7.50μM Rucaparib-treated 
subpopulation escaped from a telomere-driven crisis (p = 0.003).  However, the various 
subpopulations did not all escape from crisis at the same time.  The untreated, DMSO, 
1.00μM and 2.50μM-treated subpopulations all appeared to escape from crisis by day 
71.  While the 5.00μM subpopulation did not escape from crisis until day 92.  
 
Treating clone C cells using Olaparib had a similar effect to treatment with Rucaparib, in 
that all but the 3.75μM Olaparib subpopulation escaped from a telomere-driven crisis 
(Figure 5.2b).  By day 100, the untreated subpopulation had reached a final PD of 48.8.  
Meanwhile, the growth of the 0.50μM, 1.25μM and 2.50μM Olaparib subpopulations was 
marginally but significantly inhibited (p = 0.004; p = 0.004; p = 0.002), with higher 
concentrations of Olaparib leading to greater growth inhibition.  However, the cells 
treated with these concentrations of Olaparib were still able to escape from a telomere-
driven crisis.  Growth of those cells treated with 3.75μM Olaparib was not completely 
absent during crisis.  Between the onset of crisis at day 54 and the final measurement 
on day 100, the total PD of the 3.75μM subpopulation increased by 2.3.  However, the 
growth of this population was significantly reduced when compared to the untreated 
subpopulation (p = 0.004) and had stopped completely between day 92 and 100.   
 
When clone D was treated with Rucaparib, only the 7.50μM subpopulation failed to 
escape from a telomere-driven crisis (Figure 5.3a).  As with the previous two clones, 
Rucaparib had a slight but significant impact on population growth and marginally 
increased the time it took for each subpopulation to escape from a telomere-driven crisis.  
The untreated subpopulation underwent 47.7 PD by day 90, while the 1.25μM, 2.50μM 
and 5.00μM subpopulations underwent only 44.7, 44.1 and 41.7 PD respectively (p = 
0.005; p = 0.006; p = 0.02).  The untreated,1.00μM and 2.50μM Rucaparib 
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subpopulations appeared to escape from crisis by day 65, while the 5.00μM 
subpopulation did not escape until day 72.   
 
This result was mirrored upon treatment with Olaparib, whereby the 3.75μM 
subpopulation failed to escape from a telomere-driven crisis (Figure 5.3b).  Higher 
concentrations of Olaparib resulted in significantly reduced growth.  The final PD on day 
90 for the untreated subpopulation was 47.7, while the final PDs for the 0.50μM, 1.25μM 
and 2.50μM subpopulations were 43.5, 42.7 and 39.7 respectively (p = 0.001; p = 0.001; 
p = 0.002).  The 3.75μM-treated subpopulation failed to escape crisis, undergoing no 
more than 29.4 PDs (p = 0.01). 
 
Treatment of a JJN-3 control population (transfected with an empty vector) with 
Rucaparib or Olaparib allowed the effects of the drugs to be evaluated.  This control 
clone did not express DN-hTERT and so maintained its telomere length above that which 
could lead to a telomere-driven crisis.  When the control clone was exposed to 
Rucaparib, growth was never completely inhibited (Figure 5.4a).  Even at 7.50μM 
Rucaparib, growth continued at a steady rate.  This contrasted with the DN-hTERT 
clones, whereby treatment with 7.50μM Rucaparib during a telomere-driven crisis 
prevented any further growth of the subpopulation.  As with the previous DN-hTERT 
clones, increasing concentrations of Rucaparib significantly decreased the overall 
growth of the subpopulation.  The final PD of the untreated subpopulation was 58.5, while 
the final PDs of the 1.25μM, 2.50μM, 5.00μM and 7.50μM Rucaparib subpopulation were 
54.6, 52.5, 49.5 and 45.8 respectively (p = 0.001; p = 0.001; p = 0.001; p = 0.001).  
Treatment with Olaparib also failed to completely inhibit growth, but caused a significant 
decrease in the growth of each subpopulation (Figure 5.4b).  The final PD of the 
untreated subpopulation was 58.5, while the 1.00μM, 2.50μM, 5.00μM, and 7.50μM 
subpopulations reached final PDs of 52.4, 50.6, 46.3 and 42.3 respectively (p = 0.0008; 
p = 0.0008; p = 0.0007; p = 0.0008).   
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5.4.2 Identifying the Efficiency of PARP Inhibition by Rucaparib and Olaparib 
in Clonal Populations of JJN-3 Cells 
Western blotting was used to try and identify the extent of PARP inhibition caused by the 
different concentrations of Rucaparib and Olaparib.  PARP is activated in response to 
DNA damage, resulting in the production of PAR.  We therefore used hydrogen peroxide 
(H2O2) to induce DNA damage in our clonal subpopulations and then measured the 
quantities of PAR produced by the cells.  It was in this way that we expected to show 
whether PARP inhibition would influence the quantities of PAR produced.  We also 
quantified the retinoblastoma protein and Chk-1 protein levels in each subpopulation as 
these are also involved in coordinating a DNA damage response.  We first began by 
using the control JJN-3 clone to identify the necessary concentration of H2O2 required to 
cause a DNA damage response (Figure 5.5a).  Surprisingly, PAR could not be detected 
even when the cells were exposed to 10nM H2O2 for 30 minutes.  Regardless of the 
quantity of H2O2 added, no change in the levels of retinoblastoma protein was detected.  
However, when compared to the -H2O2 control, Chk-1 levels increased dramatically 
when H2O2 was added.  
 
Although PAR could not be detected in the control cells, western blotting was still 
performed on each clonal subpopulation using 2.5nM of H2O2.  However, it was again 
demonstrated that PAR could not be detected in the remaining JJN-3 DN-hTERT clonal 
populations.  In clone B, the quantities of Retinoblastoma protein appeared to increase 
as Rucaparib and Olaparib were added (Figure 5.5b).  As the concentration of 
Rucaparib was increased from 1.00μM to 7.50μM, the intensity of the retinoblastoma 
band increased relative to that of the untreated subpopulation.  Regardless of the 
concentration of Olaparib used, the intensity of the bands was always greater than that 
of the untreated subpopulation.  Although treatment with Rucaparib and Olaparib had 
little effect on the quantities of Chk-1 measured, not treating the cells with H2O2 resulted 
in no Chk-1 being detected.   
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When clone C subpopulations were treated with either Rucaparib or Olaparib, the 
intensity of the retinoblastoma protein band did not appear to change from that of the 
untreated control subpopulation (Figure 5.5c).  The same could be said for Chk-1 which 
did not change when either Rucaparib or Olaparib were added.  Although the quantities 
of retinoblastoma protein and Chk-1 protein were reduced in the -H2O2 control, the actin 
band was also reduced in comparison to the Rucaparib- and Olaparib-treated bands.  
This suggests that a technical artefact may have been the cause of this difference, as 
opposed to action of hydrogen peroxide.  This problem was also observed when treating 
clone D, whereby the intensity of the retinoblastoma and Chk-1 bands in the -H2O2 
control were reduced, but the actin band was also reduced (Figure 5.5d).   
 
5.4.3 The Effect of PARP Inhibition on Mean XpYp Telomere Length 
After the growth of each clonal JJN-3 population had arrested (Figure 5.1, Figure 5.2 
and Figure 5.3), a period that was thought to indicate that the cells had entered a state 
of telomere-driven crisis, samples of cells were taken for DNA extraction.  STELA was 
performed to measure the mean XpYp telomere length of each clonal subpopulation at 
a specific timepoint, while the cells were under the effects of either Rucaparib or 
Olaparib.  One-way ANOVA with Dunnett’s post-hoc test was used to determine if the 
differences in mean XpYp telomere length were statistically significant (Figure 5.9) 
 
After performing STELA on samples of the Rucaparib- and Olaparib-treated clone B 
cells, mean XpYp telomere length was calculated for each subpopulation.  It appeared 
that the presence of Rucaparib had no significant effect on the mean XpYp telomere 
lengths of cells, relative to the control subpopulations (Figures 5.6a and 5.9a).  
Meanwhile, treating clone B cells with either 1.25μM Olaparib or 3.75μM Olaparib 
resulted in a significant increase in mean XpYp telomere length when compared to the 
untreated subpopulation (Figures 5.6b and 5.9a).   
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Samples of clone C cells which were exposed to Rucaparib were taken on day 67, while 
samples of cells cultured with Olaparib were taken on day 61.  In the Rucaparib-treated 
subpopulations, no significant difference in mean XpYp telomere length was observed 
(Figures 5.7a and 5.9b).  Clone C subpopulations varied in their response to Olaparib 
treatment, with only the 3.75μM Olaparib-treated subpopulation having a significantly 
greater mean XpYp telomere length than both the untreated and DMSO-treated 
subpopulations (Figures 5.7b and 5.9b).   
 
Finally, samples of each Rucaparib- and Olaparib-treated clone D subpopulation were 
collected on day 58.  As with clone B and clone C, Rucaparib had little effect on mean 
XpYp telomere length, relative to the control subpopulation (Figures 5.8a and 5.9c).  
Only 3.75μM Olaparib had an effect, resulting in a significantly increased mean XpYp 
telomere length relative to the control subpopulation (Figures 5.8b and 5.9c).   
 
5.4.4 The Effect of PARP Inhibition on the Frequency of Chromosomal Fusion 
Events 
After measuring mean XpYp telomere length in the Rucaparib- and Olaparib-treated 
subpopulations of three JJN-3 DN-hTERT clones, chromosomal fusions were quantified 
to determine the effect that PARP inhibition had on the frequency of fusion events.  As 
in chapter 4, this analysis focused on the fusion events involving the 17p, XpYp, 16p-
family and 21q-family of chromosomal ends.  However, due to the large quantities of 
data collected and the low frequency of XpYp and 16p-family fusion events, this chapter 
emphasised the presence of 17p-21q-family fusion events and their change in frequency 
after treatment with Rucaparib or Olaparib.  A complete listing of all the fusion events 
recorded is shown in Supplementary Figure 12 (clone B – Rucaparib), Supplementary 
Figure 13 (clone B – Olaparib), Supplementary Figure 14 (clone C – Rucaparib), 
Supplementary Figure 15 (clone C – Olaparib), Supplementary Figure 16 (clone D – 
Rucaparib) and Supplementary Figure 17 (clone D – Olaparib).   
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In clone B, the frequency of 17p-21q-family fusions in the untreated and DMSO-treated 
subpopulations were 100x10-6/cell and 133x10-6/cell respectively (Figure 5.10a).  A slight 
decrease in the frequency of 17p-21q-family fusions was observed when Rucaparib was 
added, with the frequency of fusion events in 5.00μM Rucaparib-treated cells being 
27x10-6/cell and 0x10-6/cell in those treated with 7.50μM Rucaparib.   When clone B cells 
were treated using Olaparib, a similar decrease in the frequency of chromosomal fusion 
events was observed (Figure 5.10b).  The frequency of 17p-21q-family fusion events in 
the untreated and DMSO-treated subpopulations was 227x10-6/cell and 140x10-6/cell 
respectively.  Although a slight increase in fusion frequency was observed in the 0.50μM 
Olaparib subpopulation (253x10-6/cell), the 1.25μM, 2.50μM and 3,75μM Olaparib 
subpopulations all had a frequency of 17p-21q-family fusion events that was between 
100x10-6/cell and 53x10-6/cell.   
 
For clone C, the frequency of 17p-21q-family fusion events in the untreated and DMSO-
treated subpopulations was 180x10-6/cell and 213x10-6/cell respectively (Figure 5.11a).  
When treated with Rucaparib, the 1.00μM, 5.00μM and 7.50μM subpopulations all had 
a frequency of fusion below 153x10-6/cell.  However, the 2.50μM Rucaparib-treated 
subpopulation saw a slight increase in fusion frequency to 220x10-6/cell.  This contrasts 
with Olaparib treatment, whereby only the 1.00μM Olaparib-treated subpopulation had a 
fusion frequency below that of the DMSO-treated control (Figure 5.11b).  Unexpectedly, 
only two 17p-21q-family fusion events were identified from the untreated subpopulation 
of clone C cells.  This resulted in every other subpopulation having a larger frequency of 
fusion than the 13x10-6/cell recorded for the untreated control.   
 
Surprisingly, no 17p-21q-family fusion events were recorded in any of the clone D 
subpopulations (Figure 5.12).  For this reason, it became necessary to plot both the total 
frequency of 17p-21q-family fusions observed for each clonal subpopulation (Figure 
5.13), as well as the total frequency of fusions recorded.  By comparing the 
subpopulations based on the total number of 17p, XpYp, 16p-family and 21q-family 
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fusion events, we could gain a clearer picture of any change Rucaparib- and Olaparib-
treatment had on the clone D subpopulations (Figure 5.14c).  From this, we identified 
that the untreated and DMSO-treated clone D subpopulations had total fusion 
frequencies of 100x10-6/cell and 173x10-6/cell respectively.  The total fusion frequency of 
the 2.50μM, 5.00μM and 7.50μM Rucaparib-treated subpopulations all lay between 
these values (167x10-6, 173x10-6 and 153x10-6/cell respectively).  Meanwhile, only the 
3.75μM Olaparib-treated subpopulation had a total frequency of fusion which was below 
the value of 100x10-6/cell recorded in the untreated subpopulation.  The 0.50μM, 1.25μM 
and 2.50μM Olaparib-treated subpopulations each had a frequency of fusion which was 
below the value of 173x10-6/cell recorded in the DMSO-treated control.   
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5.5 Discussion 
5.5.1 PARP Inhibition and the Ability of JJN-3 Cells to Escape from a 
Telomere-Driven Crisis 
In the previous chapter, we attempted to demonstrate that the presence of critically 
shortened telomeres was associated with an increased frequency of chromosomal end-
end fusion.  By forcing clonal populations of JJN-3 cells to divide in the absence of 
telomerase (DN-hTERT), they entered a state of telomere-driven crisis which resulted in 
a period of increased fusion-frequency, followed by an escape from crisis.  In this 
chapter, we have attempted to prevent the escape of these cells from a telomere-driven 
crisis by using the PARP inhibitors Rucaparib and Olaparib.  Due to the essential roles 
played by PARP family proteins in repairing DNA damage, we hypothesised that PARP 
inhibition may limit the capacity of JJN-3 cells to repair single- and double-strand DNA 
breaks.  By disrupting the alt-NHEJ pathway, and potentially altering the balance 
between intra- and interchromosomal fusion events, we anticipated that PARP inhibition 
would prevent the escape of cells from a telomere-driven crisis.  It is in this way that we 
wished to highlight the potential therapeutic use of PARP inhibitors in treating MM.   
 
As we saw in the previous chapter, untreated subpopulations of clonal JJN-3 DN-hTERT 
cells could escape from a telomere-driven crisis after a period of stalled growth.  Treating 
each clone with either 7.50μM Rucaparib or 3.75μM Olaparib completely inhibited 
population growth and prevented an escape from a telomere-driven crisis.  This 
contrasted with the control JJN-3 clonal population, whereby treatment with 7.50μM 
Rucaparib or 3.75μM Olaparib alone was not enough to completely inhibit growth.  
 
Our result shared similarities with Neri et al. (2011), whose research documented that 
treatment with the PARP inhibitor Veliparib alone was not enough to impact on the 
viability of MM cell lines.  For Veliparib to be effective, it was necessary to combine it 
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with the proteasome inhibitor Bortezomib.  With Veliparib preventing the repair of single-
strand breaks, MM cells would have to rely on the HR pathway to repair the resulting 
double-strand breaks.  Bortezomib was found to be indirectly impairing the HR pathway, 
resulting in an accumulation of catastrophic DNA damage.     
 
HR activity is thought to be elevated in MM (Shammas et al. 2009).  It has also previously 
been shown that reactivation of telomerase occurs in late-stage MM, limiting the capacity 
of a telomere-driven crisis to work in tandem with PARP inhibitors (Shiratsuchi et al. 
2002).  For these reasons, PARP inhibition alone in late-stage MM may simply increase 
the frequency of double-strand DNA breaks and produce further genomic instability (Ito 
et al. 2016).  The rate of tumour formation is thought to be significantly increased in mice 
which are both PARP1-/- and p53-/-, an important consideration as 13% of newly 
diagnosed MM cases present with p53 abnormalities (Tong et al. 2003; Tong et al. 2007; 
Chng et al. 2008).  For PARP inhibitors to be considered safe and effective, it may be 
necessary to at least combine their use with telomerase inhibition which would prevent 
telomere maintenance and induce a telomere-driven crisis. 
 
However, the current use of PARP inhibition as a cancer treatment does not require a 
telomere-driven crisis.  PARP inhibitors are mostly limited to breast and ovarian cancers 
which contain mutations in either BRCA1 or BRCA2, genes which are necessary for a 
functional homologous recombination pathway (Venkitaraman 2002).  Further work 
should therefore focus on determining whether the effective concentration of PARP 
inhibition, during a telomere-driven crisis, can be reduced through co-treatment with 
compounds that suppress the homologous recombination pathway.  Fortunately, 
Bortezomib is already commonly prescribed in the treatment of MM and has been shown 
to indirectly suppress homologous recombination (Palumbo et al. 2014; Murakawa et al. 
2007).  It will therefore be necessary to assess the effectiveness of combining 
Rucaparib/Olaparib treatment with Bortezomib during a telomere-driven crisis.  
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Also, previous studies have demonstrated that Olaparib has the capacity to slow the 
growth of CLL cell lines which fail to express a functional ATM protein (Weston et al., 
2010).  This effect was not seen in ATMwt cell lines, but could be induced using retroviral 
knockdown of ATM.  In either case, cell death was thought to occur due to mitotic 
catastrophe.  Olaparib was also found to sensitise ATM-mutated CLL cell lines to 
cytotoxic agents such as alkylating agents and histone deacetylase inhibitors.  This 
observation was later repeated using colorectal cancer cell lines, with Olaparib 
selectively killing those cells that expressed a dysfunctional ATM protein (Wang et al., 
2017).  However, the JJN-3 cell line has not been shown to express a dysfunctional ATM 
protein, and trisomy of chromosome 11 (the ATM gene is located at 11q22.3) has also 
been commonly described in MM (Rajan and Rajkumar, 2015).  This may mean that 
PARP inhibitors, such as Olaparib, may fail to effectively treat MM and may instead 
induce genetic damage which could drive progression of the disease.   
 
Further work should also be carried out to try and understand why different 
concentrations of Rucaparib and Olaparib were required to prevent an escape from a 
telomere-driven crisis.  In the case of each JJN-3 clone, twice the concentration of 
Rucaparib (7.50μM) was required to produce the same effect as Olaparib (3.75μM).  This 
pattern shared similarities with the recommended doses identified in phase II clinical 
trials which investigated the use of Rucaparib and Olaparib in treating BRCA-mutated 
breast and ovarian cancer.  The suggested dose of Olaparib in each case was 400mg 
twice a day (Tutt et al. 2010; Ledermann et al. 2014).  While the recommended dose of 
Rucaparib for treatment of the same cancer was greater at 600mg twice a day (Drew et 
al. 2016; Swisher et al. 2017).  Although this does not answer the question of why a 
difference exists, and may even simply be explained by the maximum tolerated dose of 
each drug in the respective patient cohorts, it could also point towards differing 
mechanisms of action for each of these PARP inhibitors.     
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Wahlberg et al. (2012) characterised the targets of Rucaparib and Olaparib, 
demonstrating that each bound with the same affinity to the catalytic domains of PARP1, 
PARP2, PARP3, PARP4, PARP15 and PARP16.  Olaparib also bound with weak affinity 
to PARP12, while Rucaparib bound with moderate affinity to PARP10, strong affinity to 
PARP5a and weak affinity to PARP5b.   
 
Given these additional targets of Rucaparib, it would be expected that Olaparib would be 
the less effective PARP inhibitor but this does not appear to be the case.  One possible 
explanation for this concerns the targets not analysed by the Wahlberg et al. (2012) study 
(PARP6, PARP7, PARP8 and PARP11).  As only 13 of the 17 PARP family members 
were examined, the potential for Rucaparib and Olaparib to bind the remaining four 
PARP family members is unknown.  Vyas et al. (2013) showed that knockdown of 
PARP6 or PARP7 in HeLa cells did not have a significant effect on viability.  However, 
knockdown of PARP8 almost completely inhibited their growth.  Therefore, work should 
now be carried out to assess whether Rucaparib or Olaparib can inhibit PARP8 and 
whether the activity of this PARP family protein is necessary for MM cell viability and/or 
growth.    
 
A further explanation could be that the drugs behave differently in vivo.  The results of 
Wahlberg et al. (2012) were generated by synthetically producing the catalytic domain 
fragments of the 13 PARP family members, before exposing them to commercially 
available PARP inhibitors.  However, this assay only demonstrated the affinity each 
compound had for each catalytic domain of the PARP family members, but did not 
assess the effect that binding to each catalytic domain had on MAR/PAR synthesis and 
phenotypic changes to a cell.    For this reason, it is still not possible to describe the exact 
mechanisms by which Rucaparib and Olaparib work in our JJN-3 cells.  Future research 
should therefore focus on determining how these PARP inhibitors act, as well as the 
target PARP family member(s) whose inhibition is responsible for triggering cell death in 
MM.  As many of the catalytic subunits of the PARP family members share a certain 
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homology (Ame, Spenlehauer, and de Murcia 2004), attempting to inhibit individual 
PARP proteins may prove difficult.  Instead, identifying and inhibiting the 
upstream/downstream targets of each PARP protein may prove more selective.   
 
5.5.2 Determining the Efficiency of PARP Inhibition in JJN-3 Clonal 
Populations  
We attempted to demonstrate that treating JJN-3 clonal populations with either 
Rucaparib or Olaparib reduced the activity of the PARP family proteins.  Western blotting 
was performed to measure PAR expression, a protein which is produced by some of the 
PARP family members, in response to Rucaparib or Olaparib.  We hypothesised that 
PARP inhibition would simply lead to a reduction in the quantities of PAR produced, as 
observed in similar experiments in HCT116 cells (Greg Ngo, personal communication).  
However, we were unable to detect PAR in any of the JJN-3 clonal populations analysed.  
In response to this, the quantities of the retinoblastoma protein and checkpoint kinase 1 
(Chk-1) protein were also measured to try and detect a DNA damage response within 
the cells.  It was thought that these proteins could have been used to indirectly detect a 
change in the frequency of single- or double-strand DNA breaks.    
 
While the presence of a positive control for PAR proved that the assay appeared to be 
working correctly, we were also able to use Chk-1 as a positive control for H2O2 
treatment.  H2O2 was added to the cells, 24 hours after treatment with either Rucaparib 
or Olaparib, to induce single-strand DNA breaks and increase PAR synthesis by PARP 
family proteins.  From examination of the Western blots, each clonal subpopulation of 
JJN-3 cells that had not been exposed to H2O2 expressed less Chk-1 than those 
subpopulations that had been exposed to H2O2.  As Chk-1 expression is upregulated in 
response to single- and double-strand DNA breaks, this suggested that the addition of 
H2O2 was successfully triggering a DNA damage response within the cells. 
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However, little change was seen in the expression of Chk-1 after the addition of 
Rucaparib or Olaparib.  While it could be argued that increasing the concentration of 
PARP inhibitor might have resulted in a greater number of single-strand DNA breaks 
going unrepaired, and so greater Chk-1 expression in response to accumulating genetic 
damage, this was not apparent in these experiments.  Instead, Chk-1 expression 
remained unchanged even as the concentration of Rucaparib or Olaparib increased.  It 
was possible that, having been exposed to H2O2 for 30 minutes, Chk-1 expression was 
already at its peak and no further increase was possible.  It may therefore be necessary 
to repeat this experiment, reducing the time that cells are exposed to H2O2 so as to detect 
more subtle changes in Chk-1 expression as a response to PARP inhibition. 
 
Little change was also seen in the expression of the retinoblastoma protein after the 
addition of Rucaparib or Olaparib.  While this protein is not directly involved with PARP 
signalling or DNA repair, it is eventually involved with the initiation of cell cycle arrest in 
response to single- and double-strand DNA breaks (Burkhart and Sage 2008).  Unlike 
Chk-1, retinoblastoma protein expression was unaffected by the addition of H2O2.  This 
lack of change in response to H2O2-driven DNA damage may mean that the cells were 
able to repair the single- and/or double-strand DNA breaks that resulted, preventing the 
need for a retinoblastoma-facilitated cell cycle arrest.  However, it is also possible that 
more subtle changes in retinoblastoma protein expression were missed due to the use 
of Western blotting.  In this case, cell cycle analysis might have identified differences in 
the proportion of cells undergoing cell cycle arrest in response to treatment with H2O2 
and Rucaparib/Olaparib.  It could be expected that increasing concentrations of 
Rucaparib or Olaparib would lead to an increasing frequency of double-strand DNA 
breaks, resulting in a greater number of cells undergoing apoptosis.   
 
The lack of PAR was unexpected as it has been well documented that JJN-3 cells 
express PARP family proteins (Teoh et al. 2014; Tunquist, Woessner, and Walker 2010). 
It is therefore possible that one or more of these proteins are either not expressed or not 
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functional in the JJN-3 cell line.  As the most abundantly expressed PAR-producing 
PARP family member, loss of a functional PARP1 protein might have meant that the cells 
were unable to produce PAR in the quantities necessary for quantification using the 
method employed here.  This inactivity may also explain the increased homologous 
recombination activity detected in the JJN-3 cell line by Shammas et al. (2009), with the 
cells relying on this pathway to repair double-strand DNA breaks that arise from a 
defective PARP1-led single-strand DNA break repair pathway.   
 
Although it is possible that further assays could be used to try and detect a change in 
PAR expression after treatment with either Rucaparib or Olaparib, many of these are still 
based the use of a PAR antibody.  If PAR is not produced in sufficient quantities within 
the JJN-3 cell line, then these assays may simply yield the same result as our Western 
blot.  The use of a PAR antibody also fails to account for the activity of those PARP family 
members which are targeted by Rucaparib and Olaparib, but do not produce PAR.  
Kleine et al. (2008) have demonstrated that it is possible to detect the activity of all PARP 
family members using 32P-NAD+, regardless of whether they have MAR or PAR activity.  
NAD+ is used as a substrate by PARP family members when attaching ADP-ribose units 
to proteins, meaning that proteins expressing MAR or PAR which have incorporated 32P 
can be detected by autoradiography.  This would allow the activity of all PARP family 
members to be examined within the context of Rucaparib or Olaparib treatment, without 
biasing the assay towards PARP1.  However, the time required to develop and optimise 
this assay for use with our JJN-3 experiment was beyond the scope of this study.  It 
therefore became necessity to rely on previously reported data regarding the efficiency 
of PARP inhibition by Rucaparib and Olaparib (Murai et al. 2014). 
 
5.5.3 PARP Inhibition and the Effect on Mean XpYp Telomere Length 
Just before the JJN-3 DN-hTERT clones entered a state of telomere-driven crisis, 
samples of each subpopulation were harvested for DNA extraction.  STELA was then 
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used to identify any changes in mean XpYp telomere length that occurred due to 
treatment with either Rucaparib or Olaparib.  Surprisingly, PARP inhibition appeared to 
result in certain subpopulations of cells having a longer mean telomere length than 
controls.  In the case of each JJN-3 clone, 3.75μM Olaparib treatment lead to a 
significantly longer mean XpYp telomere length than the control subpopulations.  
However, this was not the case when cells were treated with Rucaparib.  In each case, 
1.00μM – 7.50μM Rucaparib had no significant effect on mean XpYp telomere length.   
 
Of the 17 PARP family proteins, only PARP5a and PARP5b are thought to play a role in 
telomere length maintenance.  Each works by attaching PAR to TRF1, a subunit of the 
shelterin complex (Ye and de Lange 2004).  This inhibits the activity of TRF1 and 
prevents it from binding to the telomere, thus allowing telomerase to bind instead which 
then results in telomere elongation (Kulak et al. 2015).  It should therefore follow that 
inhibition of PARP5a and PARP5b would allow TRF1 binding at the telomere and result 
in telomeric shortening.  With regards to our data, the opposite is true.  Only the addition 
of 3.75μM Olaparib led to a significant longer mean XpYp telomere length.  However, 
PARP5a and PARP5b activity would have had little effect on telomere length even 
without the presence of Rucaparib or Olaparib.  As each JJN-3 clonal population 
expresses DN-hTERT, telomerase would be unable to elongate telomeres and mean 
XpYp telomere length would decrease regardless of whether PARP5a and PARP5b were 
activated or inhibited.  Also, only Rucaparib was shown to bind to PARP5a and PARP5b 
(Wahlberg et al. 2012).  This prevents these PARP family proteins from being used to 
explain the difference in mean XpYp telomere length seen upon treatment with Olaparib.   
 
It is therefore unlikely that the difference in mean XpYp telomere length which we 
observed was the result of direct action/inaction by PARP family proteins at the telomere.  
Instead, it could be argued that Olaparib was somehow changing the rate of population 
growth.  It was suggested in the previous chapter that the chromosomal instability 
witnessed during a telomere-driven crisis led to the eventual reactivation of telomerase 
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in these clonal populations of JJN-3 cells.  This resulted in mean XpYp telomere length 
increasing as the cells escaped from crisis.  If PARP inhibition increased the rate of cell 
division, Olaparib-treated cells would enter and escape from crisis sooner than the 
untreated controls.  Theoretically, this could result in these cells eventually having an 
increased mean XpYp telomere length, relative to that of the slower-growing pre-crisis 
control subpopulations.   
 
Reducing the rate of population growth would also be a possible explanation, with 
3.75μM Olaparib-treated subpopulations simply having a longer mean XpYp telomere 
length because they had undergone fewer cell divisions.  This may be caused by PARP 
inhibition restricting the ability of a cell to repair single- and double-strand DNA breaks, 
delaying cell division as cell cycle checkpoints are activated.  Nile et al. (2016) have 
shown that treating human neuroblastoma and glioblastoma cell lines with either 
Rucaparib or Olaparib increases the proportion of cells in the G2/M phase of the cell 
cycle.  The G2/M cell cycle checkpoint is responsible for ensuring that DNA damage has 
been repaired before initiating mitosis (Yarden et al. 2002).   
 
Apoptosis may also play a role here, with PARP inhibition selectively killing cells that 
have shorter telomeres and thus greater genomic instability.  Several examples from 
other researchers exist which also demonstrate the anti-proliferative and pro-apoptotic 
effects of PARP inhibitors.  Albert et al. (2007) used Veliparib to reduce the rate of growth 
and increase the rate of apoptosis in populations of H460 lung cancer cells.  Meanwhile, 
Ihnen et al. (2013) showed increased rates of apoptosis in ovarian cancer cell lines 
treated with Rucaparib.  This explanation for the difference in mean XpYp telomere 
length would also correlate with the growth recorded for each JJN-3 DN-hTERT 
subpopulation, whereby those cells treated with either Rucaparib and Olaparib took 
longer to reach the same PD as the untreated controls.  However, it fails to explain why 
a change in mean telomere length was not also observed in Rucaparib-treated 
subpopulations. 
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5.5.4 PARP Inhibition and the Effect on Chromosomal Fusion 
PARP1, PARP2 and PARP3 are all involved in the repair of single- or double-strand DNA 
breaks.  We therefore hypothesised that treatment with Rucaparib or Olaparib would 
inhibit the activity of these PARP family proteins, preventing erroneous DNA repair and 
reducing the frequency of chromosomal end-end fusion.  Specifically, we expected 
PARP inhibition to disrupt the alt-NHEJ pathway and reduce the frequency of 
intrachromosomal fusion events.  However, Rucaparib and Olaparib had little effect on 
the incidence of chromosomal fusion.  In almost all cases, the difference between the 
control subpopulations and the treated subpopulations appeared to be negligible.  The 
only exception was JJN-3 DN-hTERT clone B, whereby Rucaparib and Olaparib both 
caused a minor reduction in chromosomal end-end fusion, with greater concentrations 
of each drug further decreasing the number of fusion events recorded.   
This observation in clone B could be caused by PARP inhibition preventing the cells from 
recognising and repairing telomere-deficient chromosomal ends as double-strand DNA 
breaks.  PARP1 is thought to promote double-strand DNA break repair via the 
alternative-NHEJ pathway (Mansour et al. 2013).  Meanwhile, PARP3 has been shown 
to have a role in promoting the classical-NHEJ pathway (Rulten et al. 2011).  It might 
therefore follow that inhibition of these PARP family proteins would impair the NHEJ 
pathways and lead to fewer chromosomal end-end fusion events.  However, it has been 
shown that PARP1-/- and PARP3-/- cells are still able to repair DNA damage via the 
homologous recombination and NHEJ pathways (Yang et al. 2004; Beck et al. 2014).  
This suggests that PARP1 and PARP3 are active in double-strand DNA break repair, but 
not strictly necessary.  This explanation also fails to account for the results of clone C 
and clone D, whereby the addition of Rucaparib and Olaparib had little effect on the 
frequency of fusion observed.   
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Instead, the reduction in chromosomal end-end fusion may simply be the result of 
increased telomere length.  We previously discussed the fact that treating clone B cells 
with Olaparib caused an apparent increase in mean XpYp telomere length.  In chapter 
4, we also demonstrated that a longer mean telomere length correlated with a reduced 
frequency of chromosomal end-end fusion.  It could therefore be argued that, as PARP 
inhibition resulted in an increased mean XpYp telomere length, fewer chromosomal ends 
had critically shortened telomeres that would result in fusion.  However, this fails to 
explain the results obtained for clone C and clone D.  When the cells were treated with 
3.75μM Olaparib, a longer mean XpYp telomere length was recorded.  However, there 
was no corresponding change in the frequency of fusion observed, relative to the control 
subpopulations.  
 
It may therefore by possible that the ability of Rucaparib and Olaparib to prevent the 
escape of JJN-3 cells from crisis is not a direct consequence of changes to telomere 
dynamics or end-end fusion frequency.  Instead, PARP inhibitors may simply generate 
significant genetic damage by inhibiting single-strand DNA repair pathways (Murai et al. 
2012).  This, combined with the additional genetic instability bought on by a telomere-
driven crisis, may overwhelm the cells ability to repair DNA damage.  In this way, 
Rucaparib and Olaparib are likely to promote apoptosis by increasing genetic instability, 
rather than specifically targeting the formation of intrachromosomal fusion by the alt-
NHEJ pathway as was originally thought.   
 
5.5.5 Conclusions 
Here, we have demonstrated that treating clonal populations of JJN-3 DN-hTERT cells 
with either 7.50μM Rucaparib or 3.75μM Olaparib prevented their escape from a 
telomere-driven crisis.  While we have also provided some evidence to suggest that 
Olaparib modulates mean XpYp telomere length, we have been unable to explain the 
mechanism involved.  We were also unable to determine whether Rucaparib or Olaparib 
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played any role in limiting the frequency of chromosomal end-end fusion.  Future work 
should therefore focus on determining the mechanism by which PARP inhibition 
prevented the escape of cells from a telomere-driven crisis.  As the effects of Rucaparib 
and Olaparib on telomere length and fusion frequency are inconsistent and inconclusive, 
focus should instead shift towards the role that PARP inhibitors have in promoting 
apoptosis.  We now hypothesise that the increased genetic damage caused by 
Rucaparib and Olaparib, combined with a telomere-driven crisis, overwhelms the cells 
capacity for DNA repair.  It is in this way that PARP inhibitors may create catastrophic 
genetic damage, stimulating apoptosis in genetically unstable cells.   
 
A new method for determining the effectiveness of PARP inhibition by Rucaparib and 
Olaparib in the JJN-3 cell line should also be utilised, with focus placed on techniques 
that avoid the requirement for the use of a PAR antibody.  Further work should be 
conducted to identify whether the PARP1 protein is functional within the JJN-3 cell line.  
Doing so may explain why PAR could not be detected in these cells via western blot, as 
well as further charactering an important and widely-used MM cell line.  Regardless, we 
feel that we have begun to demonstrate the importance of PARP inhibition as a treatment 
for MM.  While we believe that administering PARP inhibitors alone may increase the 
risk of DNA damage and chromosomal instability, Rucaparib and Olaparib should be 
able to complement existing cancer treatments.  We therefore suggest that further 
experiments are carried out to assess the effectiveness of combining PARP inhibition 
with bortezomib and telomerase inhibition as a novel treatment for MM.
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Chapter 6 
General Discussion and Future Directions 
 
6.1 Summary 
This study set out determine whether mean XpYp telomere length measurements held 
prognostic value within the context of MM.  Having shown that it did, we then attempted 
to use our findings to increase the prognostic resolution of the ISS.  By isolating CD138+ 
cells from the whole bone marrow aspirates of three MM patients, we demonstrated that 
critical telomeric erosion appeared to be confined to the plasma cells.  Telomere length 
measurements, using DNA extracted from the whole bone marrow aspirates of 141 MM 
patients, identified a mean XpYp telomere length threshold of 3.92kb which could be 
used to stratify patients as either low- or high-risk.  Combining this threshold with a serum 
β2 microglobulin concentration threshold of 5.5mg/L allowed each prognostic subset to 
be further risk-stratified.  We therefore argued for the inclusion of telomere length 
measurements within the ISS, either to complement or replace measurements of serum 
albumin concentration.  However, a prospective study of patients stratified according to 
the revised ISS (R-ISS) is now warranted to establish whether telomere length can add 
prognostic value within cytogenetic risk groups.   
 
Having demonstrated that a shorter mean XpYp telomere length (<3.92kb) was 
associated with inferior patient outcome in MM, we next sought to identify a potential 
cause for this observation.  Chromosomal end-end fusion events, a type of genetic 
instability commonly associated with critically shortened telomeres (Capper et al. 2007), 
were detected in the whole bone marrow aspirates of MM patients.  We then used clonal 
populations of the JJN-3 cell line to highlight a relationship between telomere length and 
the frequency of these fusion events in MM.  In this case, telomeric shortening resulted 
in greater fusion frequency and the initiation of a telomere-driven crisis.  Cells were 
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eventually able to escape crisis, driven by the spontaneous reactivation of telomerase 
which led to an increased mean telomere length and decreased frequency of fusion. 
 
It has been well documented that the genetic instability triggered by chromosomal end-
end fusion is crucial for the escape of cells from a telomere-driven crisis (Jones et al. 
2014).  Telomere-deficient chromosomal ends are subject to repair by the NHEJ 
pathways (Liddiard et al. 2016), resulting in the genomic deletions and rearrangements 
that drive cancer progression and characterise high-risk MM.  We therefore attempted to 
disrupt these pathways by targeting those PARP family proteins which play a role in the 
repair of single- and double-strand DNA breaks.  Exposing pre-crisis clonal populations 
of JJN-3 DN-hTERT cells to the PARP inhibitors Rucaparib (7.50μM) or Olaparib 
(3.75μM) prevented their escape from crisis, although we were unable to determine the 
exact cause of this observation.   
 
During the course of this study, we also laid the foundation for future work in a number 
of key areas.  The first of these regards our attempt to address whether telomere length 
correlated with fusion frequency in unsorted bone marrow aspirates from MM patients.  
Although a correlation between telomere length and fusion frequency was established 
using the JJN-3 cell line, the next logical step would have been to ensure that this 
relationship held true in primary cells.  Unfortunately, having access to the bone marrow 
aspirates of only 16 MM patients made this task difficult.  It was therefore concluded that 
greater patient numbers, as well as isolating plasma cells from whole bone marrow, 
might hold the key to determining why telomere length measurements held prognostic 
value in MM.   
 
Progress was also made on defining the role of p53 abnormalities during the escape of 
cells from a telomere-driven crisis.  We observed that the p53-/- JJN-3 cell line could 
escape crisis, while the p53+/+ NCI-H929 cell line could not.  However, this is clearly 
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insufficient to conclude that the presence or absence of a functional p53 protein defines 
the response of cells to crisis.  We therefore reasoned that a greater number of p53-/- 
and p53wt cell lines should be examined, with a view to extending this work to primary 
plasma cells extracted from MM patients.   
 
Finally, while we could demonstrate that exposing pre-crisis JJN-3 cells to either 
Rucaparib or Olaparib prevented their escape from a telomere-driven crisis, we could 
not explain why this might have been.  Attempts to link PARP inhibition to changes in 
telomere length or fusion frequency proved inconclusive, although exposure to 3.75μM 
Olaparib appeared to result in a longer mean XpYp telomere length when compared to 
controls.  While it was still felt that future work should involve a greater exploration of the 
mechanisms involved, the focus should be on combining PARP inhibitors with other 
drugs such as Bortezomib (Neri et al. 2011; Weiss et al. 2012).  It is in this way that we 
would hope to improve the efficiency of MM treatment, directly targeting the genetic 
instability which is thought to drive cancer progression. 
 
6.2 Comparisons to Current Knowledge 
It has long been considered that telomeric shortening acts as a tumour suppressive 
mechanism, leading countless researchers to explore the role of telomere dysfunction 
during cancer formation (Deng, Chan, and Chang 2008).  A significant body of research 
exists to explain the mechanisms underlying telomere dysfunction, with much of this work 
forming a basis for the discovery of prognostic indicators and novel cancer treatments 
(Ding et al. 2012; Lin et al. 2014; Burchett, Yan, and Ouellette 2014).  While telomeres 
have also been discussed within the context of MM, little progress has been made in 
translating this work into clinical practice (Cottliar et al. 2003; Wu et al. 2003).  We 
therefore set out to utilise our understanding of telomere dysfunction and genetic 
instability to identify new prognostic markers and treatment options for MM. 
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6.2.1 The Prognostic Value of Telomere Length Measurements in MM 
The clinical course of MM can vary significantly (Kyle, Remstein, et al. 2007; Greipp et 
al. 2005), with reliable prognostic markers being necessary to provide accurate risk 
stratification and aid in clinical decision making (Palumbo et al. 2015).  Although previous 
studies involving CLL and breast cancer had demonstrated that a shorter mean telomere 
length correlated with a poorer patient outcome (Lin et al. 2014; Simpson et al. 2015), 
little was known about whether these findings translated to MM.  Meanwhile, both Wu et 
al. (2003) and Cottliar et al. (2003) had established that telomeric shortening occurred in 
MM, with the mean telomere length of plasma cells and bone marrow aspirates being 
shorter in MM patients than in healthy controls.  Our study was the first to combine these 
findings and demonstrate that the telomeric shortening observed in MM held prognostic 
value.   
 
However, we were not the first to explore a relationship between telomere dynamics and 
disease progression in MM.  Klewes et al. (2013) observed that both mean telomere 
length and the frequency of chromosomal aggregates correlated with cancer 
progression.  The plasma cells of MGUS patients were associated with longer telomeres 
and a decreased frequency of aggregates, relative to the plasma cells of MM patients 
whose telomeres were shorter and more prone to aggregate formation.  This result 
mirrored our own finding, whereby the mean XpYp telomere length of MGUS patients 
was significantly longer than that of MM patients.  Our study even went a step further, 
demonstrating that the mean XpYp telomere length of stage I patients was significantly 
longer than that of stage II and stage III patients.  It was thought that this relationship 
was the result of clonal plasma cell growth, whereby a cell with shorter telomeres gave 
rise to a mass of cells with equivalently short telomeres.  The proliferation of these 
genetically unstable cells would then increase the risk of disease progression, a concept 
which was explored by Roger et al. (2013).  They concluded that telomere length was 
  Chapter 6 – General Discussion 
233 
 
likely established before the progression of the cancer, rather than being dynamically 
regulated throughout the course of the disease.   
 
Meanwhile, Campa et al. (2015) observed that the circulating leukocytes of MM patients 
had a longer mean telomere length than matched controls.  It was determined that a 
longer leukocyte telomere length was associated with an increased risk of MM, while 
single-nucleotide polymorphisms (SNP) which reduced the efficiency of the telomerase 
enzyme were associated with a decreased risk of MM.  With regard to telomerase, this 
result was supported by Wu et al. (2003) which identified an increased overall survival 
for those MM patients whose CD138+ cells had a lower telomerase activity.  However, it 
is well known that abnormal plasma cells primarily reside within the bone marrow.  
Therefore, in the absence of purified malignant plasma cells, it is logical that telomere 
length measurements in MM bone marrow samples will more accurately reflect the 
tumour telomere length and tumour burden (Billadeau et al. 1993; Rasmussen et al. 
1999) when compared to peripheral blood samples.   
 
Our results concerning the prognostic value of telomere length measurements in MM 
closely resembled the results of a similar study involving CLL.  Lin et al. (2014) examined 
the relationship between mean telomere length and the frequency of chromosomal end-
end fusion in the peripheral blood mononuclear cells (PBMCs) of CLL patients, 
identifying two key thresholds.  The first of these, 3.81kb, was termed the upper threshold 
of telomere dysfunction; chromosomal fusion events were only observed in a patient 
sample when the mean XpYp telomere length was <3.81kb.  It was also demonstrated 
that this threshold held significant prognostic value.  Our results identified a prognostic 
threshold of 3.92kb in MM, strikingly close to the upper threshold of telomere dysfunction 
described in CLL.   
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However, it was the 2.26kb threshold identified by Lin et al. (2014) that held the greatest 
prognostic value in CLL.  2.26kb was the mean telomere length of all those samples in 
which fusion events were detected.  This result was mirrored by Simpson et al. (2015), 
whereby the most significant mean XpYp telomere length threshold used to stratify low- 
and high-risk breast cancer patients was also 2.26kb.  Unfortunately, we were unable to 
assess the prognostic value of this threshold in MM as only four patients from our cohort 
had a mean XpYp telomere length below 2.26kb.  However, when we first isolated 
plasma cells from the bone marrow aspirates of three MM patients, the average XpYp 
telomere length was found to be 2.40kb.  This suggests that a 2.26kb threshold may hold 
greater prognostic value in MM than the 3.92kb threshold used here, but exploring this 
hypothesis would require the positive isolation and specific telomere length analysis of 
malignant plasma cells. 
 
Another key limitation of this study was the lack of data regarding cytogenetics for each 
MM patient.  Although we were able to successfully incorporate telomere length 
measurements into the ISS, increasing the prognostic resolution of this staging system, 
the ISS has recently been updated to include the presence of high-risk genetic 
abnormalities such as del(17p), t(4;14) or t(14;16).  We were therefore unable to explore 
the role of telomere length measurements in the revised ISS, combining our 3.92kb 
threshold with data regarding serum lactate dehydrogenase (LDH) concentrations or the 
cytogenetics of each patient (Palumbo et al. 2015).     
 
6.2.2 Telomere-Driven Genomic Instability in MM 
It has long been known that critically shortened telomeres, particularly within the context 
of compromised cell cycle checkpoints, have a detrimental effect on genomic stability 
(Maciejowski and de Lange 2017).  Telomeric shortening has been associated with 
chromosomal end-end fusion which can result in the deletion, translocation or gain of 
genetic material (Capper et al. 2007; Maciejowski and de Lange 2017).  Examples of 
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genetic instability in MM include IgH translocations and hyperdiploidy which are thought 
to act as initiating events (Avet-Loiseau et al. 2002; Smadja et al. 2001), with TP53 
deletion and MYC upregulation following as secondary events (Avet-Loiseau et al. 2007).  
However, ours was the first study to demonstrate a causal link between telomeric 
shortening and increased fusion frequency in MM.   
 
Although we were able to sequence chromosomal end-end fusions from the whole bone 
marrow aspirates of MM patients, we could not claim that CD138+ plasma cells were the 
source of this genetic instability.  A necessary future step would therefore be to prove 
the existence of these fusion events in isolated plasma cells.  Although Klewes et al. 
(2013) had demonstrated that telomeric aggregates were a common feature of the 
CD138+ cells of MM patients, an aggregate is not necessarily the same as a 
chromosomal end-end fusion event.  Regardless, it was observed that the frequency of 
these telomeric aggregates increased with disease progression, with MGUS patients 
having fewer aggregates than MM patients.  However, no attempt was made to link 
telomeric shortening with increased aggregate formation or fusion frequency.  
Meanwhile, our study tried to use the whole bone marrow aspirates of 16 MM patients to 
demonstrate that a shorter mean telomere length was linked to a greater frequency of 
chromosomal end-end fusion.   
 
While we could not identify a direct link between mean XpYp telomere length and fusion 
frequency, we were able to conclude that a significant relationship existed between the 
standard deviation of each patient’s STELA profile and the frequency of fusion observed.  
It was thought that the standard deviation offered an estimation of the extent to which 
the telomere length of the plasma cell population differed from that of the remaining 
marrow cells.  It will therefore be necessary to examine this theory by first isolating 
CD138+ plasma cells from the whole bone marrow aspirates of MM patients.  By 
measuring mean telomere length and fusion frequency in these isolated cells, it may 
offer an explanation as to whether the telomeric shortening observed in plasma cells is 
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responsible for the genetic instability associated with MM.  However, clinical samples are 
inherently diverse and harbour numerous cytogenetic abnormalities.  It was therefore 
concluded that establishing any mechanistic basis for the relationship between telomere 
length and fusion frequency would require the use of MM cells lines 
 
By driving clonal populations of JJN-3 cells into a telomere-driven crisis, we could offer 
an explanation for why telomere length measurements might hold prognostic value in 
MM.  At least in this cell line, telomeric shortening was associated with increased fusion 
frequency and the reactivation of telomerase, likely facilitating cell survival.  Our study 
shared similarities with Capper et al. (2007) and Lin et al. (2014), both of whom identified 
an identical relationship between telomere length and fusion frequency in fibroblast and 
CLL cells respectively.  Unlike Lin et al. (2014), however, we were unable to go a step 
further and demonstrate that the frequency of chromosomal end-end fusion increased 
during disease progression.      
 
The identification of inter- and intrachromosomal fusion was critical in explaining why 
JJN-3 cells could escape from a telomere-driven crisis.  Jones et al. (2014) demonstrated 
that the escape of HCT116 cells from crisis was ligase III-dependent, with a higher ratio 
of intra- to interchromosomal fusion thought to be primarily responsible for localised gene 
amplification.  This included the TERT locus which is one of the most distal genes on the 
short (p) arm of chromosome 5.  Our study observed that telomerase was reactivated in 
clonal populations of JJN-3 cells, each expressing DN-hTERT, following a period of 
telomere-driven crisis and increased fusion frequency.  This appeared to correlate with 
several studies examining telomerase expression in MM, with most identifying increased 
telomerase activity in the CD138+ cells of patients (Shiratsuchi et al. 2002).  Wu et al. 
(2003) not only demonstrated that telomerase was reactivated in abnormal CD138+ cells, 
but that greater telomerase activity correlated with a significantly reduced overall 
survival.   
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We therefore concluded that telomeric shortening in the abnormal plasma cells of MM 
patients would likely lead to an increased frequency of chromosomal end-end fusion.  A 
possible consequence of this genomic instability is the reactivation of telomerase, 
resulting in an increased mean XpYp telomere length which might prolong the survival 
of the abnormal cells.  Telomerase inhibition alone, particularly within the context of 
compromised cell cycle checkpoints, might simply lead to further genomic instability 
(Jones et al. 2014).  Instead, novel treatments should focus on preventing the escape of 
cells from a telomere-driven crisis, possibly by combining telomerase inhibition with 
drugs that are known to prevent chromosomal end-end fusion.   
 
6.2.3 Preventing the Escape of Cells from a Telomere-Driven Crisis 
PARP inhibitors, such as Rucaparib and Olaparib, are currently used during the 
treatment of BRCA-deficient breast and ovarian cancers (Venkitaraman 2002).  They are 
thought to work by trapping PARP family proteins at the site of single-strand DNA breaks, 
preventing their repair and leading to the formation of double-strand DNA breaks 
(Konecny and Kristeleit 2016).  When HR is compromised, such as in BRCA-deficient 
cancers, cells must rely on the error-prone NHEJ pathways to repair these double-strand 
DNA breaks.  This eventually results in catastrophic DNA damage and apoptosis.  
However, PARP family proteins have also been implicated in DNA repair mechanisms, 
most notably the alt-NHEJ pathway which is known to be necessary for the escape of 
abnormal cells from a telomere-driven crisis (Mansour et al. 2013; Jones et al. 2014).  
We therefore sought to utilise Rucaparib and Olaparib to prevent the repair of single- 
and double-strand DNA breaks during a telomere-driven crisis, with the aim of prohibiting 
cells from escaping.   
 
However, our study demonstrated that treating a JJN-3 clonal population (not expressing 
DN-hTERT) with either Rucaparib or Olaparib failed to prevent cell growth.  This result 
shared similarities with Neri et al. (2011), whose research documented that treatment 
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with the PARP inhibitor Veliparib alone was not enough to impact on the viability of MM 
cell lines.  In our study, PARP inhibition was only effective when combined with a 
reduction in telomerase activity which brought about a telomere-driven crisis.  After 
entering crisis, continued exposure to either 7.50μM Rucaparib or 3.75μM Olaparib 
prevented clonal populations of the JJN-3 cell line from escaping.   
 
In this in vitro study, we had to drive JJN-3 cells into a telomere-driven crisis by forcing 
the expression of a DN-hTERT construct, in order for PARP inhibition to be effective.  
However, effective use of PARP inhibitors for the treatment of MM may not be so 
dependent on the dual genetic knock-down of telomerase.  Alagpulinsa et al. (2016) 
demonstrated that Dinaciclib, a CDK inhibitor, sensitised MM cell lines to Veliparib by 
impairing the HR pathway.  It was observed that treating mouse MM xenograft models 
with a combination of Dinaciclib and Veliparib significantly increased overall survival.  
This is in comparison to mice treated with Veliparib alone, which unsurprisingly had the 
same overall survival as untreated controls.  Fortunately, the additional step of combining 
PARP inhibition with Dinaciclib may not be necessary.  Neri et al. (2011) demonstrated 
that MM cell lines could be sensitised to the effects of Veliparib by co-treating with 
Bortezomib, a drug which is already commonly used during the treatment of MM.   
 
Although Neri et al. (2011) found that Bortezomib indirectly impaired the HR pathway, 
Weiss et al. (2012) observed that Bortezomib was also responsible for downregulating 
telomerase activity in both MM cell lines and primary cells.  It is therefore possible that 
combining Bortezomib with PARP inhibition may have a similar effect to that observed in 
our study.  This could be tested in vitro and in mouse models of MM whereby a reduction 
in telomerase activity is combined with a PARP inhibitor like Rucaparib and Olaparib. 
     
However, the greatest limitation of this study was our inability to explain why PARP 
inhibition prevented clonal populations of JJN-3 cells from escaping a telomere-driven 
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crisis.  Although we could demonstrate that Rucaparib and Olaparib were effective in 
preventing the escape of JJN-3 cells from crisis, we had also anticipated that PARP 
inhibition would suppress the alt-NHEJ pathway and reduce the frequency of 
chromosomal end-end fusion observed.  Frustratingly, fusion frequency remained 
relatively unchanged during treatment.  Not only this, but PARP activity could not be 
detected in JJN-3 cells using the methods utilised here.  A significant amount of further 
work would therefore be necessary to understand the mechanism by which PARP 
inhibition prevents the escape of cells from a telomere-driven crisis in these MM cell 
lines.  
 
6.3 Future Directions 
One of the core aims of this study was to determine whether telomere length 
measurements held prognostic value within the context of MM.  Having demonstrated 
that a mean XpYp telomere length threshold of 3.92kb could be used to stratify low- and 
high-risk patients, and that this threshold could be further used to increase the prognostic 
resolution of the ISS, we next turned our attention to explaining why telomere length 
measurements held prognostic value.  Although we observed a relationship between 
telomere length and the frequency of chromosomal end-end fusion in the JJN-3 cell line, 
we were unable to replicate this exact relationship using the whole bone marrow 
aspirates of MM patients.  Instead, we could only identify a relationship between the 
variance of each patient’s STELA profile and the frequency of fusion, suggesting that a 
subset of critically shortened telomers may be responsible for the genomic instability and 
rearrangement that defines MM. 
 
The next step would therefore involve isolating CD138+ plasma cells from the whole bone 
marrow aspirates of a large well-characterised cohort of MM patients.  From this, we 
would seek to identify whether the prognostic resolution of telomere length 
measurements could be further increased, in much the same way as Lin et al. (2014) 
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and Simpson et al. (2015) did with purified CLL and breast tumour samples.  It is in this 
way that we could explore the value of a 2.26kb telomere length threshold in MM, as well 
using the cytogenetic data for each patient to establish its utility in the R-ISS.  Using 
isolated plasma cells would also allow for a more targeted exploration of the relationship 
between telomere length and fusion frequency in MM primary cells.  Not only would we 
hope to demonstrate that shorter telomeres correlated with increased fusion frequency, 
but we would also aim to identify a telomere dysfunction threshold for MM.  This would 
involve defining the mean telomere length at which chromosomal end-end fusion could 
first be observed in plasma cells, as well whether the frequency of fusion could be used 
as an indicator of patient outcome.   
 
Isolating CD138+ plasma cells from MM patients may also help to explore the role that 
TP53 abnormalities play during the onset of a telomere-driven crisis.  TP53 abnormalities 
are estimated to be present in around 13% of MM cases at diagnosis, limiting the ability 
of a cell to trigger cell cycle checkpoints when telomeres become critically shortened 
(Chng et al. 2007).  We observed that the p53-/- JJN-3 cell line could escape from a 
telomere-driven crisis, while the p53wt NCI-H929 cell line could not. Other researchers 
have also observed that inhibiting telomerase activity causes apoptosis in p53wt MM cell 
lines (Shammas et al. 2003; Akiyama et al. 2003).  Further work is clearly necessary 
explore the role that p53 expression plays during the escape of an abnormal plasma cell 
from a telomere-driven crisis.  This work could also extend to haploinsufficient (p53+/-) 
cells and those with genetic abnormalities which are known to result in a compromised 
DNA damage response.  
 
We would likely begin by reducing the expression of p53 in the NCI-H929 cell line, before 
using DN-hTERT expression to drive the cells into a telomere-driven crisis.  A reduction 
in p53 expression could be achieved by inhibiting translation of the p53 mRNA via RNA 
interference (He et al. 2005).  We hypothesise that, with a compromised senescent 
pathway, the cells may be able to escape from crisis in a similar manor to the JJN-3 cell 
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line.  If this were the case, and could be repeated in other p53wt MM cell lines, then it 
may be worth exploring the relationship between p53 expression and the frequency of 
chromosomal end-end fusion in the CD138+ plasma cells of MM patients.  This might 
further explain why del(17p) is consider a high-risk genetic abnormality in MM, with a 
compromised senescent pathway leading to an increased frequency of fusion which 
drives progression of the disease.   
 
One of the most important areas of future work should be exploring the use of PARP 
inhibitors as a treatment for MM.  Although we have demonstrated that exposing JJN-3 
cells to 7.50μM Rucaparib or 3.75μM Olaparib through a telomere-driven crisis was 
sufficient to prevent their escape, focus should now shift towards combining PARP 
inhibitors with Bortezomib.  Not only is Bortezomib commonly used during the treatment 
of MM, but it has also been shown to sensitise abnormal plasma cells to the effects of 
PARP inhibition by impairing both the HR pathway and telomerase activity (Neri et al. 
2011; Weiss et al. 2012).  Work should also be carried out to replicate these findings 
using other MM cell lines and eventually CD138+ plasma cells obtained from patients.  
This would be to ensure that the effects of PARP inhibition are not localised to the JJN-
3 cell line.  This isolation of CD138+ cells from MM patients could also be performed 
alongside the stratification of patients based on mean telomere length, assessing the 
prognostic value of a 2.26kb threshold.   
 
Although it would also be interesting to understand why PARP inhibition prevents the 
escape of JJN-3 cells from a telomere-driven crisis, this is not nearly as important as 
further exploring the use of PARP inhibitors as a treatment for MM.  However, 
understanding why PARP inhibition prevents cells from escaping crisis may still influence 
how we perceive and treat the disease.  It may therefore be necessary to explore the 
effects of these drugs on cell cycle progression and single-strand DNA break repair 
mechanisms.  It is in this way that we would wish to identify PARP inhibition as a novel 
treatment for MM, while simultaneously offering an explanation for its effectiveness.   
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6.4 Conclusions 
 
During the course of this study, we have determined the prognostic value of telomere 
length measurements in patients with MM.  By using STELA to measure the mean XpYp 
telomere length in 141 MM patients, we have identified a telomere length threshold of 
3.92kb which could be used to stratify patients as either low- or high-risk.  Combining 
this threshold with a serum β2 microglobulin concentration threshold of 5.5mg/L allowed 
each prognostic subset to be further risk-stratified, establishing an argument for the 
incorporation of telomere length measurements into the ISS.  We have also offered an 
explanation for the prognostic value of telomere length measurements in MM, identifying 
CD138+ plasma cells as the source of critically shortened telomeres in three patients with 
the disease.   
 
Clonal populations of JJN-3 cells were then used to show that telomeric shortening in 
this MM cell line would generate genetic instability in the form of chromosomal end-end 
fusion.  DN-hTERT expression forced the cells into a telomere-driven crisis, resulting in 
telomeric erosion that correlated with an increased frequency of fusion.  Each clonal JJN-
3 population was then able to escape crisis, accompanied by an increase in telomerase 
activity and gradual telomeric elongation.  By exposing these cells to Rucaparib or 
Olaparib, we were able to prevent this escape from crisis and highlight the potential for 
PARP inhibitors to be used as a treatment option for MM.   
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